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CHAPTER 1 
 
General Introduction 
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The kidneys’ main function is to maintain the body’s homeostasis. They maintain 
fluid, acid-base and electrolyte balance and produce several hormones, including 
erythropoietin. In patients with chronic kidney disease (CKD), the kidneys have lost 
(part of) their filtering capacity.1 End-stage renal disease (ESRD; CKD stage 5, defined 
by an estimated glomerular filtration rate (eGFR) of less than 15 mL/min per 1.73 m² 
or the need for renal replacement therapy) is a life-threatening condition as patients 
are at risk of imminent death from fluid overload or electrolyte and pH disturbances.2, 
3 Patients with ESRD can be treated with either dialysis (hemodialysis or peritoneal 
dialysis) or kidney transplantation. Kidney transplantation is the preferred treatment, 
as it provides longer patient survival and better quality of life for most patients when 
compared to dialysis.4  
The first successful kidney transplantation was performed in Boston in 1954 
by the team of Joseph Murray.5 This procedure was performed between identical 
twins and therefore there was no need to suppress the recipient’s immune system in 
order to prevent rejection of the graft. As most renal transplant candidates will not 
have a genetically identical kidney donor, prevention of rejection is essential. Under 
such conditions, the immune system of the recipient will recognize the transplanted 
organ as foreign which will lead to an immune response directed against the cells of 
the donor kidney (the so-called alloimmune response) causing destruction of the 
graft. Allograft recognition and rejection is mediated by complex immunologic 
pathways which can generally be subdivided into cellular (T cell-mediated) and 
humoral (antibody/B cell-mediated) pathways.6, 7 The discovery of the first 
immunosuppressive drugs in the 1960’s and the subsequent evolution of 
pharmacological immunosuppression ever since, have significantly increased 
allograft survival. However, it is the short-term graft survival that has improved most, 
whereas the long-term kidney transplantation results have not improved to a similar 
degree.8-10 Acute rejection remains an important problem in kidney transplantation 
with significant effects on long-term graft outcomes.  
Although kidney transplantation has become an accepted therapy with good 
results, there remains room for further improvement. There is a need to better 
understand the pathophysiology of renal transplant failure and to improve transplant 
injury diagnostics. Accurately determining risk factors associated with both short- 
and long-term renal allograft failure is essential to develop effective interventions 
that can either prevent, treat or slow the progression of kidney transplant failure. A 
core renal biopsy for histological evaluation is considered the gold standard to 
analyze renal function impairment after renal transplantation and is an important 
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tool in the identification of possible risk factors for graft failure.11, 12 The aim of this 
thesis is to identify potential important pathologic variables in kidney biopsies and 
their association with the risk of impaired renal transplant function. 
 
1. Renal transplantation 
 
In the Netherlands, 998 patients received a kidney transplant in 2018.13 The 
diseases most commonly leading to renal failure and treated by kidney 
transplantation are diabetes mellitus, hypertension and glomerulonephritis.14, 15 
Donor kidneys can be derived from deceased donors (either donation after brain 
death or donation after circulatory death) and living donors (either related or non-
related). Living donation provides a better allograft survival when compared to 
deceased-donor transplantation.16 
An important factor influencing graft function is the extent of ischemic injury 
during kidney transplant surgery. The warm ischemia time describes ischemia of cells 
under normothermic conditions: the time between circulatory arrest and cold 
perfusion (first warm ischemia time) and the time from removal of the donor kidney 
from ice until reperfusion (second warm ischemia time).17 The cold ischemia time is 
the storage time of the donor kidney in cold solution to preserve the viability of its 
cells. Optimal function of donor kidneys is achieved when the cold ischemia time is 
kept as short as possible.18, 19 In most cases the native kidneys are not removed 
during surgery and the donor kidney is usually placed in the iliac fossa. The renal 
artery and vein are anastomosed to the iliac vessels and the ureter is anastomosed 
to the bladder.20 
 
2.  The renal biopsy  
 
 Kidney function after transplantation is evaluated by serum creatinine, 
urinary sediment and protein concentration, and core renal biopsy.21 A core renal 
biopsy is an important diagnostic tool for nephrologists and can aid in diagnosing 
the cause of renal function loss and may also guide treatment.22 Renal transplant 
biopsies can be used to diagnose the type and severity of rejection, but also to reveal 
other causes of renal inflammation and injury, like BK virus nephropathy, 
pyelonephritis, interstitial nephritis or recurrence of the primary kidney disease. It has 
been shown that a core renal biopsy alters the clinical diagnosis in 24-47% of the 
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patients.23, 24 For example, IgA nephropathy, thin basement membrane nephropathy 
and C3 glomerulopathy can only be diagnosed by renal biopsy. Also, unexpected 
findings can be observed in renal biopsies from patients with diabetes mellitus and 
in patients with acute kidney injury (AKI).25 Furthermore, with the help of renal 
biopsies new disease classifications have been generated and specific pathological 
features, like the degree of irreversible kidney damage, have prognostic value in both 
native and allograft biopsies.25 Histological evaluation of pre-implantation renal 
transplant biopsies provides information on the organ quality and may be an 
important tool in the prediction of recipient outcome.26-28  
 Renal core biopsies are performed under real-time ultrasound guidance 
using a 14- to 18-gauge needle. Ideally, 2 renal core biopsies are obtained which are 
divided into a portion for light microscopy (LM), electron microscopy (EM) and 
immunofluorescence (IF). Figure 1 demonstrates the method used at the Pathology 
Department of the Erasmus MC, Rotterdam, for dividing 2 cores obtained from a 
transplant kidney. The biopsy cores should contain predominantly cortical tissue 
because this is the location of glomeruli and should be divided in a manner to 
maximize the number of glomeruli in each of the renal samples.29 
The tissue sample for LM is placed into formalin which allows rapid fixation, 
after which the sample is infiltrated with melted paraffin wax. After solidification, 2-
4 µm sections are cut and stained according to routine diagnostic practice for 
hematoxylin and eosin (H&E), periodic acid–Schiff (PAS), Jones and Masson's 
trichrome. The tissue sample for IF is frozen and stored at −80°C until cryosectioning. 
IF is performed using antibodies directed against IgA, IgG, IgM, C3c, C1q, kappa and 
lambda. A tissue sample of circa 4 mm is fixated in a glutaraldehyde solution and 
processed for EM. One or 2 glomeruli are usually selected for ultrastructural 
evaluation of the glomerular basement membrane, podocytes and endothelium, and 
for the presence of depositions.30  
 
 
Figure 1. Two renal cores biopsies are generally taken and divided into a portion for light 
microscopy (LM), electron microscopy (EM) and immunofluorescence (IF). 
LM
EM IF
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The histological diagnosis of rejection is based on the Banff Classification.31 
The Banff Foundation for Organ Transplantation originated during 
a meeting in Banff, Canada, held in August 1991. The Banff meeting is a consensus 
meeting regarding allograft pathology that has been held every two years.32 The 
Banff Classification of Kidney Allograft Pathology consists of the following six 
categories: (1) normal, (2) antibody-mediated rejection (ABMR), (3) borderline 
changes, (4) T cell-mediated rejection (TCMR), (5) interstitial fibrosis and tubular 
atrophy (IFTA), and (6) other.  
Despite the standardization of the diagnostic features of these 6 categories 
in the Banff Classification, limited reproducibility and differential diagnostic 
dilemmas remain a problem using histological evaluation. First of all, adequate 
biopsy interpretation requires an experienced nephropathologist, who is not always 
readily available. In addition, histology of rejection can show a wide range of features 
and subjective interpretations of lesions may cause interobserver variation. The 
scoring system uses arbitrary thresholds and the interobserver agreement is poor, 
with most lesions having k-values of 0.4 or less.33-35 Furthermore, renal biopsy 
findings currently do not provide sufficient insight into which transplant patients are 
at risk of future rejection episodes and allograft loss.  
Therefore, alternative methods of diagnosing rejection, such as mass 
spectrometry (MS) and molecular analysis of renal tissue, are under investigation. 
Several publications have stressed the importance of combining current diagnostic 
practice with molecular analysis.36-39 Gene expression analysis on the mRNA level in 
renal transplant biopsies can give novel insights into the underlying pathophysiology 
of rejection and could lead to the identification of diagnostic and prognostic markers 
and new therapeutic interventions. Naesens et al. reported that the examination of 
kidney biopsies at the molecular level can reveal abnormalities in the innate and 
adaptive immune response long before those abnormalities appear on 
histology.40 The Banff Foundation is encouraging molecular research on renal 
allograft biopsies and also urges to incorporate molecular analysis in the diagnostic 
classification of kidney transplant rejection.31 However, the implementation of 
molecular analysis into standard clinical practice remains challenging due to the 
requirement of large scale, multi-center validation in clinical trials. 
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3. The immune system in renal transplantation 
 
The current success of renal transplantation is the result of advances in our 
understanding of the alloimmune response. The two main classes of the immune 
system are the innate immune system and the adaptive immune system and both 
play an important role in rejection. 
 
3.1 The innate immune system 
 The innate immune system provides a non-specific first line of defense 
against viruses, bacteria, parasites, and other foreign particles. Tissue stress 
experienced during the transplantation procedure is sufficient to trigger the innate 
immune response.41 Immunological events in the donor kidney at the time of 
transplantation are caused by ischemia-reperfusion injury (IRI). IRI is initiated by 
oxygen deprivation causing ischemia and is further exacerbated once restoration of 
the blood flow is completed (reperfusion). Reperfusion of the ischemic tissue causes 
microvascular injury and the resupply of oxygen will lead to generation of reactive 
oxygen species.42 This may eventually result in lysis of kidney cells which then release 
their intracellular contents. The first responders to IRI are components of the innate 
immune system, such as the complement system and toll-like receptors (TLRs), 
resulting in activation of dendritic cells, natural killer (NK) cells and macrophages 
which induce an inflammatory response.43 
 
Toll-like receptors 
TLRs are a family of transmembrane proteins expressed on inflammatory 
cells (e.g. dendritic cells, macrophages, NK cells) and non-inflammatory cells 
(epithelial and endothelial cells).44 To date, 11 different TLRs have been identified in 
humans.45 TLRs recognize so-called pathogen-associated molecular 
patterns (PAMPs), molecules unique to groups of related micro-organisms which are 
not associated with human cells. When exposed to PAMPs, the TLRs on macrophages 
and dendritic cells induce signaling events which promote the activation of the innate 
immune system.46 All TLRs, except TLR3, require the adaptor MyD88 for signal 
transduction. TLR3 utilizes the adaptor Trif. TLR4 can signal via both MyD88 and Trif.47 
TLRs are also known to have an important role in the setting of kidney transplantation 
through the recognition of danger signals or damage-associated molecular 
patterns (DAMPs).43, 48 These DAMPs are cells and cell contents displayed on stress 
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or injury like that caused by IRI. Recognition of DAMPs by TLRs cause activation of 
the innate immune system in the absence of infection and the response is 
characterized by an inflammatory cell infiltrate, production of proinflammatory 
cytokines and chemokines, and activation of the complement system.48 
 
The complement system 
Activation of the complement system can occur through three different 
pathways: the classical, alternative and the lectin pathway. All three pathways are 
triggered by distinct stimuli. When the complement system is activated, a cascade 
reaction is initiated resulting in the creation of complement components which have 
pro-inflammatory, chemo-attractant and cell-damaging effects.49 
The classical pathway is initiated by the binding of IgM or IgG antibody-
antigen complexes to C1q. C1q is part of the C1 complex, a multimeric complex 
consisting of a C1q molecule bound to two C1r and two C1s molecules. The binding 
of C1q to the Fc portion of an IgM or IgG immune complex induces a conformational 
change in the C1 complex leading to activation of C1r and C1s. Once activated, C1s 
cleaves C4 into C4a and C4b, and C2 into C2a and C2b, leading to the formation of 
C3 convertase.50 The lectin pathway is very similar to the classical pathway. 
Mannose-binding lectin (MBL) binds to mannose proteins which are present on many 
pathogens. MBL forms a complex with mannose-associated serine protease (MASP)-
1 and MASP-2 (which are comparable to C1r and C1s) leading to the cleavage of C4 
and C2, initiating the formation of C3 convertase.50 The alternative pathway is 
activated by the spontaneous hydrolysis of C3 which changes the structure of C3. 
The formed C3b covalently binds to the cell wall of a pathogen. Factor B then binds 
to C3b, which is cleaved by factor D, forming C3 convertase.50  
All three pathways lead to the formation of homologous variants of C3 
convertase which cleaves C3 to form C3a and C3b. C3a acts as a recruiter of 
inflammatory cells. C3b opsonizes foreign antigens and apoptotic cells which 
promotes phagocytosis. Furthermore, C3b is part of C5 convertase which cleaves C5 
that leads to the activation of the final common pathway, the Membrane Attack 
Complex (MAC). MAC is composed of different complement proteins (C5b, C6, C7, 
C8 and several C9 molecules) that are able to form a cytolytic complex which 
promotes the removal of pathogens and cell debris (Figure 2).51 
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Figure 2. The complement system can be activated by the classical pathway, lectin pathway 
and the alternative pathway. All pathways lead to the cleavage of C3 by homologous variants 
of C3 convertase forming C3a and C3b. C3b opsonizes foreign antigens and apoptotic cells, 
promoting phagocytosis. C3b is also part of C5 convertase which cleaves C5 into C5a and C5b, 
leading to the activation the Membrane Attack Complex (MAC). C3a and C5a 
are anaphylatoxins that have multiple immune regulatory roles. MAC can directly kill 
pathogens or cells or can promote inflammation. 
 
Apoptosis-related markers  
 IRI eventually causes cell death by necrosis (unregulated cell death) and 
apoptosis (programmed cell death). The major B-cell lymphoma 2 (BCL2) family 
members act to promote or suppress cell death and are the key regulators of 
apoptosis. Structurally, the BCL2 family members share one or more of the four 
characteristic domains entitled the BCL2 homology domains (named BH1, BH2, BH3 
and BH4).52 They are predominantly located on the mitochondria where the release 
of cytochrome c is regulated.53 BCL2 family members are divided into two major sub-
groups: the anti-apoptotic proteins (e.g. BCL2) and the pro-apoptotic proteins (e.g. 
BAX). The overexpression of BCL2 enhances cell survival by suppressing apoptosis as 
BCL2 stabilizes the mitochondrial membrane and prevents the release of cytochrome 
c into the cytosol.54, 55 Cell death signals activate BH3 which results in inactivation of 
Classical pathway
C3
Lectin pathway Alternative pathway
C3bC3a
C5
C5a C5b MAC
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BCL2 and conformational changes of BAX.56 Oligomerization of BAX on the outer 
mitochondrial membrane leads to mitochondrial outer membrane permeabilization 
and cytochrome c release. This triggers the activation of a cascade leading to cell 
death (Figure 3).56 The balance between cell death and survival upon stimulation is 
therefore regulated by the BAX:BCL ratio.57, 58  
 
Figure 3. BAX and BCL-2 have opposing roles in apoptosis. When uninhibited, BCL-2 blocks 
BAX thereby suppressing apoptosis. Cell death signals cause activation of BH3 which results 
in the inactivation of BCL-2 and oligomerization of BAX which form pores through which 
cytochrome c is released from the inner mitochondrial membrane into the cytosol. This 
activates a subsequent cascade leading to apoptosis of the damaged cells.  
 
3.2 The adaptive immune system  
The adaptive immune system, or “acquired immunity” includes humoral and 
cell-mediated immunity. More sophisticated mechanisms are involved in the 
adaptive immune response compared to the innate immune response. The adaptive 
immune system is characterized by its high specificity for particular pathogens and 
immunologic memory. While the innate immune response occurs within minutes to 
hours after contact with a pathogen, the adaptive immune response only becomes 
fully activated after a delay of 3-5 days following the initial encounter with the 
pathogen.59  
 The activation of the adaptive immune system after kidney transplantation 
is caused by human leucocyte antigens (HLA) which are unique to each person. These 
apoptosis
Cell death signals
BH3
BH3
BCL-2
BAX
cytochrome c
BCL-2
BAX
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cell surface antigens are responsible for the regulation of the immune system in 
humans. HLA class I is found on all nucleated cells, whereas HLA class II is present on 
antigen presenting cells (APCs) such as dendritic cells, macrophages and B cells.60 
After transplantation, HLA from the donor is recognized as foreign by the recipients 
immune system which initiates a cascade of immune events resulting in infiltration 
of the kidney transplant by inflammatory cells, culminating in acute rejection.61  
The major components of the adaptive immune system are T cells and B cells 
and both are important in rejection. T cells and B cells are triggered by activated cells 
from the innate immune system (dendritic cells and macrophages) which present 
donor HLA molecules to naïve T cells. The T cells can recognize donor HLA by 3 
distinct pathways; the direct pathway, the indirect pathway and the semi-direct 
pathway.62 In the direct pathway, T cells from the recipient are activated directly by 
APCs from the donor, bearing intact HLA molecules on their surface. In the indirect 
pathway, T cells are stimulated by APCs from the recipient, which have taken up HLA 
fragments derived from the donor tissue, which are presented to the T cells. In the 
semi-direct pathway, T cells are activated by the fusion of an APC from the recipient 
with a donor-derived HLA molecule.62 Activation of T cells leads to clonal expansion 
and migration of these cells from the secondary lymphoid tissue to the renal 
transplant where they cause an acute TCMR. Activated B cells produce donor-specific 
anti-HLA antibodies (DSAs) which bind to the endothelium of the microcirculation of 
the donor kidney and activate the complement system causing damage to the 
vascular endothelium resulting in an acute ABMR.63  
 
4.  Rejection of the kidney transplant 
 
Rejection can be subdivided into different categories according to the timing 
of rejection (hyperacute, acute, chronic) or the pathophysiology (cellular or antibody-
mediated).64  
Hyperacute rejection occurs within minutes to hours after kidney 
transplantation and is mediated by preformed DSAs as a result of a previous 
transplant, blood transfusion or pregnancy.65 It is characterized histologically by 
severe endothelial injury and vessel thrombosis.65 When it occurs, the transplanted 
kidney usually cannot be salvaged and graft nephrectomy is indicated in most cases. 
Nowadays, hyperacute rejection can usually be prevented by testing for preformed 
DSAs before transplantation.66  
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Acute rejection is the most common form of rejection and occurs in 10-25% 
of patients within the first year after kidney transplantation.67 Not all acute rejection 
episodes have the same risk for renal graft failure. Factors such as severity, number 
of acute rejections and degree of recovery of kidney function to baseline after 
treatment, all affect the long-term outcome.68, 69 Acute rejection can be either TCMR 
or ABMR. Acute TCMR is caused by a cytotoxic T cell reaction directed against HLA 
of the transplanted kidney and is the most common type of acute rejection. The key 
pathological findings in acute TCMR are infiltration of the donor kidney by T cells 
which can affect different compartments of the donor kidney. Histopathology is 
characterized by interstitial infiltration of lymphocytes which invade renal tubules 
(tubulitis) and cause interstitial edema.70, 71 In severe cases, arterial subendothelial 
mononuclear cell infiltration is seen (arteritis). Examples of the histopathological 
features of acute TCMR are shown in Figure 4. 
Acute ABMR (or active ABMR) occurs most commonly within the first weeks 
after transplantation and is caused by preformed DSAs.72 Acute ABMR occurs in 
approximately 1% to 10% of all kidney transplant recipients and up to a third of pre-
sensitized recipients may develop acute ABMR after transplantation.72, 73 The 
diagnosis of ABMR requires three components: (1) histologic evidence of acute tissue 
injury, (2) evidence of current / recent antibody interaction with vascular 
endothelium, i.e. C4d staining of endothelial cells of the peritubular capillaries (PTCs) 
and medullary vasa recta and/or peritubular capillaritis, and (3) detection of DSAs.31 
Histopathology is characterized by endothelial injury in the form of endothelial cell 
swelling, neutrophil infiltration in the glomeruli (glomerulitis) and PTCs, interstitial 
edema and fibrin thrombi.70, 74 Examples of the histopathological features 
characteristic of acute ABMR are shown in Figure 5. 
Detection of the complement split product C4d in renal allograft biopsies is 
an important marker of ABMR (Figure 5C). C4d staining in the microcirculation in 
kidney transplants with ABMR was first described by Feucht et al.51, 75 C4d is a 
degradation product of the complement factor C4 which is a component of the 
classical and lectin pathways. The activation of C4 generates C4b which is then 
cleaved into C4c and smaller fragments such as C4d. Because C4d forms an internal 
thioester bond with the endothelial surface it can covalently bind to the endothelium, 
where it remains for several days to weeks. Therefore, it is a durable marker of local 
complement activation.76-78 C4d positivity of the PTCs in cases of ABMR is found to 
be a specific marker of the interaction of DSAs with the endothelium of the renal 
microcirculation and is associated with poor kidney transplant survival.79-82 
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Nowadays, C4d staining of the PTCs is a well-established feature of ABMR. Most 
centers have incorporated routine C4d staining by either immunohistochemistry 
(IHC) or IF in the diagnostic pathologic evaluation of renal allograft biopsies.  
 
 
Figure 4. Representative micrographs illustrating the main histological features of acute T cell-
mediated rejection; (A) infiltration of mononuclear cells in the interstitium (H&E, magnification 
100x) and (B) tubules (tubulitis) (PAS+, magnification 200x). (C) In higher grade TCMR, 
inflammation in the arteriolar walls is observed (PAS+, magnification 200x). 
 
 
Figure 5. Representative micrographs illustrating the main histological features of antibody-
mediated rejection; (A) infiltration of inflammatory cells in the glomeruli (glomerulitis) (H&E+, 
magnification 400x) and (B) peritubular capillaries (peritubular capillaritis) (PAS+, 
magnification 400x). (C) Immunohistochemistry showing linear staining of C4d in peritubular 
capillaries (magnification 200x). 
 
Despite this, C4d staining in the PTCs in ABMR lacks sensitivity and specificity 
and there is strong evidence that DSAs can induce ABMR in the absence of C4d 
deposition.83-85 This has led to the inclusion of C4d-negative ABMR in the 2013 Banff 
Classification.86 The requirement of the detection of DSAs to diagnose ABMR is also 
subject of debate. ABMR is usually mediated by DSAs against HLA class I or class II 
proteins but evidence of ABMR in the absence of anti-HLA antibodies suggests the 
A B C
BA C
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existence of non-anti–HLA antibodies.87 For example, antibodies against the 
angiotensin type 1 receptor have been associated with ABMR but the clinical 
implications of such antibodies remains unclear.88, 89 
 Chronic rejection can occur within months to years after transplantation. Up 
to 40% of transplanted kidneys are lost within 10 years as a result of chronic 
rejection.71, 90 Chronic rejection can be subdivided in chronic-active TCMR (c-aTCMR) 
and chronic-active ABMR (c-aABMR). c-aTCMR may be manifest in the 
tubulointerstitial compartment as well as in the vascular compartment. Updated 
criteria for c-aTCMR were included in the 2017 Banff Classification.31 Data showed 
that inflammation within areas of interstitial fibrosis and tubular atrophy (i-IFTA) is a 
consequence of chronic under-immunosuppression and previous acute TCMR.91 
Therefore, it was suggested that moderate i-IFTA plus moderate or severe tubulitis 
can represent c-aTCMR in the tubulointerstitial compartment.31  
Chronic rejection is most often caused by c-aABMR resulting from the 
development of the novo DSAs. c-aABMR develops through a number of stages 
which cause chronic allograft injury. The diagnosis of c-aABMR requires histologic 
evidence of chronic tissue injury, C4d staining of PTCs and the presence of DSAs.31 
Chronic tissue injury is histologically characterized by chronic transplant 
vasculopathy, transplant glomerulopathy (TG) and peritubular capillary basement 
membrane multilayering.92, 93 TG is characterized by pathological abnormalities of 
double contouring or multi-layering of the glomerular basement membrane and is 
often associated with a decline in renal function and poor outcome (Figure 6).94 
 
Figure 6. Representative micrographs illustrating transplant glomerulopathy; (A) histology 
showing patent capillary loops with thickened basement membrane with duplication (Jones, 
magnification 400x) and (B) electron microscopy showing reduplication of the basement 
membrane (magnification 4400x). 
BA
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5.  Calcium oxalate depositions 
 
Delayed graft function (DGF) is usually defined as impaired renal function 
with the need for dialysis in the first week after kidney transplantation.95 It is a 
complication of primary concern in patients with a renal allograft from a deceased 
donor, occurring in approximately 20% to 50% of these cases.96, 97 DGF is generally 
the consequence of acute tubular necrosis (ATN) caused by IRI.98 It is strongly 
associated with a higher risk of acute rejection, which is presumably caused by IRI 
and the following inflammatory response with increased expression of cytokines and 
HLA molecules. Changes in maintenance immunosuppressive therapy, specifically 
calcineurin inhibitor (CNI) use, during a period of DGF can increase the chance of an 
acute rejection.99-101  Also, DGF is associated with inferior graft outcome.100, 102 
Different risk factors for DGF have been described including donor characteristics 
(donor age, donor type (deceased versus living) and the presence of hypertension 
and/or diabetes mellitus), recipient characteristics (immunological response, 
immunosuppressive medications) and conditions of organ retrieval (cold and warm 
ischemia time).102, 103 The causative pathway resulting in DGF is often multifactorial 
and there are still many controversies about the most important factors associated 
with DGF.104 Patients suspected of DGF are often biopsied after several days to 
exclude concomitant acute rejection in addition to ATN.105 
Recently, the histological presence of calcium oxalate (CaOx) was suggested 
as a possible cause of impaired renal function in the early post-transplantation 
period.106, 107 Oxalic acid is the end-product of different metabolic pathways and is 
predominantly excreted by the kidney.108 When kidney function declines, oxalic acid 
elimination by the kidneys is impaired and the oxalic acid plasma concentration rises. 
High plasma oxalic acid concentrations are therefore observed in patients with 
ESRD.109-111 Neither hemo- nor peritoneal dialysis can remove sufficient amounts of 
oxalic acid to normalize the oxalic acid plasma concentrations in patients with 
ESRD.112, 113 After kidney transplantation, a large amount of oxalate is excreted by the 
newly-functioning kidney.114 Urine may then become supersaturated with oxalate, 
resulting in the formation of CaOx crystals which can accumulate in the renal 
tubules.115 These CaOx crystals attach to the renal tubular cells and can cause 
damage the tubular cells.116, 117 Whether CaOx deposition may be a cause of impaired 
renal function in the early post-transplantation period will be examined in this thesis.  
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6. C3 glomerulopathy 
 
The complement system is not only important in the field of renal 
transplantation but also plays a role in various primary kidney diseases. C3 
glomerulopathy is a rare form of glomerulonephritis and includes both C3 
glomerulonephritis (C3GN) and dense deposit disease (DDD). It is caused by 
uncontrolled activation of the alternative complement pathway.118 When the 
alternative complement pathway becomes activated, C3 is split into C3a and C3b by 
C3 convertase. C3b reacts with other components of the complement cascade 
leading to the formation of the MAC, which induces localized cell injury and 
inflammation. Degradation of C3b leads to the formation of C3c and the end product 
C3d.71, 119, 120 These C3 fragments get trapped in the glomeruli causing damage to the 
kidney.121, 122   
C3 glomerulopathy can display a range of features on LM and EM. The most 
significant feature is the finding of C3 deposits in the glomeruli by IF. In 2013, the 
definition of C3 glomerulopathy was defined by the presence of dominant C3 
staining with a staining score being at least two orders of magnitude greater than 
the other stainings (IgA, IgM, IgG and C1q).122, 123 In most laboratories, C3 is detected 
by IF using an antibody to C3c, one of the breakdown products of activated C3.122, 
124 Kidney transplantation is performed in more than 50% of patients with C3 
glomerulopathy who have developed ESRD. Unfortunately, C3 glomerulopathy often 
recurs after kidney transplantation and the median time of transplant survival is 
around five years.125-127 
 
7. Aims of this thesis 
 
The overall objective of the research described in this thesis was to evaluate 
potentially important diagnostic and prognostic pathological features of renal 
(transplant) biopsies. Histological features and immunohistochemical and molecular 
markers in renal biopsies were investigated.  
 
• A kidney biopsy is considered the gold standard for transplant pathology 
evaluation and it is vital that renal tissue is stored in a fashion that maximizes 
tissue preservation. Optimal cutting temperature (OCT) compound is often 
used for embedding tissue for snap-freezing. However, analysis by mass 
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spectrometry is difficult due to polymers in the OCT. Chapter 2 focusses on 
the use of Cryo-Gel as embedding compound for snap-freezing of renal 
biopsies in order to optimize protein extraction for mass spectrometry 
without impairing diagnostic analysis. 
 
• In Chapter 3 a retrospective analysis was performed in which the incidence 
of CaOx deposition in the renal transplant biopsy in the immediate post-
operative phase was investigated. It was hypothesized that CaOx deposition 
in the renal allograft is recipient-derived and impairs renal transplant 
recovery.  
 
• The innate immune system plays an important role in the immediate post-
transplantation period. Chapter 4 presents a study in which we investigated 
the expression of TLRs, complement- and apoptosis-related genes in pre-
implantation biopsies and in biopsies from patients with acute rejection and 
whether these genes can predict long-term allograft survival.  
 
• C4d staining in the PTCs is a well-established feature of c-aABMR. However, 
the relevance of C4d staining in other components of the renal allograft 
biopsy, in particular of the arterioles, is unclear. Chapter 5 describes the 
significance of arteriolar C4d staining by IHC in patients with suspicious and 
diagnostic c-aABMR.  
 
• C3-dominance by IF is a defining feature in the diagnosis of C3 
glomerulopathy. However, clear-cut cases of C3 glomerulopathy not 
fulfilling the consensus criteria have been observed in both native renal 
biopsies and transplant renal biopsies. In Chapter 6 it was hypothesized that 
C3d by IHC would be a more sensitive marker for the diagnosis of C3 
glomerulopathy than C3c. 
 
• Chapter 7 is a general summary and discussion of the research performed 
in this thesis. Chapter 8 describes the future perspectives. 
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Abstract 
 
Optimal preservation and biobanking of renal tissue is vital for good diagnostics and 
subsequent research. Optimal cutting temperature (OCT) compound is a commonly 
used embedding medium for freezing tissue samples. However, due to interfering 
polymers in OCT, analysis as mass spectrometry (MS) is difficult. We investigated if 
the replacement of OCT with Cryo-Gel as embedding compound for renal biopsies 
would enable proteomics and not disturb other common techniques used in tissue 
diagnostics and research. For the present study, fresh renal samples were snap-
frozen using Cryo-Gel, OCT and without embedding compound and evaluated using 
different techniques. In addition, tissue samples from normal spleen, skin, liver and 
colon were analyzed. Cryo-Gel embedded tissues showed good morphological 
preservation and no interference in immunohistochemical or immunofluorescent 
investigations. The quality of extracted RNA and DNA was good. The number of 
proteins identified using MS was similar between Cryo-Gel embedded samples, 
samples without embedding compound and OCT embedded samples. However, 
polymers in the OCT disturbed the signal in the MS, while this was not observed in 
the Cryo-Gel embedded samples. We conclude that embedding of renal biopsies in 
Cryo-Gel is an excellent and preferable alternative for OCT compound for both 
diagnostic and research purposes, especially in those cases where proteomic analysis 
might be necessary. 
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1. Introduction 
 
 A renal biopsy is often necessary to make a diagnosis in various disease 
settings affecting both native and transplant kidneys. Biobanking of clinically 
indicated kidney biopsies is an optimal reservoir for research purposes which is of 
great importance in understanding the underlying pathophysiology in many kidney 
diseases.1, 2 For future studies it is vital that renal tissue is stored in a fashion that 
maximizes tissue preservation which is crucial for the quality of RNA, DNA and 
protein retrieval, without interfering with diagnostic evaluation.  
Proteomic analysis by mass spectrometry (MS) has been proven to be a 
powerful tool in the diagnosis and investigation of many kidney diseases.3 MS is an 
analytical technique for protein assessment to identify and quantitate molecules 
based on their mass-to-charge of gas-phase ions. With the use of MS direct analysis 
of complete sets of proteins in a given tissue sample could be obtained.4 This could 
help us in the identification of disease specific proteins in kidney tissue and to better 
understand the pathogenesis of kidney diseases. For example, MS is used as an 
ancillary tool for typing of amyloidosis and is used to confirm and identify 
immunoglobulins in immune-complex mediated proliferative glomerulonephritis 
and complement factors in complement mediated proliferative glomerulonephritis.5, 
6 Furthermore, the finding of disease specific proteins could lead to diagnostic and 
prognostic biomarkers for disease diagnosis and new therapeutic interventions.7, 8  
Renal biopsies are often either fixed in formalin and then embedded in 
paraffin or fresh snap frozen. It is a challenge to perform proteomic analysis on 
formalin-fixed paraffin-embedded (FFPE) tissue due to the formation of both intra- 
and intercellular crosslinking between proteins.9,-11 MS analyses perform best on 
proteins extracted from fresh snap frozen tissue. Since frozen tissue without 
embedding compound is difficult to cut an embedding medium is often used.  
Currently the most common medium in which biopsy material is snap frozen 
is optimal cutting temperature (OCT) compound, a cryopreservative medium 
composed of polyethylene glycol (PEG), polyvinyl alcohol (PVA) and nonreactive 
ingredients.12 OCT stabilizes tissue allowing easy positioning of tissue samples in the 
microtome. Since the consistency of frozen OCT is more or less the same as the 
frozen tissue sample and since OCT provides a smooth cutting surface, the quality of 
sectioning is good. Furthermore, OCT is effective in preserving morphologic and 
immunohistochemical characteristics.4, 12 Unfortunately, OCT medium also has 
disadvantages. MS analyses of OCT embedded tissue is difficult due to the presence 
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of water soluble synthetic polymers. The interference of these polymers in the MS 
analysis causes suppression of ion formation.9 In addition, the presence of high 
polymer peaks of OCT in the mass spectra may hide other smaller peaks.13 It is 
therefore vital that OCT is removed from samples before MS analysis is performed 
which is a complex and time-consuming procedure resulting in a lower protein 
yield.9, 12, 14, 15 
Cryo-Gel, a possible alternative embedding medium for OCT, is a highly 
viscous, biodegradable and completely water-soluble medium. Cryogels are 
polymeric gels formed after freezing of the solvent (most often water). They are 
known to be of significant interest in various areas and are often used in tissue 
engineering and biotechnology.16, 17 In the current study we investigate the feasibility 
of Cryo-Gel for snap freezing of renal biopsies in routine diagnostics and subsequent 
research analysis. In addition, Cryo-Gel embedded tissue samples from normal 
spleen, skin, liver and colon were analyzed. 
 
2. Methods 
 
 Fresh samples of normal renal cortex were obtained within 2 hours after 
surgery from a 46-year-old male who had a total kidney resection due to a renal 
malignancy. Samples were snap frozen using either Cryo-Gel embedding medium 
(Leica, Surgipath, the Netherlands), Tissue-Tek OCT Compound (Sakura Finetek, the 
Netherlands) or no embedding compound. The quality of tissue histology, EM, DNA, 
RNA and proteins was evaluated (Figure 1). In addition, fresh samples from normal 
spleen, skin, liver and colon from surgical resections due to malignancies were 
collected. These tissues were snap frozen using Cryo-Gel, OCT and no compound. 
The quality of tissue histology, DNA, RNA and proteins was evaluated in these tissues. 
For each medium two samples were embedded. For renal tissues, the experiments 
were performed in duplicate. In addition, a section of a renal biopsy from a patient 
with known lupus nephritis was used to evaluate the quality of immunofluorescence 
(IF) on Cryo-Gel embedded tissue. 
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Figure 1. Flowchart showing the work-up protocol performed on normal tissue samples from 
kidney, spleen, skin, colon and liver. Samples were embedded in either Cryo-Gel, OCT or 
without compound. 
*Two samples were embedded from the different tissues for each embedding medium. For 
the renal tissues, the additional performed techniques were all performed in duplicate. 
**H&E was performed on all tissue samples. PAS, Jones, Trichrome and immunohistochemistry 
for AE1/AE3 and CD31 were performed on the renal samples. PAS, Trichrome, Sirius Red and 
Iron stain were performed on the liver samples.  
***EM was only performed on the renal samples. 
 
2.1 Cryosectioning 
 Tissue samples were placed in a cryomold and covered with either Cryo-Gel, 
OCT or no compound and immersed in cold isopentane with liquid nitrogen until 
snap-frozen. After solidification, the cryomolds were removed and tissues were 
stored at −80 °C until cryosectioning. Routine cryosectioning was performed using a 
cryostat (Leica CM 1950, Netherlands) at −20 °C. For the renal tissues, the 
experiments were performed after 9 months of storage. For all other tissue samples, 
the experiments were performed within a week after snap-freezing. For those tissues 
frozen without embedding compound, a small drop of NaCl was used to mount the 
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tissue sample on the cryostat microtome object holder to keep the tissue in place. 
Four micrometer cryostat sections were cut from the samples frozen with Cryo-Gel, 
OCT and without compound in a cryostat (Leica CM 1950, Netherlands) and 
subsequently stained with hematoxylin and eosin (H&E) and evaluated by light 
microscopy. 
 
2.2 RNA 
 Five 10 μm cryostat sections from the tissue samples frozen with Cryo-Gel, 
OCT and without embedding compound were cut to analyze the quality and quantity 
of the RNA. The cryostat sections were placed in 700 μL Qiazol (Qiagen, Germany). 
The tissue sections were disrupted by shaking the tubes vigorously for about 5 sec. 
Total RNA was isolated according to the protocol of the miRNeasy mini kit (Qiagen, 
Germany). RNA samples were subsequently placed on ice for approximately 30 min 
prior to RIN measurement with the Bioanalyzer (Agilent RNA 6000 Nano kit, Agilent 
Technologies, Germany).18 A RIN value of ≥6.5 was used as a cut-off for good RNA 
quality.19, 20 
 
2.3 DNA 
 Five cryostat sections of 10 μm from the tissue samples frozen with Cryo-
Gel, OCT and without embedding compound were cut and placed into individual 
eppendorf vials. Proteinase K (7.5 AU, Qiagen, Germany) was added to all the samples 
and left for protein digestion at 56 °C. Then, the samples were placed at 95 °C for 10 
minutes for proteinase K deactivation and spun down at 14,000 RPM for 5 minutes. 
 For subsequent DNA quality assessment, we applied multiplex PCR on 
isolated DNA from the samples embedded in Cryo-Gel, OCT and without compound. 
PCR was performed using the following primers: TBXAS1//X9U, forward PCR, GCC 
CGA CAT TCT GCA AGT CC; reversed PCR, GGT GTT GCC GGG AAG GGT T (PCR 
product of 100 bp); RAG1/ X2U, forward PCR, TGT TGA CTC GAT CCA CCC CA; 
reversed PCR, TGA GCT GCA AGT TTG GCT GAA (PCR product of 200 bp); PLZF/X1U, 
forward PCR, TCG GAT GTG GTC ATC ATG GTG; reversed PCR, CGT GTC ATT GTC GTC 
TGA GGC (PCR product of 300 bp) and AF4/X11U, forward PCR CCG CAG CAA GCA 
ACG AAC C and reversed PCR GCT TTC CTC TGG CGG CTC C (PCR product of 400 
bp). PCR was performed in 15 μl reaction volumes containing 4.5 μl H2O, 7.5 μl 
KAPA2G HotstartReadymix, 1 μl each of forward and reverse primer with 
concentration of 100 ng/μl and 1 μl DNA. Cycling conditions were 3 min at 95 °C for 
initial denaturation, 35 cycles each with 15 sec at 95 °C, 15 sec at 60 °C and 15 sec at 
Cryo-Gel embedding compound | 41 
72 °C for denaturation, annealing and extension, and a final elongation step of 7 min 
at 72 °C. This was followed by electrophoresis on agarose gel (1%) in Tris Broom 
EDTA (TBE) to analyze the bands of the corresponding PCR products. 
 
2.4 Proteomics 
 In the renal samples, frozen tissue in Cryo-Gel and without compound was 
processed for proteomic analyses. In the other tissue samples (spleen, skin, liver and 
colon), proteomics was performed on the Cryo-Gel embedded samples, samples 
without compound and the OCT embedded tissue. Ten cryostat sections of 5 μm 
from the tissue samples were processed into 100 μl digestion buffer containing 0.1% 
Rapigest (Waters, United States) in 50 mM ammonium bicarbonate (Sigma Aldrich, 
Netherlands) and was lysed through sonication at 70% amplitude. Proteins were 
incubated at 60 °C for 30 minutes after reducing with a 100 mM dithiothreithol 
solution (Sigma Aldrich, Netherlands), and alkylated with a 300 mM iodoacetamide 
solution (Sigma Aldrich, Netherlands) at room temperature and in darkness for 30 
min. Then trypsin (600 ng/sample, Promega) was added and samples were digested 
overnight at 37 °C. The digested samples were then acidified with trifluoroacetic acid 
(Sigma Aldrich, Netherlands) to a final concentration of 0.5%, and spun down at 
14,000 RPM for 30 minutes. Supernatants were collected and transferred to a LC glass 
vial for further LC-MS measurement. Digested proteins were separated on a nano-
LC (Ultimate 3000, Thermo Fisher Scientific, Germany) equipped with a reverse phase 
analytical column (PepMap C18, 75 μm ID 15 cm, 3 μm particle size and 100 Å pore 
size, Thermo Fisher Scientific, Netherlands) and peptides were eluted with the 
following gradient of solvent A and B: 4% to 38% of solvent B in 90 minutes. Solvent 
A consists of 0.1% aqueous formic acid in water and solvent B consists of 80% 
acetonitrile and 0.08% aqueous formic acid.  
MS measurements were performed on a LTQ Orbitrap XL. For electro-spray 
ionization (ESI), nano ESI emitters (New Objective, United States) were used and a 
spray voltage of 1.5 kV was applied. For MS detection a data-dependent acquisition 
method was used: a high resolution MS scan from 400 to 1600 Th was performed in 
the Orbitrap, resolution 30.000, lock mass was set to 445.120025 Th (protonated 
(Si(CH3)2 O)6). Based on this MS scan, most intense ions were consecutively isolated 
and fragmented with a ‘Top five’ setting. After selection ions were placed on a 
dynamic exclusion list for 3 min. Settings for MS/MS fragmentation were: 30 ms 
maximal fill time; isolation width of 2.0 m/z; fragmentation by collision induced 
dissociation (CID) applying 35% normalized collision energy; detection of fragment 
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ions in the linear ion trap. After precursors were selected for MS/MS, they were 
excluded within a tolerance range of 10 ppm for further MS/MS analysis for 1 min. 
To calculate the number of identified proteins and peptides we used Scaffold 
(version 4.8.4, Proteome Software Inc., United States). Filter criteria for protein 
identification were set to >99% protein probability and >99% peptide probability. 
Proteins that were associated with ≥1 peptides were included. The mean number of 
proteins identified in samples embedded in Cryo-Gel, OCT and without compound 
were calculated. Furthermore, the sum of all different proteins in each category was 
calculated in the renal samples. 
 
2.5 Formalin-fixed paraffin embedded tissue 
 Half of each snap-frozen tissue sample embedded in Cryo-Gel, OCT and 
without embedding compound was subsequently processed for FFPE. Frozen tissue 
samples were thawed in formalin and after fixation, the tissue was dehydrated, 
cleared and infiltrated with melted paraffin wax. After solidification, 4 μm sections 
were cut and stained according to routine diagnostic practice for H&E. For the renal 
tissue, 2 μm sections were cut and subsequently stained by H&E, periodic acid–Schiff 
(PAS), Jones and Trichrome. In addition, immunohistochemical stainings for AE1/AE3 
and CD31 were performed on the renal tissue to asses if snap freezing in different 
medium effects immunohistochemical staining. On the liver samples, PAS, Trichrome, 
Sirius Red staining and Iron staining were performed. The staining protocols are 
described in the Supplementary Methods. All slides were microscopically evaluated 
by three pathologists (MS, MD and MCvG). The quality of the different stainings was 
assessed by comparing the intensity of staining in both the cytoplasm and nuclei. 
Also, the degree of background staining was compared. The OCT embedded samples 
were used as golden standard. 
 
2.6 Electron microscopy 
 The remaining tissue of snap-frozen kidney samples were processed for 
transmission EM. Semi-thin (1 μm) survey sections were stained with toluidine blue 
and investigated for the presence of glomeruli. Ultra-thin (40 nm–60 nm) sections 
were cut, mounted on copper grids and contrasted with uranyl acetate and lead 
citrate. The sections were examined using a Morgagni 268D EM microscope (Thermo 
Fisher Scientific, United States). EM quality was assessed by two pathologists (MS 
and MCvG) by evaluating different structures; glomerular basement membrane (e.g. 
thickness, double contours, splitting), podocytes (effacement of podocyte foot 
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processes), endothelium (swelling, loss of fenestration, tubuloreticular inclusions) 
and depositions (subepithelial, intramembranous, subendothelial, mesangial). 
 
2.7 Immunofluorescence 
 To determine the effects of Cryo-Gel on IF, a biopsy sample of cortical renal 
tissue from a patient with known lupus nephritis was split. One half was embedded 
in OCT and the other half in Cryo-Gel. Three micrometer sections were cut and IF was 
performed for IgG, IgA, IgM, C3c, C1q, kappa and lambda according to standard 
diagnostic routine for both embedding compounds. The quality of the different 
stainings was assessed by two pathologists (MS and MCvG) by comparing the 
structures were deposition was observed, the pattern of staining (linear, granular) 
and the intensity of staining. The OCT embedded sample was used as golden 
standard. 
 
2.8 Statistical analysis 
 SPSS Statistics version 24.0 was used (IBM SPSS Statistics for Windows. 
Armonk, NY:IBM Corp.). The One-way Anova was used to compare RIN values, RNA 
concentration and the number of proteins and peptides between the different 
embedding compounds. Differences with a (two sided) p-value ≤ 0.05 were 
considered statistically significant. 
 
2.9 Medical ethics 
 The study protocol was consistent with international ethical and professional 
guidelines. The use of anonymized rest material is regulated under the code for 
proper secondary use of human tissue in the Netherlands. The local medical ethics 
committee of the Erasmus MC, University Medical Center Rotterdam, Rotterdam, The 
Netherlands, approved that our study is exempt from the requirement for approval 
(MEC-2016-350). Informed consent to the use of medical record data and rest 
material was waived in accordance with the Dutch regulations. 
 
3. Results 
 
 The work-up protocol was performed on normal tissue samples embedded 
in either Cryo-Gel, OCT or without compound (Figure 1). Sections of both Cryo-Gel 
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and OCT embedded samples were easily cut. However, samples snap-frozen without 
embedding compound were less stable and therefore less easily cut. 
 
3.1 Histology, histochemistry and immunohistochemistry 
 Tissue morphology of H&E stained frozen sections and histochemistry and 
immunohistochemistry on sections of frozen samples converted to FFPE material 
showed good results in all methods of embedding (Figure 2 and Supplementary 
Figure 1). No differences in background staining were observed. However, OCT 
embedded tissue showed more eosinophilic cytoplasm in the liver and spleen tissue 
samples and the nuclei were darker in the renal tissue samples in the H&E staining. 
 
Figure 2. H&E, Jones, PAS, CD31, Trichrome and AE1/AE3 staining on frozen renal tissue 
samples embedded in Cryo-Gel, OCT and without compound converted to FFPE material 
(magnification 20x). 
 
3.2 RNA 
 RNA analysis was performed in duplicate on both renal samples for each 
embedding method. In the renal tissues, the Cryo-Gel samples showed a mean RNA 
concentration of 289.8 ng/μl. In the OCT embedded samples and the samples 
without compound the mean RNA concentration was 210.0 ng/μl and 192.5 ng/μl 
respectively. No significant differences between RNA concentrations were measured 
between the different embedding methods (p = 0.094) in the renal samples. A mean 
RNA Integrity Number (RIN) of 9.43 ± 0.13, 9.08 ± 0.43 and 8.83 ± 0.22 was found 
for the renal samples embedded in Cryo-Gel, OCT and without compound, 
respectively (Figure 3). No significant difference was found between the RIN value in 
the Cryo-Gel and OCT embedded samples (p = 0.167). Interestingly, a significant 
higher RIN value was observed in the Cryo-Gel embedded samples compared to 
samples without compound (p = 0.003). 
Cryo-Gel
OCT
No compound
H&E PASJones CD31 Trichrome AE1/AE3
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Skin, colon and liver tissues showed good RIN values in all different 
embedding compounds. Only the spleen tissue samples showed lower RIN values in 
all embedding compounds. In one of the skin samples without compound no RIN 
value could be detected while the other skin samples showed a good RIN value 
(Supplementary Table 1). 
 
 
Figure 3. Mean RIN values for samples embedded in Cryo-Gel, OCT and without compound. 
 
3.3 DNA 
 DNA analysis using PCR was performed in duplicate on the renal samples for 
each embedding method. All samples showed products at 400, 300, 200 and 100 bp 
representing a good quality of DNA in the kidney samples (Figure 4). Skin, colon and 
liver tissue samples all showed signals up to 400 bp. The spleen samples showed 
products up to 300 and 400 bp (Supplementary Table 2). 
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Figure 4. PCR results of Cryo-Gel samples (lane 1–4), OCT samples (lane 5–8) and samples 
without compound (lane 9–12) showing a product at 400, 300, 200 and 100 bp. All experiments 
included a positive control (P) and a negative water control (W). 
 
3.4 Proteomics 
 Quantitative proteomic data from Cryo-Gel embedded renal tissues were 
compared to data from renal tissues without compound. The MS results showed no 
detectable polymers in both the Cryo-Gel samples and the samples without 
compound. A mean of 412 ± 64 proteins was identified in the Cryo-Gel samples and 
451 ± 59 in the samples without compound (p = 0.398). In the Cryo-Gel samples 558 
different proteins were identified versus 568 proteins in samples without compound. 
Four-hundred-seventy of the identified proteins were present in both groups (Figure 
5). A mean of 2397 ± 97 peptides was identified in the Cryo-Gel samples and 3019 
± 59 in the samples without compound (p = 0.066). In Cryo-Gel samples 2903 
different peptides were observed versus 3738 peptides in samples without 
compound (Figure 5). 
The identified proteins were categorized by their cellular compartment and 
biological function using gene ontology (GO) software. Virtually identical 
percentages of proteins were identified in the different categories of Cryo-Gel 
samples and samples without compound (Supplementary Figure 2). 
 In tissue samples from spleen, liver, skin and colon, no differences between 
protein and peptide identification were observed between the different embedding 
methods (Supplementary Table 3). Polymers were found in the MS results from the 
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OCT embedded samples, but not in the Cryo-Gel embedded samples. These 
polymers can be observed as repeating peaks in the MS (Figure 6) and disturb the 
MS signal.  
 
Figure 5. Venn diagram showing the number of different proteins (A) and peptides (B) 
identified by mass spectrometry and overlap between the samples embedded with Cryo-Gel 
and without compound. 
 
3.5 Electron microscopy 
 Electron microscopy (EM) analysis on previously snap-frozen Cryo-Gel 
embedded renal samples showed well-preserved material. The results were similar 
to OCT embedded samples and samples without tissue compound (Figure 7). All 
samples showed well preserved podocytes and no depositions were observed. No 
differences in glomerular basement membrane thickness were found and no double 
contours were observed. The endothelium showed normal fenestration in all the 
three embedding methods. 
 
3.6 Immunofluorescence 
 IF was performed on renal tissue from a patient with known lupus nephritis 
and showed similar results for Cryo-Gel and OCT embedded tissue. The intensity of 
the IF stainings was good in both the Cryo-Gel and OCT embedded renal tissue. No 
differences in staining pattern were observed between the renal samples embedded 
in Cryo-Gel and OCT. Intense granular membranous staining was seen for IgG. 
Moderate granular membranous staining was seen for IgA, IgM, C3c, C1q, kappa, 
and lambda (Figure 8). 
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Figure 6. Mass spectra from liver samples embedded in OCT, Cryo-Gel and without compound. 
The summed spectra at 80–90 minutes show repeating polymer peaks in the OCT embedded 
samples disturbing the signal, but not in the samples embedded in Cryo-Gel and without 
compound. 
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Figure 7. Electron microscopy for samples embedded with Cryo-Gel, OCT and without 
compound. Left: glomerular filtration membrane (magnification 4400x); middle: higher 
magnification of glomerular filtration membrane (magnification 7100x); right: peritubular 
capillary (magnification 7100x, 4400x and 5600x, respectively). Scale bar = 2 μm. 
 
 
 
Figure 8. Immunofluorescence staining for IgG, IgM, IgA, C3c, C1q, kappa and lambda from 
renal cortex form a patient with lupus nephritis embedded in Cryo-Gel and OCT compound 
(magnification 20x; scale bar = 50 μm). 
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4. Discussion 
 
 Adequate biobanking of renal biopsies is necessary for diagnostics and 
subsequent research.1 The issues that have to be considered regarding proteomics 
are the quality and quantity of the proteins that can be extracted. OCT is widely used 
for embedding tissue for snap-freezing, however it is not ideal for MS due to 
interfering polymers (e.g. PVA and PEG) in the OCT.9, 13 Therefore, we investigated 
the use of Cryo-Gel as embedding compound. This study shows that Cryo-Gel can 
be used without any technical problems in MS, which is a big advantage when 
compared to OCT compound.  
 Research in kidney proteomics is a fast moving area and has mainly been 
focused on urine due to non-invasiveness.21-23 However, using urine as sample source 
it is not possible to link the expressed proteins in kidney disease to their specific site 
of production and they might even originate from outside the kidney. The 
performance of proteomics on renal tissue itself allows for investigation of proteins 
within the affected kidney compartments.3 This can be optimized using laser capture 
microdissection (LCM) in combination with MS. With LCM, areas of interest, such as 
glomeruli, interstitium or tubuli can be isolated by cutting away the surrounding 
tissue, making it easier to evaluate protein profiles in specific structures.6, 24  
 Protein extraction of samples embedded in Cryo-Gel was feasible and Cryo-
Gel showed no interference in MS analysis. In renal samples, the number of proteins 
identified in Cryo-Gel embedded tissue was comparable to tissue without compound 
with a high overlap of identified proteins, although there were slightly fewer peptides 
identified (NS).  
 MS on OCT embedded tissue was performed on spleen, skin, colon and liver 
samples. In these tissue samples, the number of proteins detected was not significant 
different between the Cryo-Gel and OCT embedded tissues and the tissues without 
compound. Although, polymers were detected in the MS data from the OCT 
embedded samples and not in the Cryo-Gel embedded samples. The polymers in the 
OCT embedded tissue suppress other signals in the MS.9, 13  
 In the present study, the MS data is obtained on an older type of mass 
spectrometer which is slower compared to the newest generation of MS equipment. 
The polymers mainly suppress lower abundant signals in the samples which are, 
because of the speed of the used instrument, probably not sequenced. This could be 
a potential explanation for the fact that no difference in the amount of protein 
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identifications is observed even while the polymer signal is clearly present in the 
acquired spectra.  
 The polymers in OCT are very hydrophobic and have a strong interaction 
with the C18 stationary phase of the MS columns. Stringent washing steps of the 
columns are required to remove these polymers from the columns. A portion of the 
polymers may even bind irreversibly and effect the lifetime and the separation 
performance of the columns considerably. The performance of MS analysis on OCT 
embedded tissue samples is therefore discouraged. We recommend the use of Cryo-
Gel embedding compound to not exclude the possibility of MS analysis.  
 Methods to remove OCT from the tissue samples before protein extraction 
and MS have been described.10, 25 Recently, Vrana et al. described an optimized 
method to extract proteins from OCT embedded tissue samples.12 They removed the 
excess of frozen OCT compound around the kidney tissue samples before thawing 
the tissue. Then diethyl ether/methanol extraction was performed to remove the 
remaining of OCT. To decrease the risk of ion suppression by OCT in the MS analysis, 
a second cleaning step with methanol/chloroform/water extraction was added to the 
procedure. This shows that the removal of OCT from the tissue samples for MS 
analysis is a time-consuming procedure which takes multiple steps.  
 Unfortunately, the chemical compounds of Cryo-Gel are confidential. Since 
Cryo-Gel did not cause interference in MS analysis, we assume that Cryo-Gel does 
not contain polymers like those in OCT compound. It is also possible that Cryo-Gel 
only contains polymers that can be broken down in the preparation steps for 
proteomic analysis (trypsinization and digestion) and that therefore no problems in 
MS analysis are observed.  
 Tissue morphology and different stainings on the Cryo-Gel embedded 
samples showed similar results to tissue embedded in OCT and those without 
compound. Also, the quality of DNA was good in the different tissues and no major 
differences were observed between the different embedding compounds. RNA 
showed comparable yield in Cryo-Gel and OCT embedded tissues and tissues 
without embedding compound. No significant difference was observed between the 
RIN value in Cryo-Gel and OCT embedded renal tissues. Interestingly, renal tissue 
without embedding compound had a significantly lower RIN value, although the RNA 
was still of good quality. Spleen samples showed a lower RIN value in all different 
embedding methods compared to the other tissue types. This is probably caused by 
external conditions, such as changes in tissue temperature, causing RNA 
52 | Chapter 2 
degradation, for which spleen tissue is more sensitive than the other tissues that were 
used.  
 A limitation of the present study is the small number of tissue samples used 
for evaluation. However, different types of tissue were analyzed and different 
experiments to test the use of Cryo-Gel were performed. Furthermore, two samples 
of all different tissue types were obtained for each embedding compound and the 
experiments on the renal tissue samples were performed in duplicate. A vital issue 
for tissue biobanking for future research is the maintaining of protein stability over 
time. We show that Cryo-Gel compound has good protein preservation in renal 
tissue after 9 months of storage at −80 °C. Further research is necessary to analyze 
the protein stability of Cryo-Gel embedded tissue after a longer storage time.  
 We conclude that Cryo-Gel is an excellent compound for snap-freezing renal 
biopsies for both diagnostic and research purposes involving not only 
histomorphology and immunofluorescence, but also RNA, DNA and protein analysis. 
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Supplementary Files 
 
Table S1. RNA analysis in spleen, skin, liver and colon tissue. 
 Embedding compound RIN value RNA concentration (ng/µl) 
Spleen OCT 1 5,4 90 
  2 5,5 119 
 Cryo-Gel 1 5,1 297 
  2 5,1 357 
 No compound 1 5,4 163 
  2 5,3 259 
Skin OCT 1 8,5 11 
  2 9,9 51 
 Cryo-Gel 1 9,6 90 
  2 9,2 17 
 No compound 1 8 22 
  2 NA 3 
Liver OCT  1 8,9 47 
  2 8,6 24 
 Cryo-Gel 1 9 200 
  2 8,9 91 
 No compound 1 8,8 262 
  2 8,9 111 
Colon OCT 1 8,5 14 
  2 8,7 21 
 Cryo-Gel 1 7,1 10 
  2 10 26 
 No compound 1 8 17 
  2 9,7 10 
The RIN (RNA Integrity Number) and RNA concentration were measured in the spleen, skin, liver and colon 
tissue samples embedded in OCT, Cryo-Gel and without compound.  
NA = not available 
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Table S2. DNA analysis in spleen, skin, liver and colon tissue. 
  
OCT Cryo-Gel No compound 
     
DNA 
concentration 
(ng/ul) 
PCR  
 DNA 
concentration 
(ng/ul) 
PCR  
DNA 
concentration  
(ng/ul) 
PCR  
Spleen 1 33,1 
signal up 
to 400bp 26,0 
signal up 
to 300bp 42,3 
signal up 
to 400bp 
  2 35,7 
signal up  
to 400bp 54,0 
signal up 
to 300bp 36,2 
signal up 
to 300bp 
Skin 1 2,52 
signal up 
to 400bp 2,97 
signal up 
to 400bp 3,58 
signal up 
to 400bp 
  2 0,99 
signal up 
to 400bp 1,50 
signal up 
to 400bp 1,12 
signal up 
to 400bp 
Liver 1 10,5 
signal up 
to 400bp 16,5 
signal up 
to 400bp 17,1 
signal up 
to 400bp 
  2 9,4 
signal up 
to 400bp 15,7 
signal up 
to 400bp 14,0 
signal up 
to 400bp 
Colon 1 3,91 
signal up 
to 400bp 3,23 
signal up 
to 400bp 3,93 
signal up 
to 400bp 
  2 4,69 
signal up 
to 400bp 3,12 
signal up 
to 400bp 3,16 
signal up 
to 400bp 
PCR was performed on the spleen, skin, liver and colon tissue samples embedded in OCT, Cryo-Gel and 
without compound. DNA concentration and PCR signals were measured.  
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Table S3. Proteomic analysis in spleen, skin, liver and colon tissue. 
 
Embedding 
compound 
 Protein 
identification 
P Peptide 
identification 
P 
Spleen OCT 1 367 0.064 2214 0.187 
  2 370  2389  
 Cryo-Gel 1 388  2484  
  2 409  2655  
 No compound 1 370  2279  
  2 366  2419  
Skin OCT 1 73 0.866 678 0.683 
  2 64  562  
 Cryo-Gel 1 63  555  
  2 69  595  
 No compound 1 52  467  
  2 74  623  
Liver OCT 1 463 0.145 3251 0.455 
  2 473  3285  
 Cryo-Gel 1 474  3304  
  2 473  3285  
 No compound 1 463  3259  
  2 460  3287  
Colon OCT 1 291 0.518 2422 0.343 
  2 144  1321  
 Cryo-Gel 1 246  1460  
  2 124  553  
 No compound 1 252  1779  
  2 329  2197  
Proteomic analysis was performed on the spleen, skin, liver and colon tissue samples embedded in OCT, 
Cryo-Gel and without compound. The number of proteins and peptides identified in samples embedded 
in OCT, Cryo-Gel and without compound showed no significant differences.  
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Figure S1. H&E staining on spleen, skin and colon samples and H&E, PAS, Trichrome, Sirius 
Red and Iron staining on liver samples embedded in Cryo-Gel, OCT and without compound 
converted to FFPE material (magnification 20x). 
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Figure S2. Gene ontology analysis of proteins identified by mass spectrometry for renal 
samples embedded in Cryo-Gel and without compound categorized by cellular localization (A) 
and biological process (B).  
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Supplementary Methods 
Protocols of different stainings on FFPE sections: 
FFPE sections were stained with H&E using the Automated Ventana Symphony 
stainer according to manufactures instructions. Histochemical staining for PAS, 
Trichrome, Jones, Sirius Red and Iron was performed were performed on automated 
Ventana special stains after deparaffination.  
In brief for PAS, slides were heated till 75˚C and diastase was added for 12 
minutes. Next, Schiffs reagents was added for 20 minutes and lastly a counterstain 
with hematoxylin was performed.  
For Jones, slides were heated till 75˚C and then cooled till 60 ˚C. Jones Silver 
B reagents was added for 16 minutes and lastly eosin was added as counterstain. 
For Trichrome, Trich bouins A was added for 32 minutes and after additional 
washing steps, hematoxylin A+B was added for 12 minutes. After further washing 
steps, Trich Red was added for 8 minutes, Trich Mordant was added for 12 minutes 
and Trich Blue was added for 16 minutes.  
For Sirius Red, Fosformolybdeen acid 0,2% was added for 2 minutes and after 
a washing step, Picro-Sirius Red was added for 60 minutes.  
For the Iron staining, slides were heated till 75˚C and Iron reagent A was 
added for 4 minutes. After a washing step, Iron reagent B was added for 4 minutes. 
After a washing step, Iron NFR was added for 8 minutes.  
Immunohistochemical staining for AE1/AE3 and CD31 was performed. For 
CD31, following deparaffinization and heat-induced antigen retrieval with CC1 
(#950-124, Ventana) for 16 minutes, the tissue samples were incubated with CD31 
(JC70, #760-4378, Cell Marque) for 20 minutes at 36˚C.   
For AE1/AE3, following deparaffinization, protease for 3-4 minutes 
(protease3: 7601-2020, Ventana) and heat-induced antigen retrieval with CC1 (#950-
124, Ventana) for 20 minutes, the tissue samples were incubated with AE1/AE3 
(E08171, #760-2135, Ventana) for 4 minutes at 37˚C.   
All stainings were done with appropriate controls. 
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Abstract 
 
Background: Calcium oxalate (CaOx) deposition in the kidney may lead to loss of 
native renal function but little is known about the prevalence and role of CaOx 
deposition in transplanted kidneys. 
 
Methods: In patients transplanted in 2014 and 2015, all for-cause renal allograft 
biopsies obtained within 3 months post-transplantation were retrospectively 
investigated for CaOx deposition. Additionally, all pre-implantation renal biopsies 
obtained in 2000 and 2001 were studied. 
 
Results: In 2014 and 2015, 388 patients were transplanted, of whom 149 had at least 
one for-cause renal biopsy. Twenty-six (17%) patients had CaOx deposition. In the 
population with CaOx deposition: Patients had significantly more often been treated 
with dialysis before transplantation (89 vs. 64%; p = 0.011); delayed graft function 
occurred more frequently (42 vs. 23%;p = 0.038); and the eGFR at the time of first 
biopsy was significantly worse (21 vs. 29 ml/min/1.73m2; p = 0.037). In a multivariate 
logistic regression analysis, eGFR at the time of first biopsy (OR 0.958, 95%-Cl: 0.924–
0.993, p = 0.019), dialysis before transplantation (OR 4.868, 95%-Cl: 1.128–21.003, p 
= 0.034) and the time of first biopsy after transplantation (OR 1.037, 95%-Cl: 1.013–
1.062, p = 0.002) were independently associated with CaOx deposition. Graft survival 
censored for death was significantly worse in patients with CaOx deposition (p = 
0.018). In only 1 of 106 pre-implantation biopsies CaOx deposition was found 
(0.94%). 
 
Conclusion: CaOx deposition appears to be primarily recipient-derived and is 
frequently observed in for cause renal allograft biopsies obtained within 3 months 
post-transplantation. It is associated with inferior renal function at the time of biopsy 
and worse graft survival.  
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1. Introduction 
 
 Oxalic acid is a small decarboxylate ion (C2O4) and is the end-product of 
many metabolic pathways. Oxalic acid is eliminated through free glomerular filtration 
and secretion by the proximal tubule.1 The plasma concentration of oxalic acid is 
determined by the balance between dietary intake, intestinal absorption, 
endogenous production and renal excretion.2 Normal plasma concentrations are 
below 5 μmol/l.3, 4  
Hyperoxaluria, defined as an excessive urinary excretion of oxalic acid, can 
be classified as primary or secondary hyperoxaluria. Primary hyperoxaluria is caused 
by rare autosomal recessive disorders which cause an excessive production of oxalic 
acid.5-7 In primary hyperoxaluria, persistently elevated plasma oxalic acid 
concentrations cause CaOx deposition in the kidney which leads to permanent loss 
of renal function. Combined liver-kidney transplantation is recommended in these 
cases.5, 6, 8 Secondary hyperoxaluria is a more common disorder which can be caused 
by enteric conditions and increased dietary intake of oxalate. In enteric hyperoxaluria, 
increased absorption of oxalic acid occurs. These are mostly patients with 
malabsorption as a result of e.g. small bowel resections, pancreatic insufficiency or 
gastric bypass. A high intake of oxalic acid-containing food puts these patients at risk 
of renal stones or CaOx deposition in their kidneys.9-11 In addition, studies suggest a 
contribution of dietary oxalate in renal CaOx deposition in patients without enteric 
conditions as well.12-15  
When the GFR drops below 30–40 ml/min/1.73 m2 oxalic acid elimination by 
the kidneys is impaired and the plasma concentration rises.5 In patients with end-
stage renal disease (ESRD), high plasma oxalic acid concentrations, that may be up 
to 10 times above normal levels, may occur.16-18 Neither hemo- nor peritoneal dialysis 
can remove sufficient amounts of oxalic acid to normalize the oxalic acid plasma 
concentrations in patients with ESRD, although it is suggested that the clearance of 
oxalic acid by hemodialysis exceeds that of peritoneal dialysis.19, 20 The plasma oxalic 
acid concentration can be reduced by at least 60% following a single hemodialysis  
session. However, it returns to pre-dialysis levels within 48 hours.21, 22 
Plasma oxalic acid concentrations generally normalize within days to weeks 
after a successful kidney transplantation.23-25 However, in the first few days after 
transplantation, a large amount of oxalate is excreted.25 The urine becomes 
supersaturated with oxalate when concentrations >30 μmol/L are reached, and this 
may result in the formation of CaOx crystals, which can deposit in the renal tubules.5 
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Therefore, it can be expected that CaOx deposition is mainly formed in the early post 
transplantation period, while it probably is less prevalent in the late post 
transplantation period. However, it is unknown whether this phenomenon affects  
renal transplant outcome.  
The purpose of the present study was to examine if 1) CaOx deposition is 
associated with kidney allograft dysfunction in the immediate post-operative phase; 
2) CaOx deposition is associated with inferior graft survival; and 3) CaOx deposition 
in the transplanted kidney is recipient- rather than donor-derived. To investigate this, 
the incidence of CaOx deposition was studied in for-cause kidney allograft biopsies 
obtained within the first 3 months after transplantation, as well as in a series of 
preimplantation renal biopsies. 
 
2. Patients and methods 
 
  All patients transplanted between January 2014 and December 2015 in the 
Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands, 
were included. The databases of the Departments of Renal Transplantation and 
Pathology were searched to identify all for-cause renal allograft biopsies performed 
in these patients within the first 3 months after transplantation. No biopsies were 
performed for the sake of the present study. Clinical and demographic data of these 
patients were collected. These included: age at transplantation, type of dialysis 
(hemodialysis or peritoneal dialysis) and time on dialysis, donor age and type (living 
or deceased), cold ischemia time (CIT), first warm ischemia time (1st WIT), second 
warm ischemia time (2nd WIT) and delayed graft function (DGF). For those patients 
with a for-cause renal biopsy we collected: time to first biopsy, histologic diagnosis 
(acute rejection/acute tubular necrosis (ATN)/ other), best estimated GFR (eGFR) 
before biopsy and eGFR at time of the for-cause biopsy. DGF was defined as the need 
for dialysis during the first week after transplantation.26, 27  
In addition, all pre-implantation renal transplant biopsies (time zero, t0) 
obtained in 2000 and 2001 were retrospectively searched (in the database of the 
Department of Pathology) and re-analyzed for the presence of CaOx, as described 
below. Both living and deceased donor t0 biopsies were included. 
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2.1  Histological evaluation 
 All for-cause and t0 biopsies were processed according to standardized 
routine diagnostic practice. Light microscopy was performed on 3 μm sections of 
formalin-fixed paraffin embedded tissue that was stained by hematoxylin and eosin 
(H&E). CaOx deposition was analyzed on these sections using polarized light by two 
pathologists (MS and MCvG) who were blinded to patient information. In case of 
disagreement, consensus regarding the presence of CaOx deposition was reached. 
CaOx deposition was scored by counting the total number of oxalate depositions in 
each biopsy. Biopsies were defined as positive for CaOx when ≥1 CaOx deposits were 
found within the tubular lumen, tubular epithelial cells and/or interstitial space. The 
surface area of the biopsies with CaOx deposition was measured using the software 
program ImageJ and expressed as mm2. 28, 29 The amount of CaOx depositions per 
mm2 was calculated as described in the study by Bagnasco et al.30 
 
2.2 Statistical analysis 
 SPSS Statistics version 23.0 was used for all statistical analyses (IBM SPSS 
Statistics for Windows. Armonk, NY: IBM Corp.). For comparison of continuous 
variables, the one-way ANOVA-test was used. Categorical variables were compared 
using the Chi-square test. Data were presented as mean ± standard deviation (SD) 
for continuous variables and as percentages for categorical variables. Differences 
with a (two sided) p-value of less than or equal to 0.05 were considered statistically 
significant. Univariate and multivariate logistic regression analysis was used to 
evaluate which variables are independently associated with CaOx deposition. Graft 
survival censored for death was compared using Kaplan Meier analysis and log rank 
test. 
 
2.3 Medical ethics 
 The study protocol was consistent with professional guidelines; non WMO 
compliant research is research not residing under the Dutch law on medical research 
with patients and is regulated by the Dutch Code of Conduct (Federa). The local 
medical ethics committee of the Erasmus MC, University Medical Center Rotterdam, 
Rotterdam, The Netherlands, approved that our study is exempt from the 
requirement for approval (MEC-2018-1580). Informed consent to the use of medical 
record data and rest material was waived in accordance with the Dutch regulations. 
All data were anonymized prior to analysis. 
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3. Results 
 
3.1 Patient characteristics 
 A total of 388 patients were transplanted in the period studied (2014 and 
2015). Of these 388 patients, 77 (19.8%) had DGF. At least one for-cause renal 
transplant biopsy was performed in 149 patients (38%) and these patients were 
included in the present study. The characteristics of these patients are depicted in 
Table 1. In the period studied, 1 patient with primary hyperoxaluria underwent a 
combined kidney and liver transplantation. Interestingly, a renal allograft biopsy of 
this patient 9 months after transplantation did not show CaOx deposition. Renal 
function of this patient remains good 3 years after transplantation. Three patients 
with enteric hyperoxaluria as the primary kidney disease were transplanted in the 
period studied. Of these, one was not biopsied during the first year after 
transplantation. The other two were biopsied in the first 3 months after 
transplantation. In one patient, the renal biopsy showed CaOx deposition, whereas 
in the other patient no CaOx deposition was seen. Transplant function remains good 
in all patients 3.5 years after transplantation. All 4 patients described above had 
received oxalate lowering treatment pre- and post-transplantation.31  
A total of 196 biopsies from 149 patients was analyzed, with a median of 1 
biopsy per patient (range 1–3). Patients’ age ranged from 19 to 79 years (mean 54 ± 
14 years). Ninety-seven patients (65%) received a graft from a living donor and 52 
patients (35%) from a deceased donor. The histological diagnosis was rejection in 69 
patients (46%), ATN in 36 patients (24%), and ‘‘other” in the remaining 44 (30%) 
patients (Table 1).  
 
3.2 CaOx deposition in the renal allograft biopsy 
 Twenty-six patients (17%) showed CaOx deposition in their for-cause biopsy 
obtained within 3 months after transplantation. In 111 patients only 1 biopsy was 
performed and CaOx deposition was observed in 14 of them. Thirty-eight patients 
had more than 1 biopsy within 3 months after renal transplantation and CaOx 
deposition was observed in 12 of them; in 3 patients CaOx deposition was found in 
all the biopsies, in 3 patients CaOx deposition was observed in the first biopsy but 
not in the second (or third) biopsy. Six patients showed CaOx deposition in their 
repeat biopsy only.  
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Table 1. Characteristics of patients with and without CaOx depositions.  
Parameters All No oxalate Oxalate P 
N (%) 149 123 (83) 26 (17)  
Recipient age (years) 54±14 55±14 52±15 0.409 
Time on dialysis (months) 19±25 18±26 23±21 0.833 
RRT before transplantation     0.011 
      HD/PD 102 (68.5) 79 (64) 23 (89)  
      None 47 (31.5) 44 (36) 3 (11)  
Donor age (years) 55±14 55±14 55±13 0.934 
Living donor (%) 97 (65) 84 (68) 13 (50) 0.062 
CIT (min) 362±321 346±316 436±344 0.201 
1st WIT (min) 4.8±5.7 4.8±5.4 5.1±7.2 0.777 
2nd WIT (min) 21.1±6 20.9±6 21.8±6 0.493 
Time of first biopsy  
(days after Tx) 20±24 19±23 26±29 0.123 
Diagnosis (%)    0.411 
      ATN  36 (24) 29 (23) 7 (27)  
      Rejection 69 (46) 55 (45) 14 (54)  
     Other/none 44 (30) 39 (32) 5 (19)  
DGF 39 (26) 28 (23) 11 (42) 0.038 
Best eGFR before biopsy 
(ml/min/1.73m2) 36±24 37±23 33±26 0.398 
eGFR at first biopsy 
(ml/min/1.73m2) 27±17 29±17 21±17 0.037 
RRT, renal replacement therapy; HD, hemodialysis; PD, peritoneal dialysis; CIT, cold ischemia 
time; WIT, warm ischemia time; ATN, acute tubular necrosis; DGF, delayed graft function; eGFR, 
estimated glomerular filtration rate. 
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The CaOx crystals were translucent in H&E sections and birefringent 
structures were seen using polarized light (Figure 1). CaOx deposits were mostly 
observed in the lumen and within the epithelial cells of the tubules in the cortex. 
Occasionally, CaOx deposits were observed in the medulla. The mean surface of the 
biopsies containing CaOx deposition was 7.9 ± 2.3 mm2 (range 4.1–12.6 mm2) and 
the total amount of CaOx deposition varied between 1 and 33 deposits per biopsy 
(mean 6 ± 7 CaOx deposits per biopsy). The density of CaOx deposition varied 
between 0.1 and 0.4 deposits/ mm2 (mean density 0.8 ± 1.0 deposits/ mm2). 
Table 1 shows the patient characteristics of patients with and without CaOx 
depositions. Significantly more patients with CaOx deposition had renal replacement 
therapy (RRT) (hemodialysis or peritoneal dialysis) before transplantation (p = 0.011). 
CaOx depositions were more frequently observed in the population with RRT 
compared to those who were transplanted pre-emptively but the difference was not 
significant for peritoneal dialysis and hemodialysis separately (p = 0.051). Time on 
dialysis was not significantly different between those patients with and those without 
CaOx depositions (p = 0.88). The best eGFR before biopsy was not significantly 
different between patients with and those without CaOx deposition. However, eGFR 
at time of the first biopsy was significantly lower in patients with CaOx deposition (p 
= 0.037). DGF occurred more frequently in patients with CaOx deposition (p = 0.038). 
No histological diagnosis (rejection, ATN or other) prevailed in the CaOx group. All 
other variables were not significantly different between the groups. In addition, no 
significant association was observed between CaOx density (≥ 0,8 deposits/ mm2 vs. 
< 0,8 deposits/ mm2) and eGFR at time of first biopsy (p = 0.297) and between CaOx 
density and DGF (p = 0.190). 
As there were 26 patients with CaOx deposition in their allograft biopsy, the 
number of variables that could be analyzed at the same time in the regression 
analysis was limited. Three variables showed a significant influence on CaOx 
deposition in the univariate analysis: eGFR at the time of first biopsy (odds ratio (OR) 
0.971, 95%-Cl: 0.945–0.999, p = 0.040), DGF (OR 2.488, 95%-Cl: 1.027–6.028, p = 
0.043) and RRT before transplantation (OR 4.270, 95%-Cl: 1.213–15.029, p = 0.024). 
A stepwise multivariate analysis with backward elimination was performed, adding 
all variables with p < 0.2 in the univariate analysis. Eventually, three variables were 
independently associated with CaOx deposition in the multivariate analysis: eGFR at 
the time of first biopsy (OR 0.958, 95%-Cl: 0.924–0.993, p = 0.019), RRT before 
transplantation (OR 4.868, 95%-Cl: 1.128–21.003, p = 0.034) and time of first biopsy 
after transplantation (OR 1.037, 95%-Cl: 1.013–1.062, p = 0.002). 
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Figure 1. Examples of an H&E staining of a renal allograft biopsy examined by polarized light 
showing CaOx deposition (arrow) (magnification 10x and 20x respectively). 
 
3.3 CaOx in renal transplantectomies 
 Of all patients transplanted between January 2014 and December 2015, a 
total of 8 transplantectomies were performed within 3 months after transplantation. 
In 3 of them CaOx deposition was found. Of these 3 patients 1 had a prior allograft 
biopsy that showed CaOx deposition, 1 had an allograft biopsy without CaOx 
deposition and 1 did not have an allograft biopsy prior to explantation. These 3 
transplantectomies were performed on day 8, 11 and 12 after transplantation. The 
diagnosis was acute T cell-mediated rejection in all 3 patients and all had urine 
production after transplantation. The remaining 5 transplantectomies did not show 
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CaOx deposition, and all were explanted within 4 days after transplantation. No prior 
allograft biopsy was performed in these patients. The diagnosis was thrombosis in 4 
of the cases and hyperacute rejection in 1 case. Two of these patients did not have 
urine production after transplantation and in the other 3 urine volume had been low. 
The transplantectomies were not included in any of the statistical analysis performed 
in this manuscript. 
 
3.4 Graft failure 
 Graft failure censored for death was worse in the group of patients with CaOx 
deposition in their renal allograft biopsy within the first 3 months after 
transplantation compared to those patients without CaOx deposition in their 
allograft biopsy (p = 0.018; Figure 2). In the CaOx group, 5 grafts failed (19%) vs. 7 
(6%) in the group without CaOx deposition. Both DGF and eGFR ≤ 27 ml/min/1,73m2 
at time of first biopsy were not associated with graft loss (p = 0.238 and p = 0.519 
respectively; Figure 3A and 3B). No significant association was observed between 
CaOx density ≥ 0.8 deposits/ mm2 and graft loss (p = 0.133). 
 
3.5 CaOx in pre-implantation renal transplant biopsies (t0) 
 A total of 106 t0 kidney biopsies were available for analysis. Fifty-six (53%) 
biopsies were from living donors and 50 (47%) from deceased donors. CaOx 
deposition was found in 1 t0 biopsy (0.94%) which was from a living unrelated donor. 
This otherwise completely healthy donor was diagnosed with his first renal stone 
(type unknown) 7 years after donation. 
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Figure 2. Graft survival censored for death in the group with CaOx deposition (N = 26) and the 
group without CaOx deposition (N = 123) within the first 3 months after transplantation (p = 
0.018). 
 
 
 
Figure 3. (A) Graft survival censored for death in the group with DGF (N = 39) and the group 
without DGF (N = 110) (p = 0.519). (B) Graft survival censored for death in the group with eGFR 
≤27 ml/min/1,73m2 at time of first biopsy (N = 76) and the group with eGFR >27 
ml/min/1,73m2 at time of first biopsy (N = 73) (p = 0.238).
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4. Discussion 
 
 This study demonstrates that CaOx deposition is present in as many as 17% 
of the patients with a for-cause renal allograft biopsy within the first 3 months after 
transplantation and that these deposits are primarily recipient-derived. DGF was 
more common in patients with CaOx in their biopsies. In addition, the presence of 
CaOx was associated with a significantly lower eGFR at the time of biopsy in both 
univariate and multivariate analysis.  
 As there was no significant difference in best eGFR before biopsy, this 
indicates that patients with CaOx deposition had a greater loss of renal function prior 
to biopsy. The presence of CaOx deposits may have contributed to the impairment 
of renal allograft function. Risk factors for CaOx deposition are a high concentration 
of oxalic acid in the urine, damage to renal tubular cells, volume depletion and 
oliguria that leads to low tubular flow.32, 33 The CaOx crystals attach to the renal 
tubular cells and can cause (further) damage to the tubular cells.34, 35 This all can lead 
to a vicious circle of damage to the allograft due to CaOx deposition and renal 
function impairment.  
 Only a handful of other studies have examined CaOx deposition in renal 
allograft biopsies. Truong et al. reported CaOx deposition in about 4% of unselected 
renal allograft biopsies (13/315). These CaOx positive biopsies were performed 
between 4 days and 10 months after transplantation.36 Bagnasco et al. observed 
CaOx deposition in 9% of renal allograft recipients with at least one for-cause biopsy 
in the first year after transplantation.30 The study by Pinheiro et al. found CaOx 
deposition in 52.8% of renal allograft biopsies within 3 months after 
transplantation.37 The percentage reported in the latter study is remarkably high in 
comparison to the present and previous studies. There are several possible 
explanations for this difference. The use of naftidrofuryl oxalate, a peripheral 
vasodilator that was used in that time period for the management of vascular disease, 
may have been responsible for the high incidence of CaOx observed by Pinheiro et 
al. Naftidrofuryl oxalate is now known to cause high serum oxalic acid 
concentrations.38, 39 The study by Pinheiro et al. was performed in Sao Paulo, Brazil. 
Different dietary habits between populations may play a role, while the oxalic acid 
content in food may also differ considerably dependent on the oxalate content of 
the soil where it was grown. In a very recent study, Palsson et al. showed comparable 
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results to our study as they observed CaOx deposition in 19.4% (67/346) of the 
patients with a renal allograft biopsy within 3 months after transplantation.40 
 In our study, patients with CaOx deposition significantly more often received 
RRT before transplantation. Both univariate and multivariate analysis confirmed an 
association between RRT and CaOx deposition, although the duration of RRT did not 
influence results. Most probably the newly transplanted kidney is exposed to higher 
pre-transplant oxalic acid levels in patients dependent on RRT compared to those 
with impaired but functioning kidneys. Previous studies showed that hemodialysis is 
more efficient in removing oxalic acid than peritoneal dialysis.19, 20 However, no 
difference in CaOx deposition between these treatment modalities was found in the 
present study. Possibly patients with peritoneal dialysis were treated more recently 
than patients treated with hemodialysis as the first mentioned is done on a daily 
basis. However, the number of patients included in our study might be too small to 
make this distinction. 
 Multivariate analysis showed that the time after transplantation until 
performance of the first allograft biopsy significantly influenced the prevalence of 
CaOx deposition: a longer period was associated with a higher risk of CaOx 
deposition. Surprisingly, donor type (living or deceased) did not influence the 
prevalence of CaOx deposition in the population with a biopsy obtained within 3 
months after transplantation. 
 DGF was significantly more common among patients with CaOx deposition 
compared to those without (43% vs. 24%). This is consistent with the findings of 
Pinheiro et al. who found a significantly higher incidence of DGF among patients with 
CaOx in their renal allograft biopsy compared to those without CaOx deposition.37 
The sequence in the relationship between CaOx deposition and DGF in the renal 
allograft is challenging. CaOx can cause direct injury to the tubular cells which may 
promote the pathogenesis of DGF in the post-transplantation period.41, 42 However, 
it is also possible that injury to the tubular epithelial cells and low tubular flow as a 
result of DGF facilitate CaOx deposition. In our study, acute tubular injury was 
consistently observed in the majority of biopsies with CaOx deposits. 
 It is remarkable that our early transplantectomies did not show CaOx 
deposition, while transplantectomies from day 8 onwards did. An explanation may 
be that in cases with early transplantectomy there was no renal function and no urine 
production at all after transplantation, for example due to thrombosis or hyperacute 
rejection. 
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 We found that graft survival censored for death was significantly worse in 
patients with CaOx deposition within 3 months after transplantation compared to 
those without, while DGF and eGFR at time of first biopsy were not associated with 
graft loss. Due to the limited number of patients with graft loss during follow up, a 
multivariable analysis to investigate the independent causal association of CaOx 
deposition on graft survival could not be performed. Our graft survival results are in 
line with those reported by Pinheiro et al. who showed a 1-year renal allograft 
survival of 72.5% in the group with CaOx deposition and 89.1% in the group without 
CaOx (p = 0.013).37 
 Histological evaluation of pre-implantation biopsies provides information on 
organ quality and can help predict short and long-term outcomes of the renal 
allografts.43-45 Bagnasco et al. were the first to study the prevalence of CaOx 
deposition in t0 biopsies (n = 26) and found no CaOx deposition in any of the donor 
kidney biopsies.30 Our results are in line with these findings as we only observed 
CaOx deposition in 0.94% of t0 kidney biopsies. These findings suggest that CaOx 
deposition in the renal transplant is recipient rather than donor derived. 
 The 106 t0 biopsies were studied in the population that donated in 2000 and 
2001. No t0 biopsies were performed in the population that donated to our patient 
cohort transplanted in 2014 and 2015. However, it is unlikely that the results will be 
different in this specific donor population. Unfortunately, plasma oxalic acid levels 
pre-transplantation were not available in the present study. Additional studies are 
needed on the relationship between plasma oxalic acid levels pre-transplantation 
and the risk for CaOx deposition and inferior graft survival post-transplantation. This 
could aid in differentiating those patients that might benefit from preventive 
treatment to reduce plasma oxalic acid levels pre- and post-kidney transplantation. 
Avoidance of food products with high oxalic acid content and/or adequate 
hemodialysis treatment in the direct pre-transplant phase might prevent 
unnecessary CaOx deposition in the new renal allograft. In this study, we showed that 
CaOx deposition coincides with other causes of renal function impairment in the 
setting of decreased urinary flow such as DGF.  
 We showed that CaOx deposition in the renal allograft biopsy shortly after 
transplantation is common and associated with inferior long-term graft outcome. 
Therefore, we strongly advise the systematic examination of all for-cause renal 
allograft biopsies by polarized light for CaOx deposition. 
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Abstract 
 
Background: Molecules of the innate immune response are increasingly recognized 
as important mediators in allograft injury during and after kidney transplantation. 
We therefore aimed to establish the relationship between the expression of these 
genes at implantation, during an acute rejection (AR) and on graft outcome. 
 
Methods: A total of 19 genes, including Toll like receptors (TLRs), complement 
components and regulators, and apoptosis-related genes were analyzed at the 
mRNA level by qPCR in 123 biopsies with acute rejection and 75 paired pre-
transplantation biopsies. 
 
Results: Before transplantation, the BAX:BCL2 ratio (apoptosis marker) and relative 
mRNA expression of several complement genes was significantly higher in tissue 
samples from deceased donors compared to living donors. During AR, TLRs and 
complement genes showed an increased expression compared to pre-
transplantation conditions, whereas complement regulators were decreased. A 
relatively high TLR4 expression level and BAX:BCL2 ratio during AR in the deceased 
donor group was associated with adverse graft outcome, independently of clinical 
risk factors. 
 
Conclusions: Complement- and apoptosis-related gene expression is elevated in 
deceased donor transplants before transplantation. High BAX:BCL2 ratio and TLR4 
expression during AR may reflect enhanced intragraft cell death and immunogenic 
danger signals, and pose a risk factor for adverse graft outcome. 
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1. Introduction 
 
 The occurrence of an acute kidney allograft rejection, associated with 
infiltration of recipient immune cells to the kidney, is a risk factor for adverse graft 
outcome.1 The role of innate immunity, including pattern recognition receptors and 
the complement system in rejection, has been appreciated.2, 3 Toll like receptors 
(TLRs) are a family of transmembrane proteins that are capable of recognizing 
pathogen-associated molecular patterns (PAMPs) and damage-associated molecular 
patterns (DAMPs).4 TLR stimulation leads to dendritic cell maturation, characterized 
by upregulation of pro-inflammatory cytokines, chemokines, and co-stimulatory 
molecules, which initiate an immune response.5 Endogenous ligands including heat-
shock proteins (HSP), uric acid, high-mobility group box 1 protein (HMGB1), and 
genomic double-stranded DNA may stimulate TLRs.6-10 The interaction between 
HMGB1 and TLR4 leads to proinflammatory responses in the graft: after kidney 
transplantation, recipients with a donor graft containing a genotype variant in the 
coding sequence of TLR4 had lower expression of proinflammatory genes MCP-1 
and TNFα and higher expression of anti-inflammatory heme oxygenase 1, and they 
showed an increased rate of immediate graft function.11 Association of TLR2 and 
TLR4 expression was found with renal ischemia reperfusion injury (IRI) and early 
kidney allograft outcomes.12, 13 Other TLRs have not been investigated in the context 
of delayed graft function (DGF) and acute rejection (AR).  
 The complement system plays a pivotal role in IRI and allograft rejection after 
transplantation.3 The expression of complement components is significantly 
increased in deceased donor kidneys after cold ischemia.14, 15 Activation of the 
complement cascade leads to the release of anaphylatoxins (C3a and C5a) and the 
formation of the membrane attack complex (MAC) C5b–C9, which mediates the injury 
following transplantation.16, 17 C2 and C4 are essential components in the classical 
and lectin pathway, and C3 plays a central role in all pathways of the complement 
system. Complement regulators act as inhibitors of the complement cascade through 
various mechanisms.18, 19 For example, the decay acceleration factor (CD55) prevents 
the formation of C3 convertase. CD46 acts as cofactor for inactivating C3b and C4b 
by serum factor I. Complement receptor 1 both has decay-accelerating activity and 
cofactor activity. CD59 prevents the formation of MAC. Deficiency of CD55 and CD59 
in experimental settings leads to increased renal ischemia reperfusion injury.20, 21 In 
C4d-negative biopsy specimens during allograft dysfunction local CD55 expression 
was related to favorable transplant outcome.22  
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 The role of apoptosis in IRI after kidney transplantation is increasingly being 
recognized.23, 24 The anti-apoptotic protein B-cell lymphoma 2 (BCL2) was 
significantly decreased and pro-apoptotic protein BCL2-associated X protein (BAX) 
was increased during normothermic ischemia.25 The augmentation of BCL2 protects 
renal tubular cells from IRI through reducing renal tubular epithelial cell apoptosis.26 
High ratios of BAX:BCL2 in pre-transplantation biopsies are associated with an 
increased risk of DGF.27 
 In the present study, we examined innate-immune-related and apoptosis-
related markers in kidney biopsies of patients before transplantation and during an 
acute rejection episode, and investigated their relation to clinical outcome. 
 
2. Methods 
 
2.1 Patient characteristics 
 Patients who had received a kidney allograft at the Leiden University Medical 
Center (LUMC) during 1995–2005 were included. A total of 123 for-cause biopsy 
samples in case of clinical suspicion of AR were obtained within 6 months after 
transplantation. Patient characteristics are shown in Table 1. Also, 77 pre-
transplantation biopsies (75 biopsies paired to the subsequent AR biopsy) were taken 
at time of transplantation before reperfusion. DGF was defined as dialysis-
dependency in the first week after transplantation.  
 
2.2 Ethics 
 Written informed consent was obtained from donors for use of part of the 
human material for scientific purposes. The study was performed in accordance with 
the Declaration of Helsinki Good Clinical Guidelines and approved by the local 
medical ethics committee.  
 
2.3 Gene selection 
 The innate immune related genes (TLR1-TLR10), potentially acting as 
initiators of inflammation, were studied. The key complement component (C2, C3, 
C4) and complement regulators (CR1, CD46, CD55, CD59), which inhibit complement 
activation, were included. The apoptosis related genes BAX and BCL2, which may be 
associated with IRI and DGF, were also tested.  
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Table 1. Demographics of patient cohort. 
Variable  Number (%) 
Recipient age (≥50 years)  53 (43.1%) 
Recipient gender (Female)  40 (32.5%) 
Donor age (≥50 years)  52 (42.6%) 
Donor gender (Female)  74 (60.7%) 
Donor type (Living)  24 (19.5%) 
Time from transplant to rejection (days, IQR)  14 (9–37) 
First transplantation (Yes)  103 (84.4%) 
HLA–A/B matching (Yes)  20 (16.4%) 
HLA-DR matching (Yes)  43 (35.2%) 
Virtual PRA (0–5%)  81 (66.4%) 
DGF (Yes)  33 (28.7%) 
Steroid responsiveness  68 (56.2%) 
Cold ischemia time (≤ 18 h)  31 (29.8%) 
Banff score  
Glomerulitis (g=0/1/2/3)  74/25/7/3 
Interstitial inflammation (i=0/1/2/3)  5/44/36/24 
Tubulitis (t=0/1/2/3)  11/39/38/21 
Intimal arteritis (v=0/1/2/3)  62/24/7/7 
Interstitial fibrosis (ci=0/1/2)  61/41/7 
Tubular atrophy (ct=0/1/2)  60/44/5 
C4d diffuse positive 14 (11.4%) 
Rejection characteristics  
No rejection  7 (5.7%) 
Borderline rejection  33 (27.0%) 
Interstitial rejection  42 (34.4%) 
Vascular rejection  40 (32.8%) 
Graft survival (Death censored)  
> 1 year  106 (92.2%) 
> 6 year  101 (87.8%) 
HLA, human leukocyte antigen; PRA, panel reactive antibodies; DGF, delayed graft function. 
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2.4 RNA extraction and cDNA synthesis 
 RNA isolation and quality check, and cDNA synthesis were performed as 
described previously.28 
 
2.5 Real time quantitative PCR analysis 
 Optimal primer pairs were selected using Primer 3 version 4.0.0. To prevent 
amplification of genomic DNA reverse and forward primers were designed to target 
separate exons, spanning at least one intron with a size of 800 bp or more. All primer 
sets were tested on control cDNA, and PCR efficiencies were between 90% and 110%. 
The 15-μL qPCR reaction contained 3 μL of 25-times-diluted cDNA, 15 pmol forward 
and reverse primers, 7.5 μL of PCR Mix (Applied Biosystems by Life Technologies, 
Austin, Texas, USA), and nuclease-free water.29 Relative gene expression levels were 
normalized to the geometric mean of the reference genes β-actin and 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). 
 
2.6 Immunohistochemistry 
 Immunohistochemical stainings were performed on an independent set of 
34 formalin-fixed and paraffin-embedded (FFPE) kidney biopsy samples: 25 from 
patients with AR and 9 protocol biopsies from patients with stable graft function. 
Patients included in this group were transplanted between 2006 and 2015. 
Monoclonal anti-human antibodies against BAX (ab32503, Abcam, 1:1400 dilution), 
BCL2 (Sp66, Ventana), TLR4 (ab22048, Abcam, 1:800 dilution), and TLR9 (clone 
26C593.2, Novus, 1:800 dilution) were used for immunohistochemistry on sequential 
4-μm sections. Staining procedures have been described in a previous publication.30 
Semi quantitative scoring of the number of BCL2, TLR4, and TLR9 positive tubular 
epithelial cells was performed blindly by two observers (MS and MCvG) using a scale 
from 0 to 5 (0=0%, 1≤10%, 2=10–25%, 3=26–50%, 4=51–75%, 5=76–100%). 
 
2.7 Statistical analyses 
 Gene expression differences in the paired tissue samples were analyzed 
using Wilcoxon signed ranks test. Differences in gene expression between deceased 
and living donors and the occurrence of DGF were assessed by Mann-Whitney U 
tests (two-sided). Correlations between innate immunity mRNA expression levels and 
mRNA expression of general inflammation markers were analyzed by Spearman's 
rank correlation coefficients (two-sided). The Bonferroni method was used to correct 
for multiple comparisons. Death-censored graft survival curves were created using 
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the Kaplan-Meier method, and differences between curves were calculated using log 
rank tests. 
 A high expression level of inflammatory markers (CD163, CD68, CD20, CD3e) 
was defined as recipients with deceased donor graft with the highest one-third of 
gene expression. Risk factors affecting graft survival in the deceased donor group 
were analyzed by multivariate Cox-regression model including the variables that 
showed a borderline significance (P < 0.1) in univariate test. Statistical analyses were 
performed using SPSS statistics, version 23. Due to the limited number of graft loss 
events, penalized survival analysis by lasso method, including clinical and molecular 
risk factors, were performed using the “penalized” R (3.4.0 version) package.31 
 
3. Results 
 
3.1 Relation of pre-transplantation gene expression with donor type  
 No significant difference was observed between deceased (n=66) and living 
(n=11) donors regarding the donor age and donor gender. A short cold ischemia 
time (< 18 h) was more frequently seen in the living donation group. Sixteen genes, 
including the TLRs and membrane-bound complement regulators C4 and BAX, were 
not significantly different in their expression between living and deceased donors 
(Table 2). The expression of the complement genes C2 and C3 was >4-fold higher in 
the deceased donors compared to the living donors (Table 2). A significantly higher 
BAX:BCL2 ratio was observed in biopsies of deceased donor kidneys compared to 
living donor kidneys (Figure 1). Within the deceased donation group, recipients with 
relatively high expression of C2, C3 and BAX:BCL2 did not differ from recipients with 
relatively low expression in the incidence of DGF, steroid resistant rejection, and graft 
survival (data not shown). 
 
3.2 No association of pre-transplantation gene expression with DGF  
 All recipients with DGF (28.7%) had received a deceased donor renal 
allograft. Donor age of >50 years was a risk factor for DGF.  In the pre-transplantation 
biopsies of deceased donors, none of the genes investigated showed difference in 
expression between patients with DGF and those with no DGF (Table 2). 
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Table 2. Association between donor type, DGF, and gene expression in the pre-
transplantation biopsies.a 
 Living (N=11) Deceased (N=66) P DGF (N=22) No DGF (N=44) Pf 
TLR1 1.0 (0.86-1.95) 1.45 (0.90-2.06) 0.25 1.05 (0.61–1.56) 1.0 (0.65–1.42) 0.72 
TLR2 1.0 (0.38-1.65) 1.42 (0.76-2.38)b 0.05 1.10 (0.69–1.87) 1.0 (0.56–1.80)b 0.73 
TLR3 1.0 (0.79-1.55) 1.28 (0.95-1.66)b 0.30 0.99 (0.68–1.55) 1.0 (0.75–1.28)b 0.90 
TLR4 1.0 (0.69-1.19) 0.96 (0.64-1.34) 0.69 1.25 (0.83–1.65) 1.0 (0.70–1.44) 0.17 
TLR5 1.0 (0.82-2.29) 1.20 (0.67-1.89)b 0.58 1.45 (0.56–2.05) 1.0 (0.70–1.88)b 0.43 
TLR6 1.0 (0.48-2.17) 1.26 (0.70-2.49)b 0.50 1.14 (0.63–2.29) 1.0 (0.54–2.08)b 0.69 
TLR7 1.0 (0.64-2.03) 1.68 (1.05-3.07)c 0.03 0.86 (0.46–2.05) 1.0 (0.67–1.51)c 0.73 
TLR8 1.0 (0.62-2.47) 1.49 (0.81-2.45) 0.63 1.53 (1.01–2.76)b 1.0 (0.59–2.02)d 0.10 
TLR9 1.0 (0.82-2.70) 1.00 (0.38-3.13) 0.80 1.19 (0.38–3.68)b 1.0 (0.54–3.15) 0.90 
TLR10 1.0 (0.44-4.29) 2.14 (0.72-6.42) 0.29 0.90 (0.29–2.54)b 1.0 (0.31–3.87)b 0.74 
CD46 1.0 (0.94-1.15) 0.86 (0.67-1.06) 0.02 0.90 (0.72–1.18) 1.0 (0.77–1.21) 0.45 
CD55 1.0 (0.92-1.50) 0.90 (0.63-1.32) 0.09 1.06 (0.84–1.55) 1.0 (0.72–1.53) 0.36 
CD59 1.0 (0.83-1.16) 0.97 (0.85-1.26) 0.61 0.99 (0.89–1.25) 1.0 (0.87–1.29) 0.74 
C2 1.0 (0.38-1.28) 4.28 (1.81-6.81) 5.20E-6* 1.01 (0.40–1.72) 1.0 (0.48–1.58) 0.95 
C3 1.0 (0.83-1.52) 5.81 (2.88-14.43) 5.98E-6* 1.21 (0.74–2.09) 1.0 (0.47–2.97) 0.59 
C4 1.0 (0.89-1.65) 2.17 (1.38-3.03) 0.01 0.97 (0.53–1.39) 1.0 (0.70–1.38) 0.53 
CR1 1.0 (0.75-2.07) 0.99 (0.67-1.54)b 0.60 1.26 (0.89–1.82) 1.0 (0.68–1.81)b 0.41 
BCL2 1.0 (0.87-1.49) 0.71 (0.48-1.01) 2.35E-3* 1.11 (0.66–1.66) 1.0 (0.74–1.37) 0.61 
Bax 1.0 (0.83-1.24) 1.18 (0.99-1.53) 0.12 1.13 (1.00–1.58) 1.0 (0.85–1.38) 0.13 
Bax:BCL2 1.0 (0.80-1.18) 1.78 (1.50-2.34) 8.41E-6* 1.09 (0.89–1.42) 1.0 (0.87–1.30) 0.34 
a Gene expression data shown as medians with interquartile range. 
b, c, d, e Data missing for oneb, twoc, fourd and fivee patients. 
f The expression level of patients with and without DGF was analyzed in the deceased donor group. 
⁎ Statistically significant p-values after Bonferroni correction (P < 0.0025). P values were calculated by 
Mann-Whitney U tests (two-sided). 
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Figure 1. Gene expression in pre-transplantation biopsies of living and deceased donors. The 
relative expression of C2 and C3 was significantly lower in living donors than in deceased 
donors in the pre-transplantation biopsies. The BAX:BCL2 ratio was significantly lower in living 
donors in the pre-transplantation biopsies. 
Flags show median with interquartile range. P values were calculated by Mann-Whitney U tests 
(two-sided), ****P < 0.0001 (corrected for Bonferroni). 
 
3.3 Comparison of pre-transplantation and acute rejection biopsies 
 Paired pre-transplantation and acute rejection biopsies of 75 patients were 
available for analysis of gene expression dynamics (Table 3). The expression levels of 
TLR6, TLR7, TLR8, TLR9, and TLR10 were elevated >5.5 fold at the moment of AR, and 
the expression levels of TLR1, TLR2, TLR3, and C2 were increased 1.2–4.4 fold 
compared to the expression levels before implantation. The expression levels of 
TLR4, TLR5, C3 and CR1 were similar between both biopsies, and levels of C4, BCL2 
and the complement regulators (CD46, CD55, and CD59) were slightly decreased 
during AR (Figure 2). Patients whose C3 expression increased between pre-
transplantation and AR did not differ from patients whose C3 expression decreased 
with respect to incidence of steroid resistant rejection and death censored graft 
survival (data not shown). 
                        Gene expression of the innate immune response | 83 
 
 
Figure 2. Gene expression dynamics in kidney biopsies. The paired pre-transplantation 
biopsies (PreTx) and acute rejection biopsies (AR) of 75 patients were used for comparison. 
The mRNA levels were quantified by qPCR and normalized to reference genes. 
 
3.4 Gene expression correlated with inflammation and Banff score 
 Since all TLRs showed elevated levels during AR, we investigated whether 
this upregulation could be ascribed to infiltration of inflammatory cells. Correlations 
of innate immunity expression levels with expression of key inflammatory markers 
(CD163, CD68, CD20, CD3e) and Banff classification are summarized in Table S2. 
Except for TLR2, TLR3 and TLR5, all TLRs correlated with one or more inflammatory 
cell marker. C2 and C3 were significantly correlated with macrophage markers, 
whereas CD46 and CD59 showed a negative association with these molecules. In 
addition, CR1 demonstrated association with T cell, B cell, macrophage markers, and 
interstitial inflammation score. Apoptosis-related genes did not correlate with any of 
the inflammatory molecules. In summary, the altered gene expression may in part be 
the result of infiltrating inflammatory cells. 
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Table 3. Pairwise comparison of gene expression between pre-transplantation 
biopsies and biopsies with acute rejection. 
a, b, c Data missing for onea, fiveb and twoc patients. 
⁎ Statistically significant p-values based on Bonferroni correction (P < 0.0025), P values were calculated 
by Wilcoxon signed ranks test. 
 
 
 
 
 
 Pre-transplantation Acute rejection P 
TLR1 1.0 (0.65 - 1.46) 4.36 (3.24 - 5.34) 5.50E-14* 
TLR2 1.0 (0.52 - 1.63) 3.42 (2.63 - 5.21) 4.60E-12* 
TLR3 1.0 (0.74 - 1.29)a 1.42 (1.20 - 1.86)a 5.38E-08* 
TLR4 1.0 (0.70 - 1.37) 1.21 (0.95 - 1.56) 0.019 
TLR5 1.0 (0.56 - 1.59) 1.40 (1.01 - 1.70) 0.0028 
TLR6 1.0 (0.56 - 1.97) 5.59 (4.18 - 8.47) 2.22E-13* 
TLR7 1.0 (0.61 - 1.55)a 7.40 (4.60 - 9.79)a 1.48E-13* 
TLR8 1.0 (0.57 - 1.73)b 27.04 (18.94 - 34.87)b 3.56E-13* 
TLR9 1.0 (0.39 - 3.07)a 7.66 (4.99 - 13.14)a 1.62E-11* 
TLR10 1.0 (0.31 - 2.83)c 8.96 (4.55 - 14.31)c 2.25E-09* 
CD46 1.0 (0.78 - 1.22) 0.80 (0.62 - 1.07) 2.19E-03* 
CD55 1.0 (0.71 - 1.48) 0.72 (0.58 - 0.84) 4.34E-07* 
CD59 1.0 (0.86 - 1.25) 0.84 (0.63 - 1.04) 4.92E-04* 
C2 1.0 (0.47 - 1.76) 2.49 (1.71 - 3.56) 4.34E-07* 
C3 1.0 (0.43 - 2.35) 2.04 (1.32 - 3.65) 8.41E-03 
C4 1.0 (0.65 - 1.44) 0.49 (0.36 - 0.61) 2.19E-10* 
CR1 1.0 (0.70 - 1.54) 1.26 (0.87 - 1.97) 0.0087 
BCL2 1.0 (0.67 - 1.35)c 0.76 (0.60 – 1.06)c 3.14E-4⁎ 
Bax 1.0 (0.84 - 1.31)c 0.98 (0.85 - 1.27)c 0.44 
Bax:BCL2 1.0 (0.76 - 1.30)c 1.24 (0.95 - 1.49)c 6.20E-5⁎ 
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3.5 TLR4 expression and BAX:BCL2 ratio predicts graft outcome 
 The relative expression of TLR4 at the moment of AR in living and deceased 
patients was comparable. The patients with a deceased donor graft were divided into 
two groups based on their gene expression levels. One-third of patients who showed 
the highest TLR4 expression were defined as high expression group (open circles); 
and the rest of patients as low expression group (black dots) (Figure 3A). At 12.5 
years post-transplantation, patients with high TLR4 expression showed significant 
inferior graft survival (59.2%) compared to patients who had relative low TLR4 
expression (79.6%, P = 0.04, Figure 3A). >10% of the patients with high TLR4 
expression lost their graft within the first 3 months. As for the BAX:BCL2 ratio: 
patients in the deceased donor group with a BAX:BCL2 ratio higher than in the living 
donation group were defined as the high ratio group (open circles) (Figure 3B). The 
group of patients with relatively high BAX:BCL2 ratio at time of AR had an inferior 
graft survival (57.9%) compared to patients with a low BAX:BCL2 ratio (79.8%) and 
those with a living donor allograft (88.3%, P = 0.03, Figure 3B). In univariate analysis, 
Banff classification score did not predict long term graft survival.  
 In multivariate cox regression analysis within deceased donor group (Table 
4), only high TLR4 expression (HR = 3.46; CI= 1.17–10.23; P = 0.025) and a high 
BAX:BCL2 ratio (HR = 4.6; CI = 1.44–14.73; P = 0.01) were a significant independent 
risk factor for graft loss. The penalized cox regression model using the lasso showed 
that high TLR4 expression, higher donor age (>50 year) and high BAX:BCL2 ratio were 
the most significant (Figure S1). Expression levels in the pre-transplantation biopsies 
were not associated with graft survival. 
 
3.6 Localization of TLR4, TLR9, and BCL2 expression  
 To verify clinically relevant mRNA markers at the protein level and localize 
their expression in the tissue, immunohistochemical staining for TLR4, BAX and BCL2 
were performed on kidney biopsies (Figure 4). In addition, we investigated TLR9 
which was increased during AR, and which has been shown to be an inducer of 
proinflammatory signals.32 Quantification of BAX expression could not be performed 
since almost no staining was observed in the biopsies (positive area <10%). TLR4 
protein expression was detected in tubular epithelial cells and in inflammatory cells 
(Figure 4A and 4B). Semi-quantitative scoring showed a significantly higher 
expression in biopsies with AR than in those with stable graft function. Protein 
expression of TLR9 was predominantly seen in tubular epithelial cells and varied 
considerably within the AR group (Figure 4C and 4D). BCL2 expression was observed 
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in the cytoplasm of tubular epithelial cells and in infiltrating inflammatory cells, and 
showed a wide range of expression among AR biopsies (Figure 4E and 4F). The extent 
of protein expression of BCL2 and TLR9 during AR was increased in comparison to 
the stable graft group, however this difference was not significant after correction 
for multiple comparisons (Table 5). 
 
 
Figure 3. Association between gene expression at time of acute rejection and kidney graft 
survival. (A) The TLR4-high expression patient group (n=30; dash line) had significantly inferior 
graft survival compared to the TLR4-low expression patient group (n=61; solid line) and living 
donor group (n=24; dots line). (B) The high BAX:BCL2 ratio patient group (n=14; dash line) had 
significantly inferior graft survival rate compared to the low BAX:BCL2 ratio patient group 
(n=72; solid line) and the living donor group (n=23; dots line). 
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Table 4. Cox regression analysis of transplant-related risk factors and post-
transplantation gene expression levels at time of acute rejection with death censored 
graft survival. 
 Univariate Multivariate  
HR (Lower-Upper) P HR (Lower-Upper) P 
Recipient age (> 50 year) 1.19 (0.47 - 3.01) 0.72   
Transplantation date (<1999) 0.93 (0.25–3.42) 0.91   
Donor age (> 50 year) 2.10 (0.78–5.68) 0.14   
ABDR mismatching 0.95 (0.27–3.34) 0.94   
Cold ischemia time(<18h) 0.88 (0.25–3.14) 0.85   
Delayed Graft function 1.61 (0.60–4.33) 0.35   
Vascular rejection 1.28 (0.46–3.54) 0.63   
Steroid resistant 1.94 (0.72–5.21) 0.19   
Number of transplants (>1) 2.88 (1.00–8.32) 0.05   
CD163 (high expression level) 1.52 (0.55–4.20) 0.42   
CD68 (high expression level) 1.78 (0.62–5.07) 0.28   
CD20 (high expression level) 0.42 (0.12–1.47) 0.17   
CD3e (high expression level) 1.14 (0.41–3.16) 0.80   
TLR4 (high expression level) 2.89 (1.08–7.78) 0.04* 3.46 (1.17–10.23) 0.025* 
Ratio BAX:BCL2 (higher than living) 3.22 (1.09–9.51) 0.03* 4.60 (1.44–14.73) 0.01* 
*Statistically significant difference (P < 0.05). 
 
4. Discussion 
 
 In the present study, mRNA expression levels of TLRs, key complement 
components and regulators, and apoptosis-related genes were investigated in 
biopsies obtained before graft implantation and at time of AR. We found that in 
deceased donors, C2 and C3 expression and BAX:BCL2 ratio were already elevated 
before transplantation but were not indicative of DGF. High TLR4 levels and a high 
BAX:BCL2 ratio at the time of an AR were both independent risk factors of graft loss. 
Results from this exploratory study suggest that innate immune activation occurs 
both at time of graft implantation and during episodes of acute rejection. Although 
the TLR/MyD88 pathway was found to be redundant for host defense against most 
natural infections, depletion of a functional TLR pathway in mice, by knocking out 
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either TLR2, TLR4 or MyD88, protects against IRI and kidney dysfunction, and limits 
an increase in expression of cytokines, chemokines and infiltration of inflammatory 
cells.33-35 In human kidney transplants, the expression of TLR4 and HMGB1 (an 
endogenous ligand of TLR4) was significantly elevated in pre-transplantation 
biopsies from deceased donors but not in those from living donors.11 However, in 
our study we could not confirm these findings (Table 2), and none of the markers 
investigated was associated with DGF.  
 
 
Figure 4. Immunohistochemical staining pattern of TLR4, TLR9, and BCL2 in kidney transplant 
biopsies. TLR4 protein expression was detected in tubular epithelial cells and in inflammatory 
cells (A–B). TLR9 was observed in the tubular epithelial cells (C–D). BCL2 was detected in 
tubular epithelial cells and infiltrated lymphocytes (E–F). Both BCL2 and TLR9 expression varied 
extensively between acute rejection biopsies. Two representative samples from the acute 
rejection group are shown. 
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Table 5. Immunohistochemical scoring of TLR4, TLR9, and BCL2 in biopsies with 
stable graft function and acute rejection biopsies. 
IHC score  1 2 3 4 5 P 
TLR9      0.069 
     SGF 1 5 1 0 0  
     AR 4 4 7 4 4  
TRL4      0.008* 
     SGF 4 2 1 0 0  
     AR 2 7 5 5 3  
BCL2      0.024 
     SGF 1 3 2 1 0  
     AR 0 3 8 8 3  
IHC, Immunohistochemistry; SGF, stable graft function; AR, acute rejection. 
* Statistically significant p-values based on Bonferroni correction (P < 0.016), P values were calculated by 
Mann-Whitney Test. 
 
 Earlier studies showed that the expression of TLRs is significantly 
upregulated during allograft rejection, mainly because of infiltration of leukocytes.13, 
36 However, none of the previous studies has documented gene expression dynamics 
in a large patient cohort. We showed that the expression of all TLRs, except TLR4 and 
TLR5, was significantly increased in AR biopsies when compared to pre-
transplantation biopsies (Table 3). Moreover, expression of the majority of the TLRs 
was positively correlated with one or more inflammatory cell markers at the moment 
of AR (Table S1), suggesting that the elevated expression of TLRs is a result of 
inflammatory cell presence. Both TLR2 and TLR3, which showed only minor increase 
during an AR, were not correlated with any inflammatory markers, and their 
expression may be dominant in renal parenchymal tissue. Similar expression patterns 
of TLR3 were reported by Dessing et al.36 The expression of TLR4 correlated with 
CD163 and CD68 but was not increased during AR, and may be expressed by both 
parenchymal and myeloid cells. In addition, patients with relatively high levels of 
TLR4 during AR exhibited inferior graft survival 12.5 years after transplantation, which 
may mean that intracellular ligands released after cell damage bind to TLR4 and 
thereby provide additional inflammatory signals leading to long term graft loss. 
Expression of TLR4 in the renal allograft biopsy has been described previously.11, 13 
TLR4 by immunohistochemical staining was expressed in tubular cells and infiltrated 
lymphocytes, with significantly higher expression during AR compared to stable graft 
conditions. The possible explanation, that on one hand no increase in TLR4 mRNA 
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was seen between AR and pre-transplantation and on the other hand 
immunohistochemistry showed significantly higher expression during AR compared 
to stable graft conditions, may be that the epithelium expresses low levels of mRNA 
but relatively high levels of protein. The endogenous pattern recognition receptor 
TLR9 is involved in immune complex kidney disease.37 Immunohistochemical staining 
showed that TLR9 was increased during AR compared to the stable graft group with 
borderline significance.  
 The complement system acts as a bridge to the adaptive system and 
facilitates clearance of immune complexes and cellular debris. It has been shown that 
the MAC plays a central role in renal IRI and that locally synthesized C3 is important 
in kidney graft survival.17, 38 In line with a previous study, the mRNA levels of C2 and 
C3 in the living donor group were significantly lower than those in the deceased 
donor group at time of implantation, which supports the notion that the local C3 
expression is induced by donor brain death.14, 15 The observation of a slight increase 
in C4 expression in deceased donors is also in line with this previous study.14 
However, inconsistent with that study, the expression level of CR1 was comparable 
between deceased and living donor biopsies in our relatively large cohort. The 
increased C2 during AR may represent a higher activity of the classical and lectin 
pathway, whereas the decreased C4 expression during AR may be a result of injury 
of renal parenchymal cells.  
 The complement regulators CD46, CD55, and CD59 act as inhibitors of 
activation of the complement pathway. Hypersensitized rats treated with sCR1 
displayed significantly prolonged cardiac graft survival.39 Similarly, kidneys of animals 
treated with CR1 derivatives (APT070) showed less acute tubular injury, and the 
animals had a significantly higher graft survival rate.40 CD55 had a protective effect 
on renal function in C4d-negative grafts and antibody-mediated cardiac allograft 
rejection.22, 41 We found that expression of CD46, CD55 and CD59 was significantly 
reduced during an AR compared to that in the pre-transplantation biopsies. 
However, none of the complement regulators were predictive for the development 
of DGF, steroid resistant rejection and graft survival in the present study. 
Interestingly, Budding et al. showed that serum sCD59 is elevated at the time of 
bronchiolitis obliterans syndrome (BOS) after lung transplantation, and the patients 
with higher serum sCD59 titers (>400 pg/mL) had a significantly lower chance of BOS 
free survival. We observed that the expression of complement regulators at time of 
AR was slightly decreased compared to pre-transplantation conditions, and that it 
negatively correlated with expression of macrophage markers.  
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 It has been shown that kidney cell apoptosis is involved in IRI and that 
apoptotic cells are frequently present in AR biopsies.23, 24 In the present study, the 
mRNA of BCL2, an anti-apoptotic molecule, was lower in deceased donor biopsies 
than in living donor biopsies. The higher BAX:BCL2 ratio suggests that the extent of 
apoptosis is already increased in deceased donors. The BAX:BCL2 ratio tended to be 
higher in the DGF group in the deceased donor cohort but this was only marginal 
(Table 2), which is inconsistent with findings from a previous study.27 During an AR, 
the BAX:BCL2 ratio was marginally increased and it significantly correlated with 
expression of macrophage markers. Protein investigations by immunohistochemical 
staining showed that BAX was rarely detected in the biopsy samples. The BCL2 
expression was mainly observed in tubular epithelial cell and inflammatory cells, with 
a wide range of staining within the AR group. Patients who received a living donor 
graft had superior graft survival compared to those with a graft from a deceased 
donor, and thus this group acted as a reference. Moreover, patients with relatively 
high BAX:BCL2 ratio during AR in their deceased donor graft demonstrated 
significantly inferior graft survival rates (57.9%) 12.5 years after transplantation 
compared to those with a low ratio or to patients who had received a living donor 
graft (Figure 3). High BAX:BCL2 ratio during AR possibly reflects an increased number 
of apoptotic cells, which leads to attraction of phagocytic cells to the graft.42, 43 The 
accumulated phagocytes may be triggered by immunogenic danger signals and 
mediate subsequent chronic allograft loss.44, 45 
 In conclusion, complement and apoptosis pathways are elevated before 
kidney transplantation. Increased expression of the majority of genes partly reflect 
the infiltration of inflammatory cells during an AR. Relatively high TLR4 expression 
and high BAX:BCL2 ratio during AR, possibly reflecting enhanced immunogenic 
danger signals, were both independent risk factors for adverse outcome after 
transplantation of a deceased donor kidney. The results of this study suggest that 
the different impact of AR on outcome between living and deceased donor 
transplants may partly be ascribed to differences in TLR4 regulation and cell death 
related mechanisms. They form a basis to further validate and explore the functional 
relevance of these pathways in relation to transplant outcome. 
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Table S1. Primer sequence and amplification efficiency. 
 
 
Genes 
Forward primer 
(5'-3') 
Reverse primer 
(5'-3') 
Product size 
(bp) 
Efficiency 
(%) 
TLR1 ACACCAAGTTGTCAGCGATG GGGCTAATTTTGGATGGGCA 135 94.5 
TLR2 GTGATAGGTGTGAGGCAGGT GTGGCCGCCTTGATTCATAG 136 100.8 
TLR3 GAACCTCCAGCACAATGAGC TGACAAGCCATTATGAGACAGA 169 99.6 
TLR4 ACCTCCCCTTCTCAACCAAG GGCTCTGATATGCCCCATCT 150 106.9 
TLR5 TGAAGTCTTTAAACAACCAGGGA TCCAAACACAGGACCGGC 142 108.1 
TLR6 CTCTCCACTCTGCTTTCCCA CTCCGAGGACTGGTGCATAT 109 107.1 
TLR7 TGCTCTCTTCAACCAGACCT CACGATCACATGGTTCTTTGGA 196 103.5 
TLR8 TACCACCTTGAAGAGAGCCG TGCTTTGGTTGATGCTCTGC 112 99.5 
TLR9 AGATGGAGGGGAGAAGGTCT CAAGGTGAAGTTGAGGGTGC 112 98.6 
TLR10 TCCAGAGCTGCCAGAAGAAA AAATCCAGTGTCGTTGTGGC 102 97.5 
CD46 ATTCAGTGTGGAGTCGTGCT AATTGTGTCGCTGCCATCG 167 95.8 
CD55 TCCTGGCGAGAAGGACTCAGTGA AGCCTTGTTGGCACCTCGCA 96 98.0 
CD59 GCGTGTCTCATTACCAAAGCT CCTTCTTGCAGCAGTAGTACG 127 95.9 
C2 TCTGAACCTCTACCTGCTCC ACATGAGGACTTTGGGCTCT 164 92.8 
C3 AGCAGTCAAGGTCTACGCC TTGTCCAGCCGTTCTTCCA 180 95.3 
C4 CTGAACAACCGCCAGATTCG TGGCAGGTCGTGTTCTTCAT 149 98.9 
CR1 TGTTTGCGATGAAGGGTTCC GAGTTCCTGTGTGTCTCCCA 155 101.4 
BCL2 GCCCTGTGGATGACTGAGTA CTTCAGAGACAGCCAGGAGA 135 100.4 
BAX CGCCCTTTTCTACTTTGCCA CCAATGTCCAGCCCATGATG 92 102.1 
B-actin ACCACACCTTCTACAATGAG TAGCACAGCCTGGATAGC 161 94.0 
GAPDH ACCCACTCCTCCACCTTTGAC TCCACCACCCTGTTGCTGTAG 110 98.0 
CD3e CCGCCATCTTAGTAAAGTAACAG AATACCACCCATTTCTTCATTACC 131 90 
CD163 TGGAGTGACCTGCTCAGATG CACCGTCCTTGGAATTTGAT 99 103.8 
CD68 TTCCCCTATGGACACCTCAG TTGTACTCCACCGCCATGTA 86 103.9 
CD20 GGGGCTGTCCAGATTATGAA CCAGGAGTGATCCGGAAATA 148 97.2 
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Figure S1. Penalized survival analysis of clinical risk factors. The plot shows the effect of lambda 
on the fitted regression coefficients. High TLR4 expression, donor age >50, and high Bax:Bcl2 
ratio were the top three parameters in the penalized lasso model. 
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Abstract 
 
Introduction: C4d staining in peritubular capillaries (PTCs) is a well-established 
feature of antibody-mediated rejection (ABMR). The relevance of C4d staining 
outside PTCs is not well understood. We investigated the significance of arteriolar 
C4d staining in c-aABMR. 
 
Methods: All for-cause renal allograft biopsies performed in 2007-2014 at the 
Erasmus MC and meeting the criteria for suspicious/diagnostic c-aABMR using the 
Banff Classification 2015, were included. For comparison, renal allograft biopsies 
from a matched control group and native renal biopsies were analyzed. Arteriolar 
C4d staining was semi-quantitatively scored as negative (0), small deposits in 1 
arteriole (1+), small/large deposits in >1 arterioles (2+) or at least extensive deposits 
in most arterioles (3+). 
 
Results: Thirty-four of 40 (85%) patients with c-aABMR showed arteriolar C4d 
staining. A significant difference in arteriolar C4d score was observed between cases 
and matched controls (p = 0.01) and a trend toward significance difference between 
cases and native renal biopsies (p = 0.05). In the cases, arteriolar C4d staining was 
significantly associated with severity of arteriolar hyalinosis (ah) (p = 0.004) and ≥2 
arteriolar C4d staining was independently associated with better graft outcome in a 
multivariate Cox regression analysis (hazard ratio 0.260, 95%-Cl: 0.104-0.650, p = 
0.004). 
 
Conclusion: This pilot study shows that arteriolar C4d staining is more common in 
biopsies with c-aABMR compared to those without and that it is associated with ah. 
≥2 arteriolar C4d staining is associated with superior graft outcome. However, larger 
studies are needed to examine these findings in more detail to asses if arteriolar C4d 
staining is truly related to antibody-mediated injury. 
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1. Introduction 
 
 Late kidney allograft failure remains an important clinical problem and is 
mainly caused by chronic-active antibody-mediated rejection (c-aABMR).1-3 The 
diagnosis of c-aABMR according to the Banff Classification 2015 requires both 
pathological and clinical laboratory criteria, namely: (1) histologic evidence of chronic 
tissue injury, (2) evidence of current / recent antibody interaction with vascular 
endothelium, i.e. C4d staining on endothelial cells of the peritubular capillaries (PTCs) 
and medullary vasa recta and/or peritubular capillaritis (ptc) + glomerulitis (g) ≥2, 
and (3) detection of donor-specific anti-HLA antibodies (DSAs).4 Cases with 
histologic features of c-aABMR with either evidence of current / recent antibody 
interaction with vascular endothelium or the presence of DSAs but not both, may be 
diagnosed as “suspicious for c-aABMR”.  
 C4d staining was first described in renal allograft biopsies by Feucht et al. 
and has broadened our understanding of the pathogenesis and clinical 
consequences of ABMR.5, 6 C4d is a degradation product of the complement factor 
C4 which participates in the classical and lectin pathways of complement activation. 
The activation of C4 generates C4b which is then cleaved into C4d and larger 
fragments such as C4c. Because C4d forms an internal thioester bond with the 
endothelial surface it can covalently bind to the endothelium, where it remains for 
several days or weeks. Therefore, it is a durable marker of local complement 
activation.7-9 
 C4d positivity in the PTCs in cases of ABMR was found to be a specific marker 
for interaction of DSAs with the endothelium of the renal microcirculation and is 
associated with poor kidney transplant survival.10-14 C4d staining by 
immunohistochemistry or immunofluorescence is also advised by the Banff 
Classification to be offered in the routine diagnostic pathologic evaluation of all renal 
allograft biopsies.15 
 Peer reviewed literature on C4d immunohistochemistry has mainly focused 
on staining in the PTCs. The significance of C4d staining outside the PTCs and in 
particular the renal arterioles of patients with c-aABMR is unclear. This pilot study 
was designed to investigate the prevalence of C4d staining in the arterioles in cases 
with suspicious and diagnostic c-aABMR. In addition, the relationship with other 
histological and clinical features was analyzed. 
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2. Methods 
 
 In this retrospective pilot study, the database of the Department of 
Pathology of the Erasmus MC, University Medical Center Rotterdam, Rotterdam, The 
Netherlands, was searched to identify all patients with a for-cause renal allograft 
biopsy performed between 2007 and 2014 with the diagnosis suspicious or 
diagnostic for c-aABMR according to the Banff 2015 criteria.4 Clinical and 
demographic data of the patients were collected from the electronic patient files. 
These included: gender, age at transplantation, donor age and type (living or 
deceased), primary renal disease, number of renal transplantations (first vs. second 
or higher), the presence or absence of DSAs, estimated GFR at time of biopsy (eGFR), 
proteinuria at time of biopsy and the cumulative tacrolimus exposure (see below).  
 DSA testing was performed at the laboratory of immunohematology of the 
Leiden University Medical Center, which serves as the Eurotransplant reference 
laboratory. DSAs were considered present when antibodies directed against one or 
more donor HLA alleles were detected in patient serum samples. Anti-HLA status at 
time of biopsy was determined using the Luminex Screening Assay [Lifecodes 
Lifescreen Deluxe (LMX) kit, according to the manufacturer’s manual (Immunocor 
Transplant Diagnostics Inc. Stamford, CT, USA]. If anti-HLA antibodies were found to 
be present in the screening, they were further typed by use of a Luminex Single 
Antigen assay, using LAB screen HLA class-I and class-II antigen beads (OneLambda, 
CanogaPark, GA, USA). It was determined whether these were de novo DSAs based 
on DSA testing prior to transplantation. 
 The cumulative tacrolimus exposure was measured by multiplying the 
tacrolimus through levels after transplantation to time of biopsy with the post 
transplantation period (cumulative tacrolimus exposure = (C1min + C2min + C3min 
… + CXmin/X) x post-transplant time (months)) as previously described by Leal et 
al.16 
 
2.1 Histological and immunohistochemical evaluation 
 Standard H&E, PAS+, Jones and Trichrome sections were re-evaluated 
according to the Banff 2015 criteria.4 Immunohistochemical C4d staining was 
performed on 4 μm slides of formalin-fixed paraffin-embedded (FFPE) tissue with an 
automated, validated and accredited staining system (Ventana Benchmark ULTRA, 
Ventana Medical Systems, Tucsen, AZ, USA) using an ultra-view universal DAB 
detection Kit. In brief, following deparaffinization and heat-induced antigen retrieval 
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with CC1 (#950-124, Ventana) for 64 minutes, the tissue samples were incubated with 
a rabbit monoclonal antibody for C4d (SP91, #760-4803, Cell Marque) for 24 minutes 
at 36˚C. Incubation was followed by hematoxylin II counter stain for 8 minutes and 
then a blue coloring reagent for 8 minutes according to the manufactures 
instructions (Ventana). 
 C4d staining in arterioles was semi-quantitatively classified (0-3) as negative 
(0), small deposits in 1 arteriole (1+), small or large deposits in >1 arteriole (2+) or at 
least extensive deposits in most arterioles (3+). C4d staining in arteries was scored 
as negative (0), small deposits in 1 artery (1+), small or large deposits in >1 artery 
(2+) or at least extensive deposits in most arteries (3+). In the arterioles and arteries, 
both endothelial and mural staining were counted as positive. In addition, we 
compared cases with endothelial staining, mural staining and endothelial + mural 
staining. C4d staining in the PTCs and glomeruli was scored as negative (0%), minimal 
(<10%), focal (10-50%) or diffuse (>50%) staining. 
 To investigate if C4d co-localizes with arteriolar hyalinosis (ah), a proof of 
principal with 3 cases and 3 controls was performed using a C4d 
immunohistochemical staining as described above. After C4d staining, representative 
arterioles with ah were photographed and slides were subsequently stained by PAS+. 
Thereafter, the same area was photographed again to visualize co-localization. 
 To assess the specificity of C4d deposition by immunohistochemistry in the 
arterioles, an immunohistochemical staining for IgG was performed in 3 cases and 3 
controls using the Ventana Benchmark ULTRA (Ventana Medical Systems Inc.). Four 
micrometer thick FFPE sections were stained for IgG. In brief, following 
deparaffinization and heat-induced antigen retrieval with CC1 (PH 9.0) for 36 
minutes, slides were incubated with primary antibody IgG (DAKO, A0423, dilution 
1:24000) at 37 ˚C for 32 minutes. Detection was performed with the ultraview kit 
(cat:760-500, Ventana) followed by incubation with hematoxylin II counter stain for 
8 minutes and then a blue coloring reagent for 8 minutes according to the 
manufactures instructions (Ventana). 
 
2.2 Control group 
 A matched control group was included to compare arteriolar C4d staining in 
biopsies from patients with c-aABMR to a group without rejection. To select controls, 
the pathology database of our center was searched for patients with a renal allograft 
biopsy in the period 2007- 2014 without evidence of ABMR. This was the same time 
period as the c-aABMR cases allowing for similar (immunosuppressive) treatment 
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regimens. Patients were matched to controls in a 1:1 ratio based on the criterion 
ʺpresence of a for-cause renal allograft biopsy at the same time after transplantation 
as the caseʺ. Controls with a histological diagnosis of hypertensive nephropathy, 
diabetic nephropathy and calcineurin inhibitor (CNI) nephrotoxicity were also 
included since ah is often seen in these biopsies, as well as in cases with c-aABMR, 
making it possible to compare the association between ah and arteriolar C4d staining 
in both groups.17-19 
 
2.3 Native renal biopsies 
 A total of 18 native renal biopsies was included to compare arteriolar C4d 
staining in biopsies from patients with c-aABMR to a group of native renal biopsies 
with a histological diagnosis of diabetic nephropathy, hypertensive nephropathy or 
CNI nephrotoxicity. C4d immunohistochemistry was additionally performed in these 
biopsies and both arteriolar C4d staining and ah were scored. 
 
2.4 Statistical analysis 
 SPSS Statistics version 24.0 was used for all statistical analyses (IBM SPSS 
Statistics for Windows. Armonk, NY: IBM Corp.). Differences with a (two sided) p-
value of less than 0.05 were considered statistically significant. Differences in patient 
characteristics between cases and matched controls were analyzed by the 
McNemar’s test for categorical variables and the paired sample t-test or Wilcoxon 
signed rank test for continuous variables. To compare pathological features, 
including arteriolar C4d scores, in the cases and matched controls, the Wilcoxon 
signed rank test was used. To compare patient characteristics in the cases and native 
renal biopsies the Chi-square test was used for categorical variables and the 
independent sample t-test or Mann Whitney U test for continuous variables. To 
compare arteriolar C4d scores the Chi-square test was used.  
 For comparison of the patient characteristics in the c-aABMR subgroups, 
one-way ANOVA was used for comparison of continuous variables with normal 
distribution and the Kruskal-Wallis test for continuous variables without normal 
distribution. Categorical variables were compared using the Chi-square test. 
Pathological findings were analyzed using the Chi-square test. 
 To evaluate the prognostic value of arteriolar C4d staining in patients with 
suspicious/diagnostic c-aABMR, we calculated graft survival rates measured from 
time of biopsy. Allograft failure was defined as the need to return to dialysis or re-
transplantation. Graft survival was compared using Kaplan Meier survival analysis and 
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log rank test. Univariate and multivariate Cox regression analysis was performed to 
adjust for other variables associated with graft loss. 
 
2.5 Medical ethics 
 The study protocol was consistent with professional guidelines and the 
Declaration of Istanbul; non WMO compliant research is research not residing under 
the Dutch law on medical research with patients and is regulated by the Dutch Code 
of Conduct (Federa). Based on this, the study was exempt from approval from the 
local medical ethics committee. 
 
3. Results 
 
3.1 Patient characteristics 
 A total of 46 patients with suspicious/diagnostic c-aABMR diagnosed 
between 2007 and 2014 was identified. Histological slides were available for 40 of 
these patients and these were included in this pilot study. Of these, the diagnosis 
was “suspicious for c-aABMR” in 23 patients (58%) and “diagnostic for c-aABMR” in 
17 patients (42%). Patient age ranged between 19 and 72 years (mean 50 ± 15 years). 
Thirteen patients (33%) were recipients of a deceased donor allograft (mean donor 
age: 47 ± 13 years). Fourteen patients (35%) were re-transplant recipients. The 
average eGFR at time of biopsy was 31.2 ± 7.9 mL/min per 1.73 m². DSAs were 
present in 17 patients (42%). Thirty-three patients (83%) received treatment with 
tacrolimus. Transplant glomerulopathy (cg>0) was seen in all biopsies with c-aABMR 
(n=40). In most biopsies, cg3 was observed (80%). In 2 cases, cg1a was diagnosed 
based on electron microscopy. All biopsies (n=40) had a microvascular inflammation 
score (ptc + g; MVI) ≥ 2 (median 5; range 3 - 6). C4d positivity in the PTCs was found 
in 18 patients (45%); <10% in 10 patients (56%), 10-50% in 2 patients (11%) and 
>50% in 6 patients (33%). Eight patients with C4d staining in the PTCs had a diagnosis 
of suspicious c-aABMR and 10 patients diagnostic c-aABMR. 
 In addition, 40 matched controls were selected. The histological diagnoses 
in the matched controls were T-cell mediated rejection only (TCMR; n=8), 
hypertensive nephropathy (n=8, of which 3 also showed TCMR), diabetic 
nephropathy (n=2, of which 1 also showed TCMR), CNI nephrotoxicity (n=3), 
interstitial fibrosis and tubular atrophy (n=6), focal segmental glomerulosclerosis 
(n=4, of which 2 also showed TCMR), recurrent IgA nephropathy (n=6, of which 2 
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also showed TCMR), membranous glomerulopathy (n=1), acute tubular necrosis 
(n=1) and ascending urinary tract infection (n=1). 
 Eighteen native renal biopsies with a histological diagnosis of diabetic 
nephropathy (n=6), hypertensive nephropathy (n=8) and CNI nephrotoxicity (n=4) 
were included. Of the patients with CNI nephrotoxicity, 2 had a prior lung 
transplantation, 1 patient had a heart transplantation and 1 a liver transplantation. 
Patient characteristics of the 3 groups and transplant–related characteristics and 
pathological features according the Banff Classification 2015 of the c-aABMR and 
matched control group are shown in Table 1. 
 
 
Table 1. Clinical characteristics of suspicious/diagnostic c-aABMR cases, matched 
controls and native renal biopsies. 
 
c-aABMR 
cases 
matched 
controls 
P 
native 
biopsies 
P 
n (%) 40 40  18  
Recipient age (years), mean (SD) 50±15 55±14 0.08 48±13 0.66 
Male (%) 24 (60) 25 (63) 1.00 13 (72) 0.28 
Hypertension (%)1 30 (75) 28 (70) 0.77 12 (67) 0.36 
Diabetes mellitus (%)2 12 (30) 13 (33) 1.00 12 (67) 0.01 
Deceased donor (%) 13 (31) 15 (38) 0.80 NA NA 
Donor age (years), mean (SD) 47±13 54±14 0.02 NA NA 
Re-transplantation (%) 14 (35) 7 (18) 0.14 NA NA 
Time to biopsy (months), mean (SD) 72±44 73±44 0.49 NA NA 
eGFR (ml/min/1.73m2)3, mean (SD) 31.2±7.9 36.1±16.1 0.07 45.6±25.5 0.002 
Proteinuria (g/24 h)3, median (IQR) 0.8 (1.2) 0.4 (0.9) 0.02 1.1 (0.5) 0.76 
Tacrolimus treatment (%) 33 (83) 38 (95) 1.00 NA NA 
Primary kidney disease      
Hypertensive nephropathy 7 12  8  
Diabetic nephropathy 7 3  6  
PKD 3 7  4  
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Table 1. Continued      
IgA nephropathy 0 7  0  
FSGS 1 5  0  
Chronic pyelonephritis 3 0  0  
Obstructive nephropathy 1 2  0  
Other 16 4  0  
Undetermined 2 0  0  
Banff Criteria 2015, median (range)      
Total inflammation (ti) 3 (0-3) 1 (0-3) <0.001   
Interstitial inflammation (i) 2 (0-3) 0 (0-3) <0.001   
Tubulitis (t) 0 (0-3) 1 (0-3) 0.007   
Intimal arteritis (v) 0 (0-2) 0 (0-0) 0.001   
Glomerulitis (g) 3 (2-3) 0 (0-3) <0.001   
Peritubular capillaritis (ptc) 2 (0-3) 0 (0-1) <0.001   
Interstitial fibrosis (ci) 2 (0-3) 1 (0-3) 0.009   
Tubular atrophy (ct) 1 (0-3) 1 (0-3) 0.38   
Vascular intimal thickening (cv) 2 (0-3) 2 (0-3) 0.06   
Transplant glomerulopathy (cg) 3 (1-3) 0 (0-1) <0.001   
Arteriolar hyalinosis (ah) 2 (0-3) 2 (0-3) 0.30   
Mesangial matrix increase (mm) 3 (0-3) 2 (0-3) 0.008   
C4d deposition in PTCs 0 (0-3) 0 (0-0) <0.001   
C4d deposition in GBM 3 (0-3) 0 (0-3) <0.001   
C4d deposition in arterioles 2 (0-3) 1 (0-3) 0.01   
C4d deposition in arteries 0 (0-2) 1 (0-3) 0.22   
1Defined as treatment with antihypertensive drugs. 
2Defined as treatment with glucose-lowering drugs. 
3Measurements at time of biopsy. 
PKD, polycystic kidney disease; FSGS, focal segmental glomerulosclerosis, PTCs, peritubular capillaries; 
GBM, glomerular basement membrane. 
118 | Chapter 5 
 
3.2 Arteriolar C4d staining 
 Thirty-four c-aABMR cases (85%) showed arteriolar C4d staining in their 
biopsy compared to 23 of the matched controls (58%) and 14 of the native renal 
biopsies (78%). A score of ≥2 was observed in 26 c-aABMR cases (65%) compared to 
13 matched controls (32.5%) and 6 native renal biopsies (33%). A significant 
difference in arteriolar C4d staining score was observed between cases and matched 
controls (p = 0.01) and a trend toward more arteriolar C4d staining in c-aABMR cases 
compared to native renal biopsies (p = 0.05; Figure 1). Figure 2 shows microscopic 
examples of arteriolar C4d staining.  
 In the c-aABMR cases, no significant correlation was found between 
arteriolar C4d staining and recipient age, donor age or donor type (Table 2). Also, a 
clinical diagnosis of diabetes mellitus and hypertension was not associated with 
arteriolar C4d staining. Interestingly, DSAs were detectable in all patients without 
arteriolar C4d staining (n=6) while only 32% of patients with arteriolar C4d staining 
had detectable DSAs (p = 0.009). Arteriolar C4d staining was not significantly 
associated with time after transplantation (p = 0.62).   
 
Figure 1. Overview of arteriolar C4d staining scores in the suspicious/diagnostic c-aABMR 
group, the matched control group and native renal biopsies. 
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Table 2. Characteristics of the patients with suspicious/diagnostic c-aABMR and 
subgroups defined by arteriolar C4d staining (negative, 1+, 2+ and 3+) in their kidney 
allograft biopsy.  
 All C4d 0 C4d 1+ C4d 2+ C4d 3+ P 
N 40 6 8 11 15  
Recipient age (years), 
mean (SD) 
50±15 58±7 45±11 53±18 47±16 0.31 
Male 24 3 5 9 7 0.31 
Hypertension1 30 5 4 9 12 0.34 
Diabetes mellitus2 12 1 2 4 5 0.83 
Deceased donor 13 3 2 4 4 0.72 
Donor age (years), 
mean (SD) 
47±13 48±16 44±15 45±13 50±12 0.69 
Re-transplantation 14 3 4 2 5 0.43 
Time to biopsy (months), 
mean (SD) 
72±44 50±27 77±59 77±41 75±43 0.62 
PRAs current, 
median (IQR) 
0 (4) 0 (8) 1 (4) 0 (3) 0 (0) 0.78 
PRAs historical, 
median (IQR) 
4 (27) 6.5 (27) 5 (25) 4 (22) 6 (39) 0.81 
Detectable DSAs 17 6 1 5 5 0.009 
eGFR (ml/min/1.73m2)3, 
mean (SD) 
31.2±7.9 33.3±8.5 28.4±9.5 32.1±6.4 31.1±8.4 0.68 
Proteinuria (g/24 h)3, 
median (IQR) 
0.8 (1.2) 1.1 (5.2) 0.9 (1.3) 0.7 (1.1) 0.7 (1.2) 0.67 
Cumulative TAC exposure 
(ng/mL), median (IQR) 
537.5 
(554.3) 
301.7 
(564.2) 
412.2 
(317.3) 
661.2 
(517.1) 
585.2 
(695.3) 
0.52 
1Defined as treatment with antihypertensive drugs. 
2Defined as treatment with anti-diabetic drugs. 
3Measurements at time of biopsy. 
DSAs, donor‐specific antibodies; PRAs, panel reactive antibodies; TAC, tacrolimus. 
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3.3 Associations with other pathologic findings in c-aABMR cases 
 In 20 of 22 cases without C4d staining in the PTCs, arteriolar C4d staining 
was observed (90%). However, no negative significant association was found 
between arteriolar C4d staining score and C4d staining in PTCs (p = 0.07; Table 3). In 
addition, other C4d staining patterns (in glomeruli and arteries) did not show a 
significant association with arteriolar C4d staining. Ah was found in 35 biopsies of 
patients with c-aABMR (88%) and was classified as ah1 in 9 patients (26%), ah2 in 7 
patients (20%) and ah3 in 19 patients (54%). No difference in ah score was observed 
between c-ABMR cases and matched controls (p = 0.30) or between c-aABMR cases 
and native renal biopsies (p = 0.08). Arteriolar C4d staining was significantly 
associated with the severity of ah in the cases (p = 0.004) and native renal biopsies 
(p = 0.024) but not in the matched controls (p = 0.09). Furthermore, c-aABMR cases 
with arteriolar C4d staining showed significantly more interstitial inflammation (p = 
0.007) which was not observed in the matched controls (p = 0.12). 
 Arteriolar C4d staining in the c-aABMR cases was evaluated in more detail; 
endothelial C4d staining in the arterioles was observed in 9 cases (27%) and mural 
arteriolar C4d staining was observed in 10 cases (29%). Fifteen cases showed both 
endothelial and mural arteriolar C4d staining (44%). The association of the arteriolar 
C4d staining pattern in c-aABMR cases (endothelial, mural + endothelial, or 
exclusively mural C4d staining) with other pathological findings according to the 
Banff Classification 2015 was analyzed and no significant differences were found 
between these subgroups (Table S1, SDC, http://links.lww.com/TP/B809). 
 Of the 5 cases without ah, 1 case showed 1+ arteriolar C4d staining, 1 
showed 2+ arteriolar C4d staining and 3 showed 3+ arteriolar C4d staining. In 
contrast, of the 6 cases without arteriolar C4d staining, ah1 was observed in 5 cases 
and ah3 in 1 case. In cases with ah, arteriolar C4d staining seemed often located at 
the site of the hyalinosis (Figure 3). To visualize this, C4d immunohistochemistry 
followed by PAS+ staining was performed in cases as proof of principle showing that 
arteriolar C4d staining is present within the hyalinosis (Figure 4). 
 To exclude the possibility of arteriolar C4d staining not being specific (and 
therefore not reflective of real complement activation) an IgG rabbit polyclonal 
staining was performed in 3 cases and 3 controls. IgG showed no staining in the 
arteriolar walls. In particular, no staining was observed at the sites of arteriolar 
hyalinosis. Nonspecific IgG staining was observed in a heterogeneous fashion; focally 
in tubular epithelial cells, the Bowman's space and some lumen of the arterioles 
(Figure S1, SDC, http://links.lww.com/TP/B809). 
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Figure 2. Representative photomicrographs of scoring immunohistochemical arteriolar C4d 
staining in renal allograft biopsies. (A) score 1+, (B) 2+ and (C) 3+ (magnification 400x). 
 
 
Figure 3. (A) PAS+ staining with an example of severe arteriolar hyalinosis (ah3) (magnification 
200x) and (B) 3+ arteriolar C4d staining in arterioles showing severe arteriolar hyalinosis (ah3) 
(magnification 400x). 
 
 
Figure 4. (A) Example of a c-aABMR case with mural arteriolar C4d staining (magnification 
200x). (B) Immunohistochemistry for C4d was followed by PAS+ showing arteriolar C4d 
staining at the site of the hyalinosis (magnification 200x). 
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Table 3. Association of arteriolar C4d staining scores with other pathological findings 
in biopsies with suspicious/diagnostic c-aABMR. 
Banff Criteria 2015 (n=40) 
N (%) 
C4d 0 
6 (15) 
C4d 1+ 
8 (20) 
C4d 2+ 
11 (27) 
C4d 3+ 
15 (38) 
P 
 
Total inflammation (ti) 2 (0-3) 2 (1-3) 3 (1-3) 3 (0-3) 0.54 
Interstitial inflammation (i) 0 (0-3) 1 (1-3) 3 (1-3) 3 (0-3) 0.007 
Tubulitis (t) 0 (0-3) 0 (0-1) 0 (0-2) 0 (0-2) 0.53 
Intimal arteritis (v) 0 (0-0) 0 (0-1) 1 (0-2) 0 (0-2) 0.10 
Glomerulitis (g) 3 (2-3) 3 (2-3) 3 (3-3) 3 (0-3) 0.26 
Peritubular capillaritis (ptc) 2 (1-3) 2 (0-3) 2 (0-3) 3 (1-3) 0.58 
Interstitial fibrosis (ci) 1 (0-3) 1 (0-3) 1 (0-3) 2 (0-3) 0.27 
Tubular atrophy (ct) 1 (1-2) 1 (0-3) 1 (0-1) 2 (1-3) 0.06 
Vascular intimal thickening (cv) 1 (0-3) 2 (0-3) 1 (1-3) 3 (0-3) 0.06 
Transplant glomerulopathy (cg) 3 (1-3) 3 (1-3) 3 (1-3) 3 (1-3) 0.76 
Arteriolar hyalinosis (ah) 1 (1-3) 2 (0-3) 3 (0-3) 3 (0-3) 0.004 
Mesangial matrix increase (mm) 3 (0-3) 3 (0-3) 3 (0-3) 3 (0-3) 0.67 
C4d deposition in PTCs 2 (0-3) 0 (0-2) 1 (0-3) 0 (0-3) 0.07 
C4d deposition in GBM 2 (2-3) 1 (0-3) 3 (0-3) 3 (0-3) 0.35 
C4d deposition in arteries 1 (0-1) 0 (0-2) 0 (0-2) 1 (0-2) 0.29 
Pathological lesions in the cases with c-aABMR according to the Banff 2015 criteria and the association 
with arteriolar C4d staining. Median and range of the pathological lesions in the arteriolar C4d subgroups 
are showed in the table.  
PTCs, peritubular capillaries; GBM, glomerular basement membrane. 
 
3.4 Associations of arteriolar C4d staining with other pathologic findings 
 in the entire cohort 
 In the entire cohort of 80 patients (c-aABMR cases and matched controls), 
arteriolar C4d staining was observed in 57 patients (71%). No significant association 
between arteriolar C4d staining and other C4d staining patterns was observed in the 
entire cohort (Table S2, SDC, http://links.lww.com/TP/B809). Biopsies with arteriolar 
C4d staining showed significantly more interstitial inflammation (p < 0.001) and a 
higher score of total inflammation (p = 0.02) and intimal arteritis (p = 0.01). No 
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significant association was found between ah score and arteriolar C4d staining in the 
entire cohort (p = 0.07). 
 
3.5 Arteriolar C4d staining and the cumulative tacrolimus exposure 
 For the calculation of the cumulative tacrolimus exposure a mean of 41 
measurements per patient (range 9 - 83) was available in the c-aABMR cases. The 
median cumulative tacrolimus exposure was 537.5 ng/mL (IQR 554.3 ng/mL). A 
significant association was observed between severity of ah and cumulative 
tacrolimus exposure (p = 0.038). No significant association was found between 
arteriolar C4d staining score and cumulative tacrolimus exposure (p = 0.52). In the 
entire cohort, a mean of 45 measurements per patient (range 7 - 107) was available 
and median tacrolimus exposure was 523.4 ng/mL (IQR 492.4 ng/mL). No significant 
association was observed between ah and cumulative tacrolimus exposure (p = 0.24) 
or arteriolar C4d staining score and cumulative tacrolimus exposure (p = 0.46). 
 
3.6 Arteriolar C4d staining and transplant outcome in c-aABMR cases 
 Graft loss was seen in 24 c-aABMR cases (60%) and mean time after biopsy 
was 42 ± 21 months. No patients died during follow up. Since the groups were small 
we combined the 4 groups into 2 groups; arteriolar C4d 0/1+ and arteriolar C4d 
2+/3+. In the arteriolar C4d 0/1+ group 86% of the grafts failed vs. 46% in the 
arteriolar C4d 2+/3+ group. Graft survival was significantly worse in the group with 
0/1+ C4d staining in the arterioles (log rank p = 0.01; Figure 5A). Both C4d staining 
in the PTCs and DSA status was not significantly associated with graft survival (log 
rank p = 0.13 and p = 0.22 respectively; Figures 5B and 5C). 
 Univariate Cox regression analyses demonstrated that interstitial fibrosis was 
significantly associated with inferior graft survival (hazard ratio 1.559, 95%-Cl: 1.069-
2.272, p = 0.021), while ah showed a trend toward superior graft survival (hazard ratio 
0.760, 95%-Cl: 0.538-1.073, p = 0.12). A multivariate Cox regression analysis 
identified that 2+/3+ arteriolar C4d staining was independently associated with a 
decreased risk of allograft loss after adjusting for both interstitial fibrosis and ah 
(hazard ratio 0.260, 95%-Cl: 0.104-0.650, p = 0.004; Table 4). 
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Table 4. Multivariate Cox regression analysis for graft failure. 
 HR (95%-CI) P 
Arteriolar C4d staining (0/1+ vs. 2+/3+) 0.260 (0.104 – 0.650) 0.004 
Arteriolar hyalinosis 0.852 (0.582 – 1.247) 0.409 
Interstitial fibrosis 1.865 (1.211 – 2.872) 0.005 
Multivariate Cox regression analysis using those variables with a p-value <0.15 in a univariate analysis; 
arteriolar C4d staining, arteriolar hyalinosis and interstitial fibrosis. 
HR, hazard ratio; CI, confidence interval 
 
4. Discussion 
 
 C4d staining in the PTCs of renal allograft biopsies is a diagnostic criteria for 
ABMR and correlates with graft dysfunction.10-12 However, there are limited data 
about the prevalence of arteriolar C4d staining in c-aABMR. This pilot study 
demonstrates that arteriolar C4d staining is a common finding in biopsies with 
suspicious/diagnostic c-aABMR as it was present in 85% of the cases and it seems to 
be associated with superior graft function over time. In addition, we found that 
arteriolar C4d staining is significant associated with ah. 
 The presence of C4d staining outside of the PTCs has only been described in 
a few publications. Batal et al. found C4d positivity in the arterioles in 22 out 48 (46%) 
paraffin embedded biopsies from patients with a history of DSAs.20 Kikić et al. 
observed arteriolar C4d staining in 163 out 243 patients (67%) with a for-cause renal 
allograft biopsy.21 They found a significant relationship between both arteriolar and 
glomerular C4d staining and C4d staining in the PTCs and concluded that there 
might be a relationship between humoral alloimmunity and distinct less established 
staining patterns.21 It has been suggested that C4d staining in the glomerulus is 
associated with transplant glomerulopathy, most likely as a marker of structural 
capillary wall remodeling.22-25 We did not observe an association between arteriolar 
C4d staining and C4d staining in the glomeruli. Through performing additional 
stainings with IgG we also showed that the deposition of C4d in the arterioles by 
immunohistochemical staining is specific. 
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Figure 5. (A) Graft survival in patients with suspicious/diagnostic c-aABMR in the arteriolar C4d 
2+/3+ group (n=26; dotted line) and arteriolar C4d 0/1+ group (n=14; continuous line; 
p=0.01). (B) Graft survival in patients with suspicious/diagnostic c-aABMR with C4d staining in 
PTCs (n=18; dotted line) and without C4d staining in the PTCs (n=22; continuous line; p=0.13). 
(C) Graft survival in patients with suspicious/diagnostic c-aABMR with detectable DSAs (n=17; 
dotted line) and without detectable DSAs (n=13; continuous line; p=0.22). 
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 A matched control group and a cohort of native renal biopsies were included 
for further comparison. A significant difference in arteriolar C4d score was observed 
between c-aABMR cases and matched controls and there was a trend toward higher 
arteriolar C4d staining scores in the c-aABMR group compared to the group with 
native renal biopsies. 3+ arteriolar C4d staining was observed in 38% of the c-aABMR 
cases compared to only 6% of the native renal biopsies. The lower sample size in the 
cohort of native renal biopsies might be an explanation for the fact that no significant 
difference was reached. 
 Ah may be caused by any chronic endothelial cell injury and is commonly 
found in patients with diabetes mellitus and hypertension.19, 28, 29 In accordance with 
the study of Batal et al. a significant association between arteriolar C4d staining and 
severity of ah was found in the c-aABMR cases in our study.20 Arteriolar C4d staining 
showed no significant association with a clinical diagnosis of hypertension or 
diabetes mellitus. 
 As ah is frequently considered to be the consequence of chronic CNI 
nephrotoxicity, we analyzed the cumulative tacrolimus exposure.17, 18 A previous 
report from Einecke et al. suggested that ah is rather the consequence of adequate 
CNI treatment over time than CNI nephrotoxicity.30 They observed increased risk of 
graft loss in patients without ah, probably as a result of underimmunosuppression 
and nonadherence. While ah and cumulative tacrolimus exposure showed a 
significant association in the c-aABMR cases, no significant correlation between 
cumulative tacrolimus exposure and arteriolar C4d staining was found, indicating 
that, unlike ah, arteriolar C4d staining is not tightly associated with cumulative 
tacrolimus exposure. This significant association between ah and the cumulative 
tacrolimus exposure was not observed in the entire cohort. An explanation for this 
finding might be that ah is caused by other factors than tacrolimus exposure in the 
matched control group, for example diabetic and hypertensive nephropathy. 
 A small number of patients in our study showed arteriolar C4d staining but 
no ah and vice versa, indicating that these features are not completely dependent. 
In cases with ah, arteriolar C4d staining was often observed at the site of the 
hyalinosis, which was confirmed by performing immunohistochemical staining for 
C4d followed PAS+. Subsequently, arteriolar C4d staining in the c-aABMR cases was 
further analyzed by subdividing the staining pattern into endothelial and mural 
staining, which might reflect two different processes. Endothelial arteriolar C4d 
staining seems to be related to classical pathway or lectin pathway-associated C4 
activation with deposition of C4d on the luminal surface of the endothelium.7 Mural 
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arteriolar C4d staining may be caused by leakage of luminal formed C4d into the 
arteriolar wall due to increased vascular permeability or seepage of plasma into the 
arteriolar wall with local C4d formation through the activation of either the classical 
or lectin complement pathway. This mural C4d in the arterioles seems to accumulate 
at the sites of hyalinosis.7 However, no significant differences in pathological lesions, 
including ah, according to the Banff Classification 2015 were observed between the 
different staining patterns (endothelial, mural and endothelial + mural arteriolar C4d 
staining). 
 The correlation of arteriolar C4d staining with other pathologic lesions 
(besides C4d staining in the glomeruli and PTCs and ah) according to the Banff 
Classification has not been evaluated before. We showed that interstitial 
inflammation was significantly associated with arteriolar C4d staining in both the c-
ABMR cases and the entire cohort. Furthermore, intimal arteritis and total 
inflammation were significantly associated with arteriolar C4d staining in the entire 
cohort. 
 The Banff classification 2015 was used in this pilot study which allowed us to 
use the category “suspicious for c-aABMR”. Since all biopsies showed histologic 
evidence of chronic tissue injury and evidence of current / recent antibody 
interaction with vascular endothelium (MVI≥2), the difference between suspicious 
and diagnostic c-aABMR in this study was based on the absence or presence of DSAs. 
In a previous study, Sablik et al. observed no difference in histomorphology between 
biopsies with c-aABMR with and without detectable DSAs.31 In our study, all 23 
patients with suspicious c-aABMR (without detectable DSAs) showed arteriolar C4d 
staining and in 10 cases (43%) 3+ staining was observed. Interestingly, we noticed 
that arteriolar C4d staining was significantly more often found in cases without 
detectable DSAs. In contrast to our study, Kikić et al. observed a trend towards more 
frequent detectable DSAs in patients with arteriolar C4d deposition compared to 
patients without arteriolar C4d deposition (13% vs 4%; p=0.06).21 
 In contrast to other studies, no significant relationship was shown between 
C4d staining in the PTCs and inferior graft survival.9-11, 13 Curve separation was 
observed but no significance difference in graft survival was reached in this pilot 
study. There are a few studies showing no differences in graft survival rates 
irrespective of the presence or absence of C4d staining in PTCs in late allograft 
biopsies with c-aABMR (after six months after transplantation).32 We observed that 
graft survival was better in c-aABMR patients with 2+/3+ arteriolar C4d staining 
compared to patients with 0/1+ arteriolar C4d staining. In a univariate Cox regression 
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analysis, as previously described in the literature, we found interstitial fibrosis to be 
associated with inferior graft outcome.33, 34 In a multivariate Cox regression analysis, 
the presence of 2+/3+ arteriolar C4d staining remained independently associated 
with superior graft outcome, regardless of the presence of interstitial fibrosis and ah. 
This finding is surprising and we cannot exclude the possibility that it is a confounder 
or a chance finding resulting from a limiting sample size. Since the c-aABMR group 
is small, we were not able to analyze this into more detail. Therefore, we cannot draw 
any conclusions from this observation and more research is needed to assess if 
arteriolar C4d staining is indeed related to superior graft outcome. 
 We recognize the limitations associated with this pilot due to the relatively 
small sample size and therefore no firm conclusions can be drawn. However, we did 
have complete information about the patient characteristics which made detailed 
evaluation possible. Furthermore, a matched control group and a cohort of native 
renal biopsies were included to examine arteriolar C4d staining in these groups and 
compare the results to the c-aABMR cases. 
 In conclusion, this pilot study shows that arteriolar C4d staining is a common 
finding in patients with c-aABMR and that it is significantly associated with the 
severity of ah. No significant relation was found with C4d staining in the PTCs. This 
study provides the first insights of arteriolar C4d staining in c-aABMR, however it 
remains to be confirmed if arteriolar C4d staining is truly specific for antibody-
mediated injury and related to superior graft function. These findings make it 
worthwhile to further investigate the etiology of arteriolar C4d staining in a larger 
cohort of patients with c-aABMR. 
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Table S1. Association of arteriolar C4d staining pattern (endothelial, mural and 
endothelial + mural C4d staining) with other pathological findings in the c-aABMR 
cases. 
Banff criteria 2015 (n=34) 
 
endothelial mural 
endothelial 
+ mural 
P 
 
N (%) 9 (27) 10 (29) 15 (44)  
Total inflammation (ti) 3 (1-3) 3 (1-3) 3 (0-3) 0.126 
Interstitial inflammation (i) 2 (1-3) 2 (1-3) 2 (0-3) 0.292 
Tubulitis (t) 0 (0-2) 0 (0-2) 0 (0-1) 0.765 
Intimal arteritis (v) 0 (0-2) 0 (0-1) 0 (0-2) 0.515 
Glomerulitis (g) 3 (2-3) 3 (3-3) 3 (3-3) 0.290 
Peritubular capillaritis (ptc) 3 (2-3) 2 (0-3) 3 (1-3) 0.126 
Interstitial fibrosis (ci) 1 (0-3) 2 (0-3) 2 (0-3) 0.653 
Tubular atrophy (ct) 1 (0-2) 1 (0-3) 1 (1-3) 0.474 
Vascular intimal thickening (cv) 2 (0-3) 3 (1-3) 3 (0-3) 0.504 
Transplant glomerulopathy (cg) 3 (1-3) 3 (1-3) 3 (1-3) 0.379 
Arteriolar hyalinosis (ah) 2 (0-3) 3 (1-3) 2 (0-3) 0.223 
Mesangial matrix increase (mm) 3 (0-3) 3 (0-3) 3 (1-3) 0.453 
C4d deposition in PTCs 1 (0-3) 0 (0-3) 0 (0-3) 0.969 
C4d deposition in GBM 3 (0-3) 2 (0-3) 3 (0-3) 0.286 
C4d deposition in arteries 0 (0-2) 0 (0-1) 1 (0-2) 0.140 
Pathological lesions in the c‐aABMR cases with endothelial, mural and endothelial + mural arteriolar C4d 
staining. The pathological features were scored according to the Banff 2015 criteria. Median and range of 
the pathological lesions in the subgroups (endothelial, mural and endothelial + mural arteriolar C4d 
staining) are showed in the table.  
PTCs, peritubular capillaries; GBM, glomerular basement membrane. 
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Table S2. Association of arteriolar C4d staining scores with other pathological 
findings in the entire group of 80 patients.   
Banff Criteria 2015 (n=80) 
N (%) 
C4d 0 
23 (29) 
C4d 1+ 
18 (22) 
 C4d 2+ 
16 (20) 
C4d 3+ 
23 (29) 
P 
 
Total inflammation (ti) 1 (0-3) 2 (0-3) 2 (0-3) 3 (0-3) 0.02 
Interstitial inflammation (i) 0 (0-3) 1 (0-3) 1 (0-3) 2 (0-3) <0.001 
Tubulitis (t) 0 (0-3) 0 (0-3) 0 (0-2) 0 (0-3) 0.86 
Intimal arteritis (v) 0 (0-0) 0 (0-1) 0 (0-2) 0 (0-2) 0.01 
Glomerulitis (g) 0 (0-3) 2 (0-3) 3 (0-3) 3 (0-3) 0.13 
Peritubular capillaritis (ptc) 0 (0-3) 0 (0-3) 2 (0-3) 2 (0-3) 0.11 
Interstitial fibrosis (ci) 1 (0-3) 1 (0-3) 1 (0-3) 2 (0-3) 0.10 
Tubular atrophy (ct) 1 (0-3) 1 (0-2) 1 (0-2) 2 (1-3) 0.05 
Vascular intimal thickening (cv) 1 (0-3) 2 (0-3) 2 (0-3) 3 (0-3) 0.08 
Transplant glomerulopathy (cg) 0 (0-3) 0 (0-3) 3 (0-3) 2 (0-3) 0.09 
Arteriolar hyalinosis (ah) 1 (0-3) 2 (0-3) 3 (0-3) 3 (0-3) 0.07 
Mesangial matrix increase (mm) 2 (0-3) 3 (0-3) 3 (0-3) 3 (0-3) 0.23 
C4d deposition in PTCs 0 (0-3) 0 (0-2) 0 (0-3) 0 (0-3) 0.07 
C4d deposition in GBM 0 (0-3) 0 (0-3) 2 (0-3) 2 (0-3) 0.47 
C4d deposition arteries 0 (0-2) 1 (0-3) 0 (0-3) 1 (0-2) 0.34 
Pathological lesions in the entire cohort of 80 patients (c‐aABMR cases and matched controls) according 
to the Banff 2015 criteria and the association with arteriolar C4d staining. Median and range of the 
pathological lesions in the arteriolar C4d subgroups are shown in the table.  
art, arteriolar; PTCs, peritubular capillaries; GBM, glomerular basement membrane 
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Figure S1. Examples of immunohistochemical C4d and IgG staining in 3 c-aABMR cases and 3 
matched controls. IgG immunohistochemistry is negative in the arterioles and no staining is 
observed at the sites of arteriolar hyalinosis (arrows).
C4d IgG
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Abstract 
 
C3-dominance by immunofluorescence is a defining feature in the diagnosis of C3 
glomerulopathy. Most pathologists stain for C3c, which has been reported as a 
trace/negative even in otherwise clear-cut cases of dense deposit disease. We 
investigated the usefulness of C3d immunohistochemistry in biopsies with C3 
glomerulopathy as an ancillary diagnostic tool. All biopsies from patients diagnosed 
with C3 glomerulopathy in the period January 2005 to June 2017 in the Erasmus MC, 
Rotterdam were included (n=14; 10 C3 glomerulonephritis, 4 dense deposit disease). 
The staining pattern of C3d and C4d by immunohistochemistry was analyzed. As 
controls, biopsies from patients with immune complex membranoproliferative 
glomerulonephritis (n=2), infection-associated glomerulonephritis (n=6), pauci-
immune crescentic glomerulonephritis (n=7), tubulointerstitial nephritis (n=7) and 
chronic-active antibody-mediated rejection (n=9) were included. All 14 biopsies with 
C3 glomerulopathy showed a C3d score of ≥2, including two clear-cut biopsies with 
C3 glomerulopathy originally showing a trace/negative staining for C3c. In the 
control group, a C3d score ≥2 was observed in 11 biopsies (35%; 2 with immune 
complex membranoproliferative glomerulonephritis (100%), 6 with infection-
associated glomerulonephritis (100%), 1 with pauci-immune crescentic 
glomerulonephritis (14%), 1 with tubulointerstitial nephritis (14%) and 1 with chronic-
active antibody-mediated rejection (11%)). C4d was positive in 71% of the biopsies 
with C3 glomerulopathy (10/14). In conclusion, C3d immunohistochemistry is a 
valuable tool in the diagnosis of C3 glomerulopathy, especially in cases in which C3c 
immunofluorescence shows a trace/negative. We recommend the use of C3d in 
addition to C3c in cases suspicious for C3 glomerulopathy. 
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1. Introduction 
 
 C3 glomerulopathy is a rare type of glomerulonephritis that encompasses 
both C3 glomerulonephritis and dense deposit disease.1 C3 glomerulopathy is 
characterized by C3 deposits in the glomeruli and is caused by uncontrolled 
activation of the alternative pathway of the complement system.2, 3 When the 
alternative complement pathway becomes activated, C3 is split into C3a and C3b by 
C3 convertase. C3b can react with other components of the complement cascade 
leading to the formation of the membrane attack complex (C5−C9), which together 
with C3a induces localized cell injury and inflammation. Degradation of C3b leads to 
the formation of C3c and the end product C3d.4-6  
Activation of the alternative complement pathway in patients with C3 
glomerulopathy can be caused by mutations in the complement genes, regulatory 
factors or by acquired defects.7 For example, specific autoantibodies called C3 
nephritic factor, inhibitory autoantibodies against complement factor H as well as 
inhibitory genetic alterations in the complement factor H gene can impair normal 
regulation of the alternative complement system.8-11 Rarely, monoclonal 
immunoglobulin may cause C3 glomerulopathy.12  
Renal biopsies from patients with C3 glomerulopathy can reveal various 
patterns of glomerular injury by light microscopy. In rare cases, no abnormalities are 
visualized by light microscopy.3 The main feature of C3 glomerulopathy is the 
presence of isolated C3 deposits in the glomeruli.2, 3 In 2013, the definition of C3 
glomerulopathy was further defined by the presence of dominant C3 staining with a 
staining score being at least two orders of magnitude greater than the other 
stainings (i.e. IgG, IgM, IgA and C1q).3, 13 Based on electron microscopy findings, C3 
glomerulopathy can be further subclassified into C3 glomerulonephritis and dense 
deposit disease, the prototypical form of C3 glomerulopathy.2 
In most laboratories, C3 is detected by immunofluorescence on frozen 
kidney tissue using an antibody against C3c.3, 14 However, even in clear-cut cases of 
dense deposit disease, C4d has been shown to be dominant on immunostaining 
instead of C3c in the experience of others,15, 16 as well as in our own experience. C4d 
is a fragment of C4 that can be derived from activation of both the classical and lectin 
complement pathway.17 In contrast, the activation of C4 is bypassed in the alternative 
pathway of complement.18 After the activation of C4, C4b is generated which is then 
cleaved into C4d and other fragments such as C4c.17, 19  
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C3d has been suggested to be a more sensitive marker to detect 
complement activation than the currently used immunofluorescence antibody to 
C3c.20 While C3c and other components of the complement system disappear after 
recovery from cell injury, C3d remains attached to the target cell.20 Therefore, C3d 
might be a more robust marker of C3 activation than C3c. Moreover, recent mass 
spectrometry data have shown that C3b, which also covalently binds surrounding 
structures, and C3d rather than C3c, accumulate in C3 glomerulopathy.21 
These observations challenge the traditional use of an antibody against C3c 
as the sole means of detecting C3 activation and deposition. In the present study we 
investigated if C3d staining by immunohistochemistry could be a useful 
complementary tool for detecting C3 deposits in the diagnosis of C3 
glomerulopathy, particularly in those cases that are pathogenetically defined but do 
not meet the consensus criterion of C3-dominance with the traditionally used C3c 
immunofluorescence. 
 
2. Methods 
 
2.1 Study cohort 
 The database of the Department of Pathology (Erasmus MC, University 
Medical Center, Rotterdam, the Netherlands) was searched retrospectively for 
biopsies from patients diagnosed with C3 glomerulopathy between January 2005 
and June 2017. The following clinical data were collected: age, gender, serum 
creatinine, proteinuria, C-reactive protein and serum C3 and C4 concentrations at the 
time of biopsy. The presence of antinuclear antigen antibodies, antineutrophil 
cytoplasmic antibodies, double stranded DNA antibodies, C3 nephritic factor 
autoantibodies and complement factor H autoantibodies, and genetic mutations in 
the complement genes was evaluated within 1 month before to 1 month after the 
first biopsy. 
 
2.2 Cases 
 A total of 14 biopsies from 11 different patients with C3 glomerulopathy 
were identified; eight patients were diagnosed with C3 glomerulonephritis and three 
with dense deposit disease. In two patients, more than one biopsy was performed 
(Table 1). In patient 11, two biopsies were performed: the first biopsy did not show 
specific glomerular deposition for C3c by immunofluorescence. Therefore, a second 
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biopsy was performed 6 weeks later. In patient 8, four biopsies were performed; the 
first biopsy was a native kidney biopsy that showed C3 glomerulonephritis. Four 
years later the patient received a kidney transplant with a decline of renal function 2 
weeks after transplantation. A total of three allograft biopsies was subsequently 
performed (2 weeks, 8 months and 13 months after transplantation, respectively) 
which all showed features of a recurrence of C3 glomerulonephritis. The renal 
allograft biopsy taken 13 months after transplantation also showed light microscopic 
features of a borderline acute cellular rejection and was therefore excluded from the 
present study. 
 
2.3 Controls 
 Two biopsies from patients with immune complex membranoproliferative 
glomerulonephritis (both cases of hepatitis C-associated immune complex 
membranoproliferative glomerulonephritis), six biopsies from patients with infection 
associated glomerulonephritis, seven biopsies from patients with pauci-immune 
crescentic glomerulonephritis, seven biopsies from patients with tubulointerstitial 
nephritis and nine from patients with chronic-active antibody-mediated rejection 
with transplant glomerulopathy (Banff Lesion Score cg>0) were included as 
controls.22 
 
2.4 Tissue processing 
 For light microscopy, paraffin-embedded sections were routinely stained 
with hematoxylin and eosin, periodic acid-Schiff, Jones and Trichrome, according to 
the standardized diagnostic protocols for renal biopsy processing. 
Immunofluorescence staining for IgG, IgA, IgM, C3c, C1q, kappa and lambda on fresh 
snap-frozen renal tissue was routinely performed immediately after renal biopsy in 
all cases. Immunofluorescence was performed on 5 μm sections of fresh snap-frozen 
tissue, which were air dried on adhesive glass slides and pretreated with acetone for 
10 min. Fluorescein-tagged polyclonal rabbit antihuman antibodies to IgG, IgA, IgM, 
C3c, C1q, kappa and lambda were all performed on a VENTANA BenchMark ULTRA 
according to the BenchMark Ultra protocol. For C3c, incubation with anti-C3c-FITC 
conjugated (Ventana 760–2686) for 24 min at 36 °C was performed. 
Immunofluorescence results, including C3c, were collected retrospectively from the 
biopsy reports. Electron microscopy was performed in all cases to differentiate 
between C3 glomerulonephritis and dense deposit disease.  
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For the purpose of the present study, immunohistochemical C3d staining 
was performed on 2–3 μm sections of formalin-fixed paraffin-embedded tissue. 
Tissue sections were dried overnight at 58 °C and subsequently deparaffinized, 
rehydrated and subjected to antigen retrieval using Lab Vision™ PT Module™ 
Deparaffinization and Heat-Induced Epitope Retrieval Solutions at pH 8. The tissue 
samples were incubated with the polyclonal antibody against C3d (#403A-76, Cell 
Marque) at 97 °C for 20 min and dilution 1:50. The detection system was used as 
recommended by the manufacturer.   
Immunohistochemical C4d staining was performed on 4 μm slides of 
formalin-fixed paraffin-embedded tissue with an automated, validated and 
accredited staining system (Ventana Benchmark ULTRA, Ventana Medical Systems, 
Tucsen, AZ, USA) using an ultra-view universal DAB detection kit. In brief, following 
deparaffinization and heat induced antigen retrieval with CC1 (#950-124, Ventana) 
for 64 min, the tissue samples were incubated with C4d (SP91, #760-4803, Cell 
Marque) for 24 min at 36 °C. C3d and C4d immunohistochemistry were scored on a 
scale from 0 to 3+ by two pathologists (MS and JUB) who were blinded to patient 
information. 
 We ruled out the entity of masked IgG kappa deposits recently described by 
Larsen et al. by staining all biopsies for kappa-light chains by immunohistochemistry 
after proteinase treatment of paraffin sections.23, 24 Five biopsies from patients with 
C3 glomerulopathy showed positivity for kappa (36%); three biopsies showed 2+ 
staining (21%) and two biopsies 1+ staining (14%). 3+ staining for kappa was not 
observed in any of the biopsies with C3 glomerulopathy, effectively ruling out this 
entity in all biopsies. 
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 3. Results 
  
 Patient characteristics are given in Table 1. The mean age at the time of 
diagnosis was 26 ± 22 years (range 5–76 years). Six patients (55%) were male. The 
mean serum creatinine concentration at the time of diagnosis was 412 ± 151 μmol/L. 
The degree of proteinuria at the time of biopsy was highly variable and ranged from 
0.4 to 11.8 g/L (mean proteinuria 4.5 ± 3.4 g/L). Nephrotic-range proteinuria was 
present in 6 of 11 patients. C-reactive protein was relatively low in all patients (mean 
10.1 mg/L, range 0.30–25.2 mg/L; reference range < 10 mg/L). Mean serum C3 at the 
time of diagnosis was 0.51 g/L (range 0.04–0.98 g/L; reference range: 0.65–1.65 g/L) 
and a low serum C3 (< 0.65 g/L) was observed in six patients. Mean serum C4 at the 
time of diagnosis was 0.22 g/L (range 0.05–0.54 g/L; reference range: 0.16–0.6 g/L); 
a decreased serum C4 was observed in four patients. Antinuclear antigen antibodies 
were found in five patients (45%); none of the patients tested positive for 
antineutrophil cytoplasmic antibodies. Evaluation of the alternative complement 
pathway was performed in nine patients. C3 nephritic factor autoantibodies were 
present in two patients (patients 2 and 10; Table 1). In one patient (patient 2) a 
heterozygous mutation with unknown significance was found in the C3 gene ((c.691A 
> C p.(Ser231Arg)). Complement factor H autoantibodies were dubiously positive in 
two patients (patients 2 and 4). 
 
3.1 Glomerular C3c staining by IF  
 A staining score of 2+ or 3+ for C3c by immunofluorescence was observed 
in 12 biopsies from patients with C3 glomerulopathy (ten biopsies showed 3+ 
staining and two biopsies 2+ staining). In two biopsies (patients 2 and 11) C3c by 
immunofluorescence showed negative to 1+ staining only (Figure 1). C3c by 
immunofluorescence was also dominant with 3+ in all biopsies with infection-
associated glomerulonephritis.  
 
3.2 Immunohistochemical glomerular C3d staining 
 All 14 biopsies with C3 glomerulopathy were positive for C3d: 11 biopsies 
showed 3+ staining for C3d and three biopsies showed 2+ staining for C3d (Figure 
2). A score of 2+ and 3+ was observed in the two biopsies showing 1+ and negative 
C3c staining by immunofluorescence, respectively (Table 2). 
 In the control group, C3d immunohistochemistry was positive in 22 of 31 
biopsies; 2+ or 3+ C3d staining was observed in 11 of 31 biopsies (35%): two biopsies 
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with immune complex membranoproliferative glomerulonephritis (100%), six 
biopsies with infection-associated glomerulonephritis (100%), one biopsy with pauci-
immune crescentic glomerulonephritis (14%), one biopsy with tubulointerstitial 
nephritis (14%) and one biopsy with chronic-active antibody-mediated rejection 
(11%). A score of 1+ for C3d was seen in 11 of 31 biopsies (35%): four biopsies with 
pauci-immune crescentic glomerulonephritis (57%), one biopsy with 
tubulointerstitial nephritis (14%), six biopsies with chronic-active antibody-mediated 
rejection (67%). The immunohistochemical findings are shown in Table 3. 
  
Table 2. Overview of C3c staining score by immunofluorescence and C3d staining 
by immunohistochemistry in biopsies from patients with C3 glomerulopathy. 
 
 C3GN C3 glomerulonephritis, DDD dense deposit disease, NA not available 
 a No glomeruli present in the snap frozen renal biopsy 
 
 
3.3 Consensus criteria for C3 glomerulopathy 
 Ten of 14 biopsies fulfilled the consensus criteria for C3 glomerulopathy 
based on C3c immunofluorescence staining alone (8/10 C3 glomerulonephritis and 
2/4 dense deposit disease).3 These ten biopsies showed dominant C3c staining by 
immunofluorescence and electron-dense deposits without substructure by electron 
microscopy. 
Patient Biopsy Diagnosis C3c IF  C3d IHC 
1    1 C3GN 3  3 
2    2 C3GN 0  3 
3    3 C3GN 3  3 
4    4 C3GN 3  3 
5    5 C3GN 2  3 
6    6 C3GN 3  3 
7    7 C3GN 3  2 
8    8.1 C3GN 3  3 
    8.2 C3GN NAa  3 
    8.3 C3GN 3  3 
9    9 DDD 3  3 
10    10 DDD 3  3 
11    11.1 DDD 1  2 
    11.2 DDD 2  2 
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 Based on both C3c immunofluorescence and C3d immunohistochemistry, 12 
of 14 biopsies (10/10 C3 glomerulonephritis, 2/4 dense deposit disease) fulfilled the 
criteria for C3 glomerulopathy. In patient 2, the diagnosis of C3 glomerulopathy 
could only be made after C3d immunohistochemistry staining because C3c 
immunofluorescence was negative while C3d immunohistochemistry showed 3+ 
staining. This patient showed characteristic ribbon-like electron-dense deposits in 
the thickened glomerular basement membrane by electron microscopy. One of the 
three biopsies performed in patient 8 did not contain glomeruli in the snap-frozen 
tissue and therefore the diagnosis of C3 glomerulopathy could not be made on this 
biopsy based on C3c immunofluorescence. However, C3d immunohistochemistry on 
the formalin-fixed paraffin-embedded slide showed 3+ staining in this biopsy. In 
patient 11, the diagnosis of C3 glomerulopathy could not be made according to the 
consensus criteria using both C3c immunofluorescence and C3d 
immunohistochemistry. However, electron microscopy showed glomerular basement 
membrane thickening with dense osmiophilic intramembranous electron deposits 
diagnostic of dense deposit disease. In this patient, two biopsies were performed, 
showing 1+ and 2+ staining for C3c immunofluorescence respectively, whereas both 
biopsies showed 2+ staining for C3d immunohistochemistry, raising the C3 staining 
to codominant. C1q showed 2+ staining in both biopsies. 
 
3.4 Immunohistochemical glomerular C4d staining 
 C4d staining was positive in 10 of 14 biopsies with C3 glomerulopathy (71%); 
six biopsies showed 3+ staining (43%), three biopsies 2+ staining (21%) and one 
biopsy 1+ staining (7%) (Figure 3). In addition, both biopsies with immune complex 
membranoproliferative glomerulonephritis showed 3+ staining for C4d (100%). Only 
2/6 biopsies with infection-associated glomerulonephritis showed ≥2+ staining for 
C4d (33%), the other four were negative. Three biopsies with pauci-immune 
crescentic glomerulonephritis showed 2+ staining (43%), while the other four were 
negative for C4d (57%). All seven biopsies with tubulointerstitial nephritis were 
negative for C4d. In biopsies with chronic active antibody-mediated rejection, one 
showed 3+ staining (11%), one showed 2+ staining (11%), four showed 1+ staining 
(45%) and three biopsies were negative (33%). 
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Figure 1. Examples of C3c by immunofluorescence in biopsies from patients with C3 
glomerulopathy (negative (A; biopsy 2), 1+ (B;  biopsy 11.1), 2+ (C; biopsy 5) and 3+ (D; biopsy 
8.3). 
 
 
Figure 2. Examples of C3d immunohistochemistry 1+ (A; biopsy 23), 2+ (B; biopsy 11.1) and 
3+ (C; biopsy 2). 
 
 
Figure 3. Examples of C4d immunohistochemistry 1+ (A; biopsy 4), 2+ (B; biopsy 2) and 3+ (C; 
biopsy 11.2). 
C
BA
D
A B C
A B C
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Table 3. Immunohistochemical staining with C3d, C4d and kappa in biopsies from 
patients with C3 glomerulonephritis, dense deposit disease, immune complex 
membranoproliferative glomerulonephritis, infection-associated glomerulonephritis, 
pauci-immune glomerulonephritis, tubulointerstitial nephritis and chronic-active 
antibody-mediated rejection. 
Patient Biopsy Diagnosis C3d C4d kappa 
1    1 C3GN 3 3 0 
2    2 C3GN 3 2 0 
3    3 C3GN 3 0 2 
4    4 C3GN 3 1 0 
5    5 C3GN 3 3 0 
6    6 C3GN 3 2 0 
7    7 C3GN 2 3 0 
8    8.1 C3GN 3 3 0 
    8.2 C3GN 3 2 2 
    8.3 C3GN 3 0 1 
9    9 DDD 3 0 0 
10    10 DDD 3 3 2 
11    11.1 DDD 2 0 0 
    11.2 DDD 2 3 1 
    
     
12    12 ICMGNP 3 3 1 
13    13 ICMGNP 3 3 2 
         
14    14 IAGN 3 3 0 
15    15 IAGN 3 2 0 
16    16 IAGN 3 0 0 
17    17 IAGN 3 0 0 
18    18 IAGN 3 0 0 
19    19 IAGN 3 0 0 
20    20 PCGN 1 0 1 
21    21 PCGN 0 0 1 
22    22 PCGN 1 2 0 
23    23 PCGN 1 0 0 
24    24 PCGN 2 2 3 
25    25 PCGN 1 2 0 
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Table 3. Continued 
26    26 PCGN 0 0 0 
    
     
27    27 TIN 0 0 0 
28    28 TIN 0 0 0 
29    29 TIN 0 0 0 
30    30 TIN 0 0 0 
31    31 TIN 2 0 0 
32    32 TIN 0 0 0 
33 
 
34 
35 
36 
37 
38 
39 
40 
41 
42 
 
   33 
 
34 
35 
36 
37 
38 
39 
40 
41 
42 
TIN 
 
c-aABMR 
c-aABMR 
c-aABMR 
c-aABMR 
c-aABMR 
c-aABMR 
c-aABMR 
c-aABMR 
c-aABMR 
1 
 
0 
1 
1 
0 
1 
1 
1 
2 
1 
0 
 
3 
1 
0 
0 
1 
1 
2 
1 
0 
0 
 
0 
0 
0 
1 
0 
1 
0 
0 
0 
c-aABMR chronic-active antibody-mediated rejection, C3GN C3 glomerulonephritis, DDD dense deposit 
disease, IAGN infection-associated glomerulonephritis, ICMGNP immune complex membranoproliferative 
glomerulonephritis, PCGN pauci-immune glomerulonephritis, TIN tubulointerstitial nephritis. 
 
4. Discussion 
 
 C3 glomerulopathy is a disease entity defined by dysregulation of the 
alternative complement pathway.2, 3 This results in the deposition of complement C3 
fragments in the glomerulus which is currently detected using immunofluorescence 
with an antibody to C3c.3 However, cases of dense deposit disease, the prototypical 
form of C3 glomerulopathy, with C4d-dominance (C4-dense deposit disease) not 
fulfilling the consensus criteria, have been observed.16, 25 C3d is one of the final 
degradation products of C3 and is more stable in vivo than C3c, because C3d remains 
attached to the tissue site after recovery of injury leaving a visible footprint.20 
Therefore, we hypothesized that C3d would be a more sensitive and robust 
immunostaining marker for the diagnosis of C3 glomerulopathy than C3c. 
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 We observed at least 2+ staining for C3d in all 14 biopsies with C3 
glomerulopathy. Interestingly, two biopsies with C3 glomerulopathy, in which C3c 
staining by immunofluorescence was negative/sparse, showed ≥2+ staining with 
C3d by immunohistochemistry (patients 2 and 11), enabling the reclassification as at 
least C3-codominant. In patient 11, two biopsies were performed in which the 
diagnosis of C3 glomerulopathy, according to the consensus criteria, could still not 
be made after C3d immunohistochemistry since both C3d immunohistochemistry 
and C1q immunofluorescence showed 2+ staining in both biopsies.3 However, 
electron microscopy showed glomerular basement membrane thickening with dense 
osmiophilic intramembranous deposits characteristic for dense deposit disease. So 
even after the use of C3d immunohistochemistry we are left with cases that, as either 
codominant or as only dominant by one magnitude do not fulfill the consensus 
criteria for C3 glomerulopathy. These findings raise the question whether the current 
consensus criteria are sensitive enough. 
 In patient 2, C4d immunohistochemistry was also performed at the time of 
diagnosis. Sethi et al. recently described three cases with C3 glomerulopathy in which 
no or only sparse C3c staining was observed by immunofluorescence and introduced 
a new entity called C4 glomerulopathy characterized by mesangial electron-dense 
deposits and bright staining for C4d with either immunohistochemistry or 
immunofluorescence and absent to a trace staining for C3 and immunoglobulins.15, 
16 In patient 2, C4d immunohistochemistry showed 2+ staining and therefore the 
diagnosis of C4 glomerulopathy was made at that time. However, C3d staining by 
immunohistochemistry showed 3+ staining and therefore this case might in fact 
represent a case of C3 glomerulopathy. Of course, we cannot rule out with absolute 
certainty a role for abnormal C1 or lectin pathway activation in this patient. However, 
positive C3 nephritic factor autoantibodies and a genetic mutation in the C3 gene 
were found, arguing for the diagnosis of C3 glomerulopathy in this particular case. 
Just relying on the traditional C3c immunofluorescence along with C4d staining, 
cases might be misdiagnosed as C4 glomerulonephritis or C4 dense deposit disease. 
C3d immunohistochemistry could be helpful in avoiding this mistake and to 
demonstrate a histopathological correlate to C3 activation. 
 In a study by Sethi et al, the use of C4d was evaluated to distinguish C3 
glomerulopathy from immune complex membranoproliferative 
glomerulonephritis.26 They observed ≥2+ C4d staining in 89% (16/18) of the biopsies 
with immune complex membranoproliferative glomerulonephritis, while C4d 
staining was found in only 20% (6/30) of the biopsies with C3 glomerulopathy 
                                                C3d in C3 glomerulopathy | 151 
 
 
showing only a trace or 1+ staining. Based on these results, they suggested that 
negative glomerular staining for C4d can serve as a marker for C3 glomerulopathy. 
In contrast, we observed C4d immunohistochemical staining in 10/14 biopsies with 
C3 glomerulopathy (71%), suggesting that C4d staining is in fact often observed in 
patients with C3 glomerulopathy. In line with our findings, Bouatou et al. concluded 
that C4d staining is of limited value for the discrimination between C3 
glomerulopathy and immune complex membranoproliferative glomerulonephritis.27 
 We observed the presence of both ≥2+ staining for C3 (either C3c or C3d) 
and C4d in a total of nine biopsies with C3 glomerulopathy (64%) showing evidence 
of a complement-mediated glomerular disease driven by both the alternative and 
classical/lectin pathway. This finding has been described previously in a single case 
of dense deposit disease by Vankalakunt et al.28 Singh et al. performed an 
observational study including 27 dense deposit disease cases and 14 C3 
glomerulonephritis cases. They observed C4d staining of variable intensity with ≥2+ 
staining in 48% of dense deposit disease cases and 21% of C3 glomerulonephritis 
cases.29 It has been hypothesized that in these cases the alternative complement 
pathway is upregulated in addition to activation of the classical or lectin pathway 
caused by infection, auto-immune disease or monoclonal gammopathy.18 We 
stained for kappa after protease digestion on all biopsies and excluded monoclonal 
gammopathy in all C3 glomerulopathy cases in our study, effectively ruling out 
monoclonal gammopathy-associated forms of glomerulonephritis and the peculiar 
entity of masked kappa deposits recently described.23, 24 The possibility of an 
infection as a trigger for C3 glomerulopathy in some of the patients reported here 
could not be totally excluded.30 However, the rather low C-reactive protein 
concentration at the time of biopsy and the clinical findings in all patients argues 
against this. 
 The “typical” work-up for patients with suspicion for C3 glomerulopathy 
includes testing for antinuclear antigen antibodies, antineutrophil cytoplasmic 
antibodies, double-stranded DNA antibodies and exclusion of infections with 
hepatitis B and C, and HIV, as well as monoclonal gammopathy. In addition, patients 
are tested for serum complement C3, C4 and C1q, autoantibodies against 
complement factor H, C3 nephritic factor, C4 nephritic factor, terminal complement 
complex, Bb, C3bc, C3bBbP, Factor H, Factor I, Factor B and abnormalities in 
complement protein encoding or regulating genes.  
 Abnormalities in the alternative complement pathway are observed in most 
patients with C3 glomerulopathy.31, 32 In contrast to other studies, no abnormalities 
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in the alternative complement pathway were observed in the majority of C3 
glomerulopathy patients in our study. This may be explained by the small cohort size 
or the fact that alternative complement pathway abnormalities were only thoroughly 
evaluated in 9 out 11 patients (82%).   
 Limitations of this proof-of-principle study are the small cohort size and the 
fact that this was a retrospective study and therefore some clinical data were not 
available. However, a relatively large control group was included to compare 
immunohistochemical C3d staining results in renal biopsies from patients with C3 
glomerulopathy to biopsies from patients with such diverse diagnoses as immune 
complex membranoproliferative glomerulonephritis, infection-associated 
glomerulonephritis, pauci-immune crescentic glomerulonephritis, tubulointerstitial 
nephritis and chronic-active antibody-mediated rejection. As expected, biopsies 
from patients with immune complex membranoproliferative glomerulonephritis and 
infection associated glomerulonephritis showed 3+ staining for C3d 
immunohistochemistry. Biopsies with tubulointerstitial nephritis, pauci-immune 
crescentic glomerulonephritis and chronic-active antibody-mediated rejection were 
negative or showed only 1+ staining for C3d immunohistochemistry in most of the 
cases. C3 glomerulopathy can show overlapping histomorphologic features with 
pauci-immune crescentic glomerulonephritis and chronic-active antibody-mediated 
rejection which can make it difficult to distinguish between these entities by light 
microscopy.33-35 Dominant C3d staining by immunohistochemistry may support the 
diagnosis of C3 glomerulopathy in these cases. 
 Based on the findings in the present study, we recommend the use of C3d 
immunohistochemistry in addition to C3c immunofluorescence in all cases with 
membranoproliferative glomerulonephritis. In addition, both clinical suspicion and 
electron microscopy findings indicative of dense deposit disease could be of 
guidance to recommend the use of C3d immunohistochemistry, especially in those 
cases in which C3c immunofluorescence shows a trace/negative. Furthermore, C3d 
immunohistochemistry can be of value in those cases with a trace/negative C3c 
immunofluorescence and positive C4d staining, since these cases could be 
incorrectly labeled as C4d-dominant glomerulopathy. Also, in those cases where 
frozen renal tissue is not available, C3d immunohistochemistry could be used in 
common practice (in combination with C3c immunohistochemistry when this is 
available). For example, in our study no glomeruli were present in a snap-frozen renal 
biopsy from patient 8 (biopsy 8.2). This is a problem in cases with a strong suspicion 
for C3 glomerulopathy. C3c immunofluorescence has been reported to not be 
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reliable by salvage technique on formalin-fixed paraffin-embedded tissue by some 
laboratories.36 In those situations, C3d immunohistochemistry can be performed on 
the formalin fixed paraffin-embedded tissue.  
 In conclusion, C3d immunohistochemistry shows at least codominant 
staining in all biopsies with C3 glomerulopathy and could especially be helpful in 
those C3 glomerulopathy cases with absent or a trace C3c staining by 
immunofluorescence. Therefore, we recommend the use of C3d in addition to C3c 
on all biopsies suspicious for C3 glomerulopathy. Our results about the usefulness of 
C3d need validation in large, multicenter studies employing cluster-analysis 
approaches as has been suggested recently.37 
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Kidney transplantation is the treatment of choice for patients with end stage 
renal disease.1 Long-term transplant survival is determined by different variables 
including donor and recipient conditions, duration of cold and warm ischemia, 
degree of human leucocyte antigens (HLA) matching, ischemia-reperfusion injury 
(IRI) and acute and chronic rejection.2, 3 Improvement of immunosuppressive drug 
regimens, as well as pre-transplantation screening, have provided better donor-
recipient matching and reduced the chances of developing rejection. However, acute 
rejection and late graft failure remain common and difficult obstacles.4 Up to 50% of 
all renal allografts are lost within 10 years after transplantation.5 Better 
understanding of the various factors that contribute to allograft failure can provide 
insight into which patients are at risk for inferior graft outcome. This can result in the 
development of new treatment options leading to longer transplant survival rates, as 
well as an increase in the quality of life. The scope of this thesis was to evaluate 
potentially important pathological features in renal transplant biopsies in the post-
transplantation period. 
 
Histological and immunohistochemical features are important in the 
evaluation of renal allograft biopsies, but the presence of specific proteins and 
molecular markers in renal allograft tissue can also give deeper insight to predict 
which patients are at risk for future graft loss. For both diagnostics and future 
research purposes, it is vital that renal tissue is stored in a fashion that maximizes 
tissue preservation.6, 7 The most common embedding medium in which biopsy 
samples are snap-frozen is optimal cutting temperature (OCT) compound, a 
cryopreservative medium composed of polyethylene glycol (PEG), polyvinyl alcohol 
(PVA) and nonreactive ingredients. OCT stabilizes tissue allowing easy positioning of 
tissue samples in the microtome and provides a smooth cutting surface resulting in 
good quality of the tissue sections.8  
The analysis of complete sets of proteins in a given tissue sample can be 
performed by mass spectrometry (MS).9 MS analyses of OCT embedded tissue is 
difficult due to the presence of polymers in the OCT. The interference of these 
polymers in the MS analysis can cause suppression of ion formation and the presence 
of high polymer peaks of OCT in the mass spectra may hide other smaller peaks.8, 9 
These polymers are difficult to remove from the MS columns as they have a strong 
interaction with them. A portion of the polymers may even bind irreversibly which 
affect the separation performance and the lifetime of the columns considerably. 
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Therefore, the OCT has to be removed from the tissue samples before MS analysis is 
performed, which is a complex and time-consuming procedure.8, 10-12 
In Chapter 2 the use of Cryo-Gel as embedding compound for snap-freezing 
of renal biopsies, as a replacement for OCT, was evaluated. In this study, fresh renal 
samples were snap-frozen using Cryo-Gel, OCT and without embedding compound. 
In addition, samples from other tissue (spleen, skin, liver and colon) were analyzed. 
Cryo-Gel embedded tissue showed good morphological preservation, no 
interference with immunohistochemical or immunofluorescent investigations and a 
good quality of extracted RNA and DNA was observed. Polymers in the OCT 
embedded samples disturbed the signal in the MS, which was not observed in the 
Cryo-Gel embedded samples. Although the chemical compounds of Cryo-Gel are 
confidential, we assume that Cryo-Gel does not contain polymers like those in OCT 
compound.  
The polymers in OCT compound mainly suppress lower abundant signals 
which can only be observed using a mass spectrometer with high speed. In our study, 
protein analyses were obtained on an older type of mass spectrometer which is 
slower compared to the newest generation of mass spectrometers. This could be a 
potential explanation for the fact that no difference in the amount of identified 
proteins was observed, even while the polymer signal was clearly present in the 
acquired spectra. Based on the findings in the present study, it was concluded that 
Cryo-Gel is a preferable alternative for OCT compound for both diagnostic and 
research purposes of renal biopsies when MS is (possibly) required.  
 
In Chapter 3 the incidence of calcium oxalate (CaOx) deposition in the renal 
transplant biopsy within 3 months after transplantation as a cause of impaired graft 
function and its influence on graft survival was evaluated. CaOx deposition was 
observed in 26/149 biopsies (17%). Risk factors for CaOx deposition as described in 
literature are a high concentration of oxalic acid in the urine, damage to renal tubular 
cells, volume depletion and oliguria that leads to low tubular flow.13, 14 After renal 
transplantation, a large amount of oxalate is excreted. When the urine becomes 
supersaturated with oxalate, CaOx crystals are formed which can deposit in the renal 
tubules and cause damage to the renal tubular cells.15, 16 
In the present study, patients with CaOx deposition were significantly more 
often treated with dialysis before transplantation. This can be explained by the fact 
that the newly transplanted kidney is exposed to higher pre-transplant oxalic acid 
concentrations in patients dependent on dialysis compared to those with impaired 
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but functioning kidneys. Delayed graft function (DGF) was more common in patients 
with CaOx in their biopsies and the presence of CaOx was associated with a 
significantly lower estimated glomerular filtration rate at the time of biopsy. Also, 
graft survival was significantly worse in patients with CaOx deposition.  
The exact relationship between CaOx deposition and DGF in the renal 
allograft is challenging. CaOx can cause direct injury to the tubular cells which may 
promote the pathogenesis of DGF in the post-transplantation period.17, 18 However, 
it is also possible that injury to the tubular epithelial cells and low tubular flow as a 
result of DGF facilitate CaOx deposition. This all can lead to a vicious circle of damage 
to the renal allograft. Following this injury, impaired tubular repair can lead to tubulo-
interstitial fibrosis resulting in loss of function of the kidney transplant.19-21 Bagnasco 
et al. showed increased tubulo-interstitial scarring in biopsies with CaOx compared 
to those without in the analysis of repeating renal allograft biopsies.22 Based on these 
findings, the systematic examination of all for-cause renal allograft biopsies by 
polarized light for CaOx deposition is strongly advised. 
The relationship between plasma oxalic acid levels pre-transplantation and 
the risk for CaOx deposition was not evaluated in the present study, since plasma 
oxalic acid levels pre-transplantation were not available. However, it would be 
interesting to investigate this because it could identify those patients that may 
benefit from preventive treatment to reduce plasma oxalic acid levels pre- and post-
renal transplantation. A low oxalate diet (40-50 mg/day) and/or intensive 
hemodialysis treatment in the direct pre- and post-transplant phase, to lower the 
serum oxalate acid levels as much as possible and thereby reducing the risk of CaOx 
deposition in the renal allograft, should be considered in these patients.23  
 
The innate immune system has been shown to play an important role in the 
pathogenesis of renal transplant related injury. In Chapter 4 the mRNA expression 
of TLRs, complement and apoptosis‐related genes was examined in renal allograft 
biopsies from patients with acute rejection and paired pre‐implantation biopsies. In 
the pre‐implantation biopsies, the expression of the complement genes C2 and C3 
and the BAX:BCL2 ratio was higher in deceased donor kidneys compared to living 
donor kidneys. This is most likely the result of extensive IRI in deceased donor 
kidneys which initiates the activation of the innate immune system.24 High C2 and C3 
expression levels and a high BAX:BCL2 ratio might serve as early warning for IRI, 
before the renal transplant function deteriorates. Interestingly, no difference in the 
expression of TRLs was observed between pre‐implantation biopsies from living and 
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deceased donors. This could indicate that the TLR pathway is not as important as the 
complement pathway in the occurrence of IRI.  
IRI is considered the main cause of DGF. Interestingly, all recipients who 
developed DGF had received a renal allograft from a deceased donor. While a high 
BAX:BCL2 ratio in pre‐implantation biopsies has been associated with an increased 
risk of DGF by others, none of the markers investigated was predictive for DGF in the 
present study.25 
Paired pre-implantation and acute rejection biopsies were available for 75 
patients. TRL1-TLR3, TLR6-TLR10 and C2 showed higher expression levels in the 
acute rejection biopsies than in the pre-implantation biopsies, while the complement 
regulators CD46, CD55 and CD59 were slightly decreased during acute rejection. 
Additionally, we analyzed if the upregulation of TRLs during acute rejection could be 
ascribed to the infiltration of inflammatory cells in the renal biopsy. Therefore, the 
mRNA expression levels of CD163, CD68, CD20 and CD3e were evaluated. The TRLs 
each correlated with one or more inflammatory cell markers, except for TRL2, TLR3 
and TLR5. Also, C2 and C3 expression levels and the BAX:BCL2 ratio significantly 
correlated with the expression of macrophage makers (CD68, CD163). These findings 
show that the altered gene expression of TRLs and complement factors during an 
acute rejection may at least partly be the result of infiltrating inflammatory cells. TLR2 
and TLR3 expression levels were increased at the time of acute rejection but did not 
show a correlation with inflammatory markers. This suggests that TLR2 and TLR3 are 
dominantly expressed in the renal parenchyma itself, as has been described in a 
previous study.26   
Relatively high TLR4 expression and a high BAX:BCL2 ratio during acute 
rejection were shown to be independent risk factors for adverse outcome after 
transplantation in patients with a deceased donor kidney. Furthermore, a donor age 
of >50 years was shown to be a significant independent risk factor for allograft loss. 
None of the investigated genes in the pre-implantation biopsies was associated with 
graft loss.  
The findings presented in this study show that activation of the innate 
immune system occurs both at time of graft implantation and during acute rejection. 
Inhibition of complement pathways may act as a therapeutic target to protect the 
renal transplant from effects of IRI, especially in patients with a deceased donor renal 
allograft. Monitoring the TRL4 expression levels and BAX:BCL2 ratio during acute 
rejection may be of additional value in predicting future renal allograft outcome. 
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During antibody‐mediated rejection, the interaction between B cell 
responses and the classical complement pathway activation is demonstrated by 
positive C4d staining in the peritubular capillaries (PTCs).27 The significance of C4d 
staining in other structures of the renal allograft, like the glomeruli and arterioles, is 
not clear. In Chapter 5 the importance of arteriolar C4d staining by 
immunohistochemistry  (IHC) in patients with suspicious and diagnostic chronic 
active antibody‐mediated rejection (c‐aABMR) was analyzed. Arteriolar C4d staining 
was observed in 85% of the biopsies from patients with c‐aABMR and was less 
common in the control groups (renal allograft biopsies without rejection and a group 
of native renal biopsies). It was excluded that arteriolar C4d staining is a form of 
nonspecific staining through performing additional staining with IgG IHC. Arteriolar 
C4d staining showed no significant association with C4d staining in the PTCs or C4d 
staining in the glomeruli. Also, a C4d staining score of ≥2 in the arterioles was 
independently associated with superior graft outcome in a multivariate Cox 
regression analysis.  
In patients with c‐aABMR, arteriolar C4d staining was significantly associated 
with the severity of arteriolar hyalinosis (ah). In cases with ah, arteriolar C4d staining 
was often observed at the site of hyalinosis. Subsequently, arteriolar C4d staining in 
the c‐aABMR cases was further analyzed by subdividing the staining pattern into 
endothelial and mural staining, which might reflect two different processes. 
Endothelial arteriolar C4d staining is related to classical pathway or lectin pathway‐
associated C4 activation with deposition of C4d on the luminal surface of the 
endothelium.27 Mural arteriolar C4d staining is more likely to be caused by leakage 
of luminally formed C4d into the arteriolar wall or seeping of plasma into the 
arteriolar wall due to increased vascular permeability with local C4d formation 
through the activation of either the classical or lectin complement pathway.27 Mural 
C4d in the arterioles seems to accumulate at the sites of hyalinosis. 
Due to the relatively small sample size, the findings in this pilot study do not 
allow for any definitive conclusions about the finding of C4d staining in arterioles in 
the setting of c‐aABMR, but it is a useful starting point for further research. Larger 
studies are needed to examine in more detail if arteriolar C4d staining is truly related 
to antibody‐mediated injury. 
 
C3 glomerulopathy is a rare renal disease caused by excessive activation of 
the alternative complement pathway resulting in deposition of complement factor 
C3 in glomeruli.28, 29 A renal biopsy is required to evaluate the presence of these 
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depositions and to confirm the diagnosis. C3-dominance by immunofluorescence 
(IF) is a defining feature in the diagnosis of C3 glomerulopathy. However, clear-cut 
cases with C3 glomerulopathy not fulfilling the consensus criteria have been 
observed.30, 31 In Chapter 6 the usefulness of C3d IHC in biopsies with C3 
glomerulopathy as an ancillary diagnostic tool was evaluated. C3d IHC was analyzed 
in 14 biopsies with C3 glomerulopathy which all showed a C3d staining score of ≥2. 
In 4 biopsies, the diagnosis of C3 glomerulopathy according to the consensus criteria 
could not be made, as dominant C3c staining by IF was not observed. Interestingly, 
in 2 of these biopsies C3c IF was negative/sparse, while dominant staining with C3d 
by IHC (with a score of ≥2) was observed, thus confirming the diagnosis C3 
glomerulopathy. In the remaining 2 biopsies, the diagnosis C3 glomerulopathy, 
according to the consensus criteria, could still not be made after the use of C3d IHC, 
since both C3d and C1q showed 2+ staining in both biopsies. So even after the use 
of C3d IHC we are left with cases that do not fulfill the consensus criteria for C3 
glomerulopathy.  
Deposition of C4 and its breakdown products (e.g. C4d) in the kidney result 
from activation of the classical and/or lectin pathway.27 It has been suggested that 
C4d could be used to distinguish C3 glomerulopathy from immune complex 
membranoproliferative glomerulonephritis.32 Sethi et al. described that negative 
glomerular staining for C4d can serve as a marker for C3 glomerulopathy.32 However, 
this could not be confirmed in the present study as glomerular C4d staining by IHC 
was observed in 10 of 14 biopsies with C3 glomerulopathy (71%). In line with our 
findings, Bouatou et al. concluded that C4d staining is of limited value for the 
discrimination between C3 glomerulopathy and immune complex 
membranoproliferative glomerulonephritis.33 
The presence of both ≥2+ staining for C3 (either C3c or C3d) and C4d IHC 
was observed in 64% of the biopsies, showing evidence of a complement-mediated 
glomerular disease driven by both the alternative and classical and/or lectin pathway. 
It has been hypothesized that in these cases the alternative complement pathway is 
upregulated in addition to activation of the classical or lectin pathway caused by 
infection, auto-immune disease or monoclonal gammopathy.34 The possibility of an 
infection as a trigger for C3 glomerulopathy in some of the patients reported could 
not be completely excluded. The presence of kappa light chains as observed in 
monoclonal gammopathy can remain masked when performing IF on fresh frozen 
renal biopsies. Therefore, kappa staining was performed on formalin fixed paraffin 
embedded renal biopsies after protease digestion which effectively ruled out 
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monoclonal gammopathy-associated forms of glomerulonephritis in all C3 
glomerulopathy cases.35, 36   
This study shows that the current consensus criteria are not conclusive in a 
minority of the cases with C3 glomerulopathy. The use of C3d IHC in addition to C3c 
IF is recommended in all cases suspicious for C3 glomerulopathy, especially in those 
cases in which C3c IF is negative/sparse.  
 
The results presented in this thesis show specific histological characteristics 
and immunohistochemical and molecular markers in renal (transplant) biopsies that 
could be helpful in diagnostics and are associated with renal transplant outcome. 
The identification of these features in kidney tissue help us to better understand the 
pathogenesis of kidney diseases and could lead to new diagnostic and prognostic 
markers and subsequent superior (tailored) therapeutic regimens. 
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A renal core biopsy for histological evaluation is the gold standard to 
investigate renal (transplant) biopsies.1 However, histological interpretation of renal 
biopsies is subjective and differential diagnostic dilemmas remain a problem. 
Histology of rejection for example, can show a wide range of features and subjective 
interpretations of lesions may cause interobserver variation, despite the 
standardization of the histopathological features to diagnose rejection in the Banff 
Classification.2, 3 Molecular analysis may provide more clarity in renal transplant 
biopsies in which histological features are difficult to classify. Several publications 
have stressed the importance of combining current histological diagnostic practice 
with molecular analysis in renal transplant biopsies.4-7 The upregulation of specific 
molecular markers can improve diagnostics and predict renal transplant outcome 
more accurately than histological features. The Banff Foundation for Organ 
Transplantation is encouraging research to incorporate molecular analysis in the 
classification of kidney diseases.8 
Over time, different molecular techniques have been used to identify genes 
involved in allograft rejection.9 In recent years, molecular analysis using microarray 
expression analysis has garnered considerable interest. Advantages of these 
techniques are that small amounts of renal tissue are needed and the possibility to 
measure the expression of tens of thousands of genes simultaneously.10 A suitable 
platform to perform microarray analysis is the novel nCounter analysis system from 
NanoString. With the use of NanoString methodology, mRNA target molecules can 
be measured directly and therefore no reverse transcription step is required, which 
is innovative compared to other microarray platforms.11 It uses molecular barcodes 
in which up to 770 unique transcripts can be detected in one hybridization reaction. 
Only small amounts of RNA from formalin-fixed paraffin-embedded (FFPE) biopsies 
are needed (100 ng) and the analysis can be performed within two days, parallel and 
complementary to histology.11 
 
1. Molecular analysis in diagnosing acute TCMR 
 
Acute T cell-mediated rejection (TCMR) is characterized by infiltration of 
effector T cells and macrophages in the renal transplant. In acute TCMR, donor 
human leucocyte antigens (HLA) expressed on antigen presenting cells (e.g. dendritic 
cells and macrophages) and donor cells activate effector T cells in secondary 
lymphoid tissues resulting in clonal expansion of these cells.12 Activated effector T 
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cells migrate to the allograft, exit the microcirculation and enter the interstitium, 
where they trigger an inflammatory response with upregulation of interferon-gamma 
(IFNγ).13 IFNγ plays an important role in the establishment of the typical phenotype 
of TCMR, because it induces expression of different genes in the kidney allograft, 
including chemokines such as CCL5, CXCL9, CXCL10, CXCL11 and major 
histocompatibility complex class I and II.13 The transcripts which contribute to the 
profile for TCMR are mostly related to effector T cells (CTLA4, ICOS, BTLA, CD96, 
LAG3, SIRPG, LCP2, DUSP2, CD8A), macrophages (CD84, SLAMF8, ADAMDEC1), B 
cells (CD274, BTLA), and IFNγ related transcripts (ANKRD22, FCGR1B, SLAMF8).4 
Figure 1A shows a schematic picture of the histological features in acute TCMR and 
the involved genes. 
Acute TCMR is histologically diagnosed by scoring interstitial inflammation, 
tubulitis and vasculitis.14, 15 Renal transplant biopsies with histological inflammation 
and tubulitis below the thresholds for a diagnosis of acute TCMR are diagnosed as 
borderline rejection, which denotes possible TCMR. Only 30% of these patients will 
eventually develop an acute TCMR but solely based on histology it cannot be 
determined which patients will develop acute TCMR and therefore will benefit from 
treatment.16-18 Molecular phenotyping may have the potential to reclassify borderline 
cases into TCMR and nonrejection, thereby eliminating the need for the category of 
borderline rejection.19, 20 
The significance of isolated v-lesions, defined as intimal arteritis that occurs 
with minimal concurrent tubulointerstitial inflammation, is also problematic.21 
According to the Banff Classification, isolated v-lesions are to be classified as an acute 
TCMR vascular type (aTCMR2A) or are considered an activity marker for ABMR.22-24 
However, many biopsies classified as having acute TCMR by histology on the basis 
of v-lesions alone have no evidence of a molecular TCMR.4, 25 Molecular profiling of 
transplant biopsies could therefore be of additional value in cases with an isolated 
v-lesion and guide in personalized treatment regimens.  
Another obstacle is the diagnosis of TCMR in biopsies with BK virus  
nephropathy. The histology of BK virus nephropathy includes interstitial 
inflammation and tubulitis which can be confused with acute TCMR.26 Furthermore, 
the reduction of immunosuppressive drugs after a diagnosis of BK virus nephropathy 
can trigger an acute TCMR.27 Positive molecular TCMR scores in biopsies with BK virus 
nephropathy without a histological diagnosis of TCMR may provide evidence that 
some of these patients have concurrent TCMR.28 
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2. Molecular analysis in diagnosing active ABMR 
 
 In active antibody-mediated rejection (ABMR), the activation of B cells and 
plasma cells result in the formation of donor specific antibodies (DSAs), which bind 
to the endothelium in the microcirculation. The pathogenesis of endothelial damage 
involves the direct action of DSAs and complement factors.29 Also, the presence of 
NK cells in the glomerular or peritubular capillaries can mediate endothelial injury by 
triggering of CD16a Fc receptors.30 The CD16a Fc receptors engage the Fc portions 
of DSAs on the endothelium which in turn activates the release of IFNγ and cytokines, 
causing an injury response in the endothelium.30 These patterns of acute cellular 
injury can result in a relatively rapid decline in renal allograft function. 
The gene expression profiles in ABMR display three molecular pathways: natural 
killer (NK) cell-associated transcripts (SH2D1B, GNLY, FGFBP2, CD160), endothelial 
cell-associated transcripts (DARC, ROBO4, CDH5, CDH13, COL13A1) and IFNγ-
induced transcripts (phospholipase PLA1A and chemokine CXCL11).30-33 Hidalgo et 
al. identified 23 transcripts associated with DSAs, the so called DSA-specific 
transcripts (DSASTs), which are primarily expressed in NK cells (CX3CR1, MYBL1, 
FGFBP2, KLRF1, SH2D1B, GNLY) and the endothelium (CDH13, CDH5, COL13A1, 
MALL, PLAT, ROBO4, SOX7, TEK, ICAM2).30 Figure 1B shows a schematic picture of 
the histological features in active ABMR and the involved genes. 
The histologic diagnosis of ABMR is problematic because its appearance is 
heterogeneous and has a remarkable dynamic range, from subtle with mild acute 
tubular necrosis, to fulminant with microvascular inflammation (MVI) and 
hemorrhage.6 Furthermore, there is strong evidence that DSAs can induce 
histological and molecular features similar to that of ABMR in the absence of C4d 
deposition, which has led to the inclusion of C4d negative ABMR in the 2013 Banff 
Classification.24 The evaluation of the expression of endothelial cell transcripts could 
serve as a marker for endothelial injury in C4d negative cases and might predict 
allograft loss better than C4d staining itself.32-34 It has been proposed that ABMR 
could be diagnosed in the absence of C4d positivity if there are DSAs, microvascular 
inflammation or molecular findings such as endothelial cell‐associated transcripts.32  
Likewise, the clinical significance of C4d positive biopsies without evidence of 
rejection is unknown.35, 36 Molecular analysis in these biopsies has the potential to 
identify patients with a higher risk of developing ABMR. 
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Figure 1. Schematic representations of the histological features of acute TCMR and active 
ABMR and the involved genes. A) Activated effector T cells* cross the capillary endothelium 
and enter the interstitium where they cause upregulation of IFNγ-associated transcripts# and 
chemokines$. Histology shows infiltration of the interstitium and tubules by T cells and 
macrophages&, dendritic cells and B cells@ which induce local injury through direct effects on 
the renal parenchyma, tubular epithelium and arteries. B) DSAs cause direct injury to the 
capillary endothelium resulting in upregulation of endothelial cell-associated transcripts*. 
DSAs can also cause indirect injury via complement activation and recruitment of NK-cells# 
with Fc receptors resulting in the upregulation of IFNγ-associated transcripts$ and cytokines&. 
This all induces microvascular inflammation (glomerulitis and peritubular capillaritis) including 
neutrophils and mononuclear cells. 
* BTLA, CD8A, CD28, CD72, CD96,
CTLA4, DUSP2, ICOS, LAG3, LCP2,
SIRPG
# AIM2, ANKRD22
$ CXCL9, CXCL10, CXCL11
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The requirement of the detection of DSAs to diagnose ABMR is another 
debatable subject.37-39 Evidence of ABMR in the absence of anti-HLA antibodies 
suggests the presence of non-anti–HLA antibodies.40 Current standard DSA testing  
methods do not detect all antibodies that are potentially causing the injury as non-
anti-HLA antibodies are not included in these tests. The expression of transcripts 
associated with DSAs may be useful in those cases with histological features of ABMR 
but without C4d positivity of PTCs and without detectable DSAs. 
 
3. Molecular markers predicting allograft outcome 
 
 Better insight in the early pathogenesis of chronic damage by evaluating 
gene expression in renal allograft biopsies performed in the first weeks or months 
after transplantation could offer a way to identify those patients who are at risk of 
future allograft loss. Microarray analysis on renal allograft biopsies is able to detect 
subtle levels of inflammation that are below the diagnostic threshold of histological 
diagnosis as defined by the current Banff Classification months before histologic 
lesions appear.41 This allows for early interventions that slow the progression of 
kidney failure. The Paris Transplant Group has recently developed the integrative Box 
(iBox) system; a multidimensional prognostic score to predict transplant patients' 
individual risks of allograft loss. Allograft parameters including patient 
characteristics, transplant characteristics, renal allograft histology, treatment and 
prospective anti-HLA DSA measurements are integrated in this scoring system.7, 42 
Inclusion of molecular transcripts and novel predictive markers in this scoring system 
could be of added value in identifying those patients who are at risk of future 
allograft loss.  
 
4. Molecular classifier scores 
 
 Molecular classifiers could be helpful in diagnosing rejection in renal 
allograft biopsies.  These classifiers are derived via machine learning algorithms 
evaluating those genes that distinguish rejection from other diagnoses. The 
Edmonton group has built an molecular classifier system for both TCMR and ABMR 
in which a score between 0 and 1 for each biopsy is used, reflecting the probability 
of the diagnosis of rejection in the tissue.43 The TCMR score is based on 403 for-
cause renal allograft biopsies diagnosed according to the Banff Classification by 
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three different pathologists and was considered positive for TCMR above a cut-off 
of 0.1.4 High scores correspond with histological unanimity among the three 
pathologists. Discrepancies were primarily observed in those cases where histology 
resulted in diagnostic difficulties (e.g. histological borderline rejection, isolated v-
lesions).  
The Edmonton group also developed a molecular ABMR score that correlates 
with the presence of microvascular inflammation and DSAs.6, 7 A score exceeding 0.2 
was selected as positive for ABMR. Positive scores were compared with the 
conventional diagnosis of ABMR (histology plus serology) showing diagnostic 
agreement in 85% of the cases. High ABMR scores were associated with unanimity 
among pathologists and were observed in both C4d-positive and C4d-negative 
ABMR. In addition, the molecular score was shown to be an independent predictor 
of allograft survival.6 
 
5. Issues in molecular analysis of renal allograft biopsies 
 
 Discrepancies between molecular scores and conventional histological 
diagnosis are an area of investigation. The lack of a robust gold standard, caused by 
controversies in the histological diagnosis and poor reproducibility in the setting of 
rejection, is a major problem in the development and validation of a molecular 
classifier score. Machine learning classifiers are expected to be more accurate than 
single genes or unweighted gene sets. A disadvantage of the developed molecular 
classifier scores is that they are platform specific and therefore they cannot easily be 
used on other platforms. Furthermore, the developed molecular classifier scores have 
been performed on a relatively small number of patients (maximal a few hundreds 
of patients) and literature does not give clear transparency about the specific genes 
included in the molecular classifier scores for TCMR and ABMR. At the moment, it is 
not clear which genes discriminate the best between rejection and non-rejection and 
it remains a question how many genes should be included in the molecular test. The 
optimal molecular test is able the identify the type of rejection (TCMR or ABMR), but 
can also distinguish between other types of kidney injury. 
It is also important to realize that the analysis of pure TCMR and pure ABMR 
represent extremes of a rejection continuum with different degrees of inflammation 
resulting in different gene expression levels. Furthermore, it is likely that many 
biopsies simply labeled as ABMR have concurrent TCMR.44 Both the molecular ABMR 
and TCMR score are using arbitrary cut-offs, but the actual score seems more 
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accurately expressed as a continuum. For the use of molecular analysis in renal 
allograft diagnostics, it is important to be able to give an accurate assessment of 
where we are on the spectrum and to place cut-offs for those diagnostic categories 
that require treatment.  
 Molecular classifier scores and cut-offs for rejection (and treatment 
decisions) would ideally be based on large-scale multicenter studies. For the 
development of a multicentered validated classifier score it is important to 1) further 
define the molecular phenotypes of TCMR and of ABMR, 2) create a reliable machine 
learning classifier score, and 3) to use a freely accessible, affordable diagnostic 
platform. 
The recently introduced Banff Human Organ Transplant Panel (B-HOT panel) 
is a panel of 770 genes in which genes known to be involved in transplant rejection, 
tissue damage and even genes for viruses are included. This gene panel has been 
created through a collaboration between NanoString and the Banff Foundation for 
Allograft Pathology. The B-HOT panel can be run on the widely available nCounter 
platform from NanoString. Through the use of this 770-gene panel and the 
development of a data sharing platform, the Banff community aims to validate the 
B-HOT panel on a multicenter level. This panel could give us the ability to optimize 
the molecular diagnostic classification of renal transplant biopsies. 
 
6. Concluding remarks 
 
 The use of molecular analysis can improve the diagnosis of rejection in renal 
allograft biopsies. Upregulation of specific transcripts might help to predict rejection 
even before the injury is visible by light microscopy, which can help nephrologists to 
determine which patients are at risk of rejection and predict possible future allograft 
loss. This is especially important since long-term immunosuppression is associated 
with severe side effects and knowing which patient should receive further therapy 
could specify treatment to the needs of the individual patient. Molecular profiling of 
kidney transplant biopsies has the potential to be more precise and more 
reproducible than traditional histological evaluation in the diagnostic setting. The 
combination of conventional approaches (histology, serology and clinical data) and 
molecular analysis will most likely offer the best diagnostic approach in the 
evaluation of renal transplant biopsies (Figure 2). Large-scale, multicenter validation 
using an affordable and reliable platform will be the next step to prove that molecular 
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diagnostics can be broadly implemented in the diagnostics of renal transplant 
biopsies. With this we are on our way to significantly improve not only diagnostics 
but also personalized therapeutic regimens and long-term transplant outcome.  
 
 
 
Figure 2. The combination of serology, histology and molecular evaluation offers new 
strategies in the handling and assessment of renal allograft biopsies and could improve 
diagnostics, treatment regimens and long-term transplant outcome. 
  
Diagnosis
Treatment
Outcome
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De belangrijkste functie van de nieren is het verwijderen van afvalstoffen uit 
het lichaam door uitscheiding via de urine. Daarnaast zorgen de nieren voor het op 
peil houden van de water-zoutbalans in het bloed. Door schade aan de nieren kan 
de nierfunctie achteruit gaan, met als gevolg dat afvalstoffen zich in het lichaam 
ophopen en de water-zoutbalans verstoord raakt.  In het laatste stadium van 
chronische nierschade is er sprake van eindstadium nierfalen en is behandeling 
met dialyse of transplantatie noodzakelijk om in leven te blijven. Bij het 
verrichten van een niertransplantatie wordt een gezonde nier van iemand anders 
in de patiënt met slecht werkende nieren geïmplanteerd. Het probleem hierbij is 
dat het niertransplantaat door de ontvanger als lichaamsvreemd wordt gezien, 
waardoor het afweersysteem wordt geactiveerd en de nieuwe nier wordt afgestoten. 
Om dit te voorkomen moet het afweersysteem van de ontvanger onderdrukt worden 
met afweer onderdrukkende medicatie, genaamd immunosuppressiva.  
Door de ontwikkeling van steeds betere immunosuppressiva is de kans op 
afstoting de afgelopen jaren sterk gedaald. Echter, zowel acute als chronische 
afstoting blijven een veel voorkomend probleem en leiden tot schade aan het 
niertransplantaat.  Circa 50% van de niertransplantaten faalt binnen 10 jaar na de 
transplantatie. Een beter begrip van de verschillende factoren die geassocieerd zijn 
met transplantaatfalen - op zowel korte als lange termijn - is essentieel om effectieve 
behandelingen te ontwikkelen die de achteruitgang van de niertransplantaatfunctie 
kunnen vertragen of voorkomen. Het verrichten van een nierbiopt wordt beschouwd 
als de gouden standaard om de achteruitgang van de nierfunctie te analyseren en is 
tevens een belangrijk hulpmiddel bij het onderzoeken van mogelijke risicofactoren 
voor transplantaatfalen. Het doel van dit proefschrift is om potentieel belangrijke 
kenmerken in niertransplantaatbiopten te identificeren en de associatie met het 
risico op transplantaatfalen te evalueren. 
 
1. Cryo-Gel voor vriezen van nierbiopten 
 
Nierbiopten kunnen zowel op microscopisch niveau (histologie, 
immunohistochemie) als op eiwit niveau en moleculair niveau worden onderzocht 
op specifieke kenmerken die een rol spelen bij het risico op (toekomstig) 
transplantaatfalen. Voor zowel diagnostiek als toekomstige onderzoeksdoeleinden 
is het van belang dat het nierweefsel wordt opgeslagen op een manier die de 
weefselconservering maximaliseert. Voor het vriezen van het nierweefsel wordt 
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meestal optimal cutting temperature (OCT) compound als inbedmedium gebruikt. 
Echter, het verrichten van eiwitanalyse middels massaspectometrie is lastig bij 
weefsels die ingebed zijn in OCT. Dit komt doordat OCT polymeren bevat die de 
massaspectometrie uitslagen kunnen vertroebelen. In Hoofdstuk 2 werd het nieuwe 
inbedmedium Cryo-Gel voor het vriezen van nierbiopten onderzocht. Er werd 
aangetoond dat Cryo-Gel geschikt is als inbedmedium. Bij het verrichten van 
massaspectometrie werd een goed signaal waargenomen, zonder vertroebeling 
door polymeren, zoals gezien wordt bij OCT.  Op basis van deze bevindingen kan 
worden geconcludeerd dat het inbedmedium Cryo-Gel de voorkeur heeft boven OCT 
voor het vriezen van nierbiopten, met name wanneer massaspectometrie (mogelijk) 
verricht zal worden.  
 
2. Calcium oxalaat deposities 
 
Vrij recent werd gesuggereerd dat de histologische aanwezigheid van 
calciumoxalaat (CaOx) een mogelijke oorzaak is van de achteruitgang in de 
nierfunctie in de vroege post-transplantatieperiode. Oxaalzuur is het eindproduct 
van verschillende metabole routes en wordt voornamelijk uitgescheiden via de 
nieren. Wanneer de nierfunctie daalt, zal minder oxaalzuur via de urine worden 
uitgescheiden met als gevolg dat de plasmaconcentratie van oxaalzuur stijgt. Dit is 
de reden dat hoge plasma oxaalzuurconcentraties worden waargenomen bij 
patiënten met eindstadium nierfalen. Behandeling met dialyse is niet voldoende om 
deze hoge oxaalzuurconcentraties te doen dalen. Na niertransplantatie zal een grote 
hoeveelheid oxaalzuur worden uitgescheiden door de ‘nieuwe’ nier. De urine zal 
hierdoor verzadigd raken met oxaalzuur, waardoor dit neerslaat in de vorm van 
calciumoxalaat (CaOx) kristallen die zich kunnen ophopen in de niertubuli en hieraan 
schade kunnen veroorzaken.  
In Hoofdstuk 3 werden CaOx deposities aangetoond in 17% van de 
niertransplantatiebiopten afgenomen binnen 3 maanden na transplantatie. Patiënten 
met CaOx deposities in hun nierbiopt werden significant vaker behandeld met 
dialyse voor transplantatie. Dit kan worden verklaard door het feit dat hogere plasma 
oxaalzuurconcentraties worden gezien bij dialyse patiënten dan bij patiënten met 
een verminderde nierfunctie waarbij dialyse nog niet noodzakelijk is. Bij deze laatste 
groep patiënten zal de resterende nierfunctie ervoor zorgen dat een deel van het 
oxaalzuur via de nieren wordt uitgescheiden.  
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Een verminderde nierfunctie in de vroege post-transplantatieperiode kwam 
vaker voor bij patiënten met CaOx deposities in hun nierbiopt. Bovendien werd 
gezien dat de overleving van het transplantaat significant slechter is bij patiënten 
met CaOx deposities in hun nierbiopt. De exacte relatie tussen CaOx deposities en 
verminderde nierfunctie in de vroege post-transplantatieperiode blijft lastig te 
achterhalen. CaOx deposities kunnen directe schade aan de niertubuli veroorzaken, 
waardoor de nierfunctie achteruit gaat. Het is echter ook mogelijk dat reeds ontstane 
schade aan de niertubuli ten tijde van de verminderde nierfunctie het neerslaan van 
CaOx deposities vergemakkelijkt. Dit alles kan leiden tot een vicieuze cirkel van 
schade aan het niertransplantaat met uiteindelijk functieverlies van het transplantaat. 
Op basis van deze bevindingen is het systematisch beoordelen van nierbiopten op 
de aanwezigheid van CaOx deposities sterk geadviseerd.   
 
3. Genexpressie levels van het aangeboren immuunsysteem 
 
Het aangeboren immuunsysteem - waaronder 'toll-like' receptoren, 
complement en apoptose gerelateerde genen - speelt een belangrijke rol bij het 
ontstaan van schade in niertransplantaties. In Hoofdstuk 4 werd de mRNA expressie 
van deze genen onderzocht in nierbiopten die net voor transplantatie en op het 
moment van acute afstoting genomen zijn. In de nierbiopten afgenomen net voor 
transplantatie, was de mRNA expressie van de complement factoren C2 en C3 en de 
apoptose (geprogrammeerde celdood) gerelateerde BAX:BCL2 ratio hoger in 
biopten van postmortale donornieren dan in biopten van levende donornieren. 
Activatie van het aangeboren immuunsysteem kan onder andere ontstaan door 
ischemische-reperfursie schade, wat vaak wordt gezien in postmortale donornieren. 
Het onderdrukken van complement en apoptose gerelateerde genen zou 
bescherming kunnen bieden tegen ischemische-reperfursie schade, met name in 
niertransplantaties afkomstig van postmortale donoren. 
Gedurende acute afstoting speelt activatie van het aangeboren 
immuunsysteem een belangrijke rol. De meeste 'toll-like' receptoren en complement 
factor C2 toonden hogere expressie levels in de nierbiopten met acute afstoting dan 
in de nierbiopten afgenomen net voor transplantatie. Deze verhoogde expressie 
bleek grotendeels gerelateerd aan influx van ontstekingscellen in het 
niertransplantaat. Bovendien werd gezien dat relatief hoge 'toll-like' receptor 4 
expressie levels en een hoge BAX:BCL2 ratio tijdens acute afstoting onafhankelijke 
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risicofactoren zijn voor transplantaatfalen in de groep patiënten met een 
postmortale donornier.  
De bevindingen gepresenteerd in deze studie tonen aan dat activering van 
het aangeboren immuunsysteem zowel vlak voor transplantatie als tijdens een acute 
rejectie plaatsvindt. Het onderdrukken van complement en apoptose gerelateerde 
markers kan als therapeutisch doelwit fungeren om het niertransplantaat te 
beschermen tegen de effecten van ischemische-reperfursie schade. Bovendien kan 
monitoren van de 'toll-like' receptor 4 expressie en BAX:BCL2 ratio tijdens acute 
afstoting van prognostische waarde zijn bij het voorspellen van 
transplantaatuitkomst.  
 
4. Arteriolaire C4d in antilichaam gemedieerde afstoting 
 
C4d aankleuring in het endotheel van de peritubulaire capillairen is een 
belangrijk kenmerk van antilichaam gemedieerde afstoting. De betekenis van C4d 
aankleuring in andere structuren van de nier, zoals de glomeruli en arteriolen, bij 
patiënten met antilichaam gemedieerde afstoting is niet duidelijk. In Hoofdstuk 5 
werd de significantie van C4d aankleuring in de arteriolen bij patiënten met chronisch 
actieve antilichaam gemedieerde afstoting onderzocht. Arteriolaire C4d aankleuring 
was aanwezig in 85% van de nierbiopten met chronisch actieve antilichaam 
gemedieerde afstoting en werd significant minder vaak gezien in de 
controlegroepen (niertransplantaten zonder antilichaam gemedieerde afstoting en 
een groep van natieve nierbiopten). Bovendien werd gezien dat sterke (score ≥2) 
arteriolaire C4d aankleuring onafhankelijk geassocieerd is met betere 
transplantaatoverleving in een multivariate Cox-regressie analyse.  
 Arteriolaire C4d aankleuring was geassocieerd de ernst van arteriolaire 
hyalinose. In casus met arteriolaire hyalinose werd de arteriolaire C4d aankleuring 
vaak waargenomen op de plaats van de hyalinose. Deze casus werden verder 
geanalyseerd door het aankleuringspatroon van C4d onder te verdelen in 
endotheliale en murale aankleuring. Deze verschillende aankleuringspatronen 
zouden op verschillende processen kunnen duiden; endotheliale aankleuring van 
C4d in de arteriolen is gerelateerd aan complement activatie met afzetting van C4d 
aan de luminale zijde van het endotheel. Murale aankleuring van C4d wordt 
daarentegen waarschijnlijk veroorzaakt door lekkage van de luminaal afgezette C4d 
in de wand van de arteriolen of door het lekken van plasma in de wand van de 
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arteriolen als gevolg van verhoogde permeabiliteit van het endotheel met lokale C4d 
afzetting ter plaatse.  
 Deze pilot studie geeft de eerste inzichten in arteriolaire C4d aankleuring in 
chronisch actieve antilichaam gemedieerde afstoting. Echter, de vraag of arteriolaire 
C4d aankleuring echt specifiek is voor chronisch actieve antilichaam gemedieerde 
schade blijft bestaan en maakt het de moeite waard om dit verder te onderzoeken 
in een groter patiënten cohort.  
 
5. C3d immunohistochemie in C3 glomerulopathie 
 
 C3 glomerulopathie is een zeldzame nierziekte die wordt veroorzaakt door 
overmatige activering van de alternatieve route van het complementsysteem. Dit 
resulteert in de depositie van complement factor C3 in de glomeruli van de nieren. 
Volgens de consensus criteria is een nierbiopt noodzakelijk om de aanwezigheid van 
deze C3 deposities aan te tonen; dominante aankleuring met C3c 
immunofluorescentie ten opzichte van de andere kleuringen (IgA, IgG, IgM en C1q) 
wordt namelijk beschouwd als karakteristiek kenmerk voor de diagnose C3 
glomerulopathie. Echter, in een aantal evidente gevallen van C3 glomerulopathie kan 
niet aan de consensus criteria worden voldaan. Hierdoor ontstaat de vraag of de 
huidige consensus criteria toereikend zijn en of andere markers wellicht van 
toegevoegde waarde kunnen zijn. 
 In Hoofdstuk 6 werd de meerwaarde van C3d immunohistochemie in 
biopten met C3 glomerulopathie geëvalueerd.  In totaal werden 14 nierbiopten met 
C3 glomerulopathie onderzocht, welke allemaal matige tot sterke aankleuring met 
C3d toonden. In 4 van de biopten kon de diagnose C3 glomerulopathie – volgens de 
consensus criteria ‐ niet worden gesteld, doordat geen dominante aankleuring met 
C3c bij immunofluorescentie werd gezien. In 2 van deze biopten was C3c aankleuring 
nihil/negatief, terwijl met C3d immunohistochemie sterke en dominante aankleuring 
werd gezien, waardoor de diagnose alsnog bevestigd werd. In de 2 overgebleven 
biopten toonden zowel C3d als C3c matige aankleuring. Dit betrof echter geen 
dominante aankleuring, aangezien ook C1q matige aankleuring liet zien en hierdoor 
kon de diagnose C3 glomerulopathie niet worden gesteld.  
Concluderend kan gesteld worden dat C3d immunohistochemie van 
toegevoegde waarde is bij het diagnosticeren van C3 glomerulopathie, vooral in de 
gevallen waar geen of geringe aankleuring wordt gezien met C3c. Echter, ook na het 
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gebruik van C3d immunohistochemie is er een klein percentage waarbij de 
consensus criteria voor het stellen van de diagnose C3 glomerulopathie niet 
toereikend zijn. 
 
De resultaten gepresenteerd in dit proefschrift tonen histologische, 
immunohistochemische en moleculaire kenmerken in nier(transplantaat)biopten die 
van toegevoegde waarde kunnen zijn binnen de diagnostiek en geassocieerd zijn 
met de uitkomst van niertransplantaties. Het identificeren van deze markers helpt 
ons de pathogenese van nierziekten beter te begrijpen en kan tot nieuwe 
diagnostische en prognostische markers leiden en uiteindelijk de ontwikkeling van 
op maat gemaakte therapeutische behandelingen bevorderen.  
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